Annals of Diagnostic Paediatric Pathology
Annals of Diagnostic Paediatric Pathology
Annals of Diagnostic Paediatric Pathology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong><br />
Official Journal <strong>of</strong> the Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
and Section <strong>of</strong> Oncological Surgery <strong>of</strong> Polish Association <strong>of</strong> <strong>Paediatric</strong> Surgeons<br />
Editor-in-Chief<br />
Co-Editors<br />
Associate Editors<br />
ProductIon Editor<br />
B. M. WoŸniewicz, Warsaw<br />
B. M. Cukrowska, Warsaw<br />
A. I. Prokurat, Bydgoszcz<br />
J. Cielecka-Kuszyk, Warsaw<br />
E. Czarnowska, Warsaw<br />
W. T. Dura, Warsaw<br />
W. Grajkowska, Warsaw<br />
M. Liebhardt, Warsaw<br />
A. Wasiutyñski, Warsaw<br />
G. Napiórkowski, Warsaw<br />
A. Bysiek, Cracow<br />
P. Czauderna, Gdansk<br />
J. Godziñski, Wroc³aw<br />
J. Niedzielski, Lodz<br />
W. WoŸniak, Warsaw<br />
M. Wysoki, Bydgoszcz<br />
Editorial Office<br />
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong><br />
Department <strong>of</strong> <strong>Pathology</strong><br />
The Children´s Memorial Health Institute<br />
Aleja Dzieci Polskich 20<br />
04 736 Warszawa, Poland<br />
Tel.: +48-22-815-19-72<br />
Fax: +48-22-815-19-73<br />
E-mail: ptpd@czd.waw.pl<br />
Editorial Board<br />
J. P. Barbet, Paris<br />
L. A. Boccon-Gibod, Paris<br />
P. E. Campbell, Melbourne<br />
A. Chilarski, Lodz<br />
J. Czernik, Wroclaw<br />
E. Gilbert-Baarness, Tampa<br />
A. A. Greco, New York<br />
M. D. Haust, Londyn<br />
A. Hinek, Toronto<br />
J. Huber, Utrecht<br />
C. G. Gopalakrishnam, Trivandrum<br />
S. Gogus, Ankara<br />
A. Jankowski, Poznan<br />
P. Januszewicz, Warsaw<br />
B. Jarz¹b, Gliwice<br />
B. A. Kakulas, Perth<br />
R. O. C. Kaschula, Rondebosch<br />
W. Kawalec, Warsaw<br />
J. Kobos, Lodz<br />
G. Karpati, Montreal<br />
J. Las Heras, Santiago de Chile<br />
K. Madaliñski, Warsaw<br />
D. M. F. Menezes, Rio de Janeiro<br />
W. A. Newton, Jr., Johnstown<br />
B. Otte, Brussels<br />
S. A. Pileri, Bologna<br />
J. Plaschkes, Berne<br />
F. Raafat, Birmingham<br />
S. W. Sadowinski, Mexico City<br />
K. Sawicz-Birkowska, Wroclaw<br />
J. Stejskal, Prague<br />
Cz. Stoba, Gdansk<br />
G. Thiene, Padova<br />
S. Variend, Shieffield<br />
T. H. Wyszyñska, Warsaw<br />
A. Zimmermann, Berne<br />
The journal is supported by the State Committee for Research.<br />
Aims and scope<br />
The <strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> is an international peer-reviewed journal. The focus <strong>of</strong> the journal is current<br />
progress in clinical paediatric pathology and surgical oncology in both basic and clinical applications. Experimental studies and<br />
clinical trials are accepted for publication, as are case reports supported by literature review. The main policy <strong>of</strong> the <strong>Annals</strong> is<br />
to publish papers that present practical knowledge that can be applied by clinicians.<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society, 2001<br />
ISSN 1427-4426
Review<br />
Papers<br />
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong><br />
Official Journal <strong>of</strong> the Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
and Section <strong>of</strong> Oncological Surgery <strong>of</strong> Polish Association <strong>of</strong> <strong>Paediatric</strong> Surgeons<br />
Volume 8 Number 3-4 Winter 2004<br />
CONTENTS<br />
Genetics and biology <strong>of</strong> neuroblastoma – an overview ....................................................................................69<br />
Peter F. Ambros, Ruth Ladenstein, Helmut Gadner, Ingeborg M. Ambros<br />
Neuroblastoma: histoprognostic classification and handling <strong>of</strong> material for biology<br />
– a challenge for the pathologist .........................................................................................................................73<br />
Klaus Beiske<br />
Original<br />
Papers<br />
Intracranial ependymomas in children: correlation <strong>of</strong> selected factors and event-free<br />
survival in the group <strong>of</strong> 142 consecutive patients treated at one institution. .................................................83<br />
S³awomir Barszcz, Wies³awa Grajkowska, Danuta Perek, Marcin Roszkowski, Monika Drogosiewicz,<br />
Marta Perek-Polnik, El¿bieta Jurkiewicz, Pawe³ Daszkiewicz<br />
<strong>Pathology</strong> <strong>of</strong> fatty liver in children with LCHAD deficiency...........................................................................89<br />
Katarzyna Iwanicka, Janusz Ksi¹¿yk, Monika Pohorecka, Maciej Pronicki<br />
Isolation <strong>of</strong> urothelial cells for tissue engineered bladder augmentation ....................................................... 95<br />
Tomasz Drewa, Przemys³aw Galazka, Zbigniew Wolski, Andrzej I. Prokurat, Jan Sir<br />
Status <strong>of</strong> oral hygiene and dentition in children exposed to anticancer treatment .......................................99<br />
Dorota Olczak-Kowalczyk, Marta Daszkiewicz, Barbara Adamowicz-Klepalska, El¿bieta Czarnowska, Agnieszka Sowiñska,<br />
Bo¿ena Dembowska-Bagiñska, Danuta Perek, Pawe³ Daszkiewicz<br />
Preliminary review <strong>of</strong> the treatment results <strong>of</strong> hepatoblastoma and hepatocarcinoma<br />
in children in Poland in the period 1998-2002 ................................................................................................107<br />
Czes³aw Stoba, Katarzyna Nierzwicka, Piotr Czauderna, Barbara Skoczylas-Stoba , Stefan Popadiuk, Jolanta Bonar,<br />
Krystyna Sawicz-Birkowska, Hanna Kaczmarek-Kanold, Przemys³aw Mañkowski, Krzyszt<strong>of</strong> K¹tski, Wojciech Madziara,<br />
Magdalena Rych³owska, Anna Sitkiewicz, Anna Szo³kiewicz, Sabina Szymik-Kantorowicz, Violetta Œwi¹tkiewicz<br />
Liver transplantation for primary malignant liver tumors in children – single center experience ...........111<br />
Piotr Kaliciñski, Hor Ismail, Andrzej Kamiñski, Danuta Perek, Joanna Paw³owska, Przemys³aw Kluge, Joanna Teisserye,<br />
Marek Szymczak, Tomasz Drewniak, Pawe³ Nachulewicz, Bo¿ena Dembowska-Bagiñska, Marek Stefanowicz,<br />
Andrzej Byszewski, Ma³gorzata Manowska<br />
Hepatocyte ultrastructure in non-hemolytic hyperbilirubinemias ...............................................................115<br />
El¿bieta Czarnowska, Bogdan WoŸniewicz<br />
Congenital Heart Diseases Database: analysis <strong>of</strong> occurrence,<br />
diagnostics and coexistence with anomalies <strong>of</strong> other systems. Single institution experience .....................119<br />
Anna Rybak, Aneta Wójcik, Bogdan WoŸniewicz<br />
Case<br />
Reports<br />
Invited<br />
Lectures<br />
Solid pseudopapillary tumor <strong>of</strong> pancreas. Case report and the review <strong>of</strong> literature ..................................121<br />
Andrzej Chilarski, Anna Piaseczna-Piotrowska, Jan Strzelczyk, Stanis³aw £ukaszek, Andrzej Kulig<br />
Liver tumors <strong>of</strong> childhood - pathology. Report <strong>of</strong> the Kiel Pediatric Tumor Registry................................125<br />
Dieter Harms
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Genetics and biology <strong>of</strong> neuroblastoma – an overview<br />
Peter F. Ambros 1 , Ruth Ladenstein 2 , Helmut Gadner 1, 2 , Ingeborg M. Ambros 1<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
1<br />
CCRI, Children’s Cancer Research Institute,<br />
St. Anna Children’s Hospital,<br />
A-1090 Vienna, Austria<br />
2<br />
St. Anna Children’s Hospital,<br />
A-1090 Vienna, Austria<br />
Abstract<br />
Neuroblastoma, the most common extra cranial solid tumor in early childhood, is a heterogeneous disease<br />
with different clinical and biological behavior. Unique features are the spontaneous regression and maturation<br />
which both require similar genetic prerequisites and, in the case <strong>of</strong> maturation, also the presence <strong>of</strong> the<br />
non-neoplastic Schwann cells. However, over the half <strong>of</strong> the tumors display an aggressive clinical course.<br />
Besides the stage and age at diagnosis, the MYCN oncogene (amplified versus non-amplified) has gained<br />
fundamental importance for therapy stratification, particularly in patients with localized disease and in infants.<br />
Further prognostic markers associated with an unfavorable outcome are DNA di-tetraploidy, deletion<br />
at chromosomal regions 1p36, 3p and 11q and gain <strong>of</strong> 17q, besides others. Most <strong>of</strong> these genetic markers<br />
have been shown to predict outcome in patients with localized disease while their impact in stage 4 patients<br />
is discussed controversially. Recent data indicate that not even MYCN amplification can separate prognostic<br />
subgroups in the latter patient group. However, a rapid BM-clearing seems to be associated with a far more<br />
favorable outcome even in the group <strong>of</strong> patients with unfavorable genetic features, thus expressing the response<br />
to chemotherapy and possibly providing an excellent prognostic marker. Furthermore, recent gene<br />
expression studies highlighting the whole transcriptome may provide also valuable information on the dignity<br />
<strong>of</strong> neuroblastic tumors. We can conclude that MYCN amplification still represents an excellent way to<br />
discriminate aggressive from non- or less aggressive tumors especially in patients with localized disease or<br />
infants. However, new biological and genetic information is necessary to be able to reach our final goal<br />
which is patient tailored therapy based on the genetic and biological pr<strong>of</strong>ile <strong>of</strong> the tumor.<br />
Key words: genetics, MYCN, oncogene<br />
Genetic hallmarks in neuroblastic tumors<br />
Over the last few years the amplification <strong>of</strong> the MYCN<br />
oncogene [11, 32] has taken shape as the most important<br />
marker for the assessment <strong>of</strong> the dignity <strong>of</strong> neuroblastic tumors.<br />
Amplifications <strong>of</strong> this oncogene can be observed in approximately<br />
20% <strong>of</strong> tumors and are <strong>of</strong>ten associated with a<br />
deletion at the short arm <strong>of</strong> chromosome 1, del1p36 [10]. Both<br />
aberrations can be found in both genetic subgroups (Fig. 1)<br />
which are based on the different DNA-content (di-/tetraploid<br />
versus near-triploid or penta-/hexaploid). What up to now is<br />
entirely unclear is why MYCN amplifications and/or aberrations<br />
<strong>of</strong> the chromosomal region 1p36.3 occur in only about<br />
15% <strong>of</strong> the near-triploid neuroblastic tumors while the same<br />
aberrations can be found in approx. 56% <strong>of</strong> the diploid group<br />
(unpublished data). The genetic aberration which is most frequently<br />
detected in neuroblastic tumors is gain <strong>of</strong> the long<br />
arm <strong>of</strong> chromosome 17 (in 66-69% <strong>of</strong> all cases) [9, 20, 39].<br />
The prognostic value <strong>of</strong> this aberration has however not yet<br />
been completely clarified and was already opposed [36]. Also<br />
other chromosome aberrations like del11q23 [13, 15, 22, 35,<br />
40] and del3p26 [13, 40] have been described frequently.<br />
Whereby, loss <strong>of</strong> sequences at 11q may indicate a rather promising<br />
genetic marker especially in MYCN non amplified tumors.<br />
However, one has to keep in mind that genetic/biological<br />
studies will only give clear results when the material to be<br />
tested is <strong>of</strong> good quality and is present in sufficient amount.<br />
Address for correspondence<br />
Assoc. Pr<strong>of</strong>. Dr. Peter F. Ambros<br />
CCRI, Children's Cancer Research Institute, St. Anna Kinderspital<br />
Kinderspitalgasse 6<br />
A-1090 Vienna, Austria<br />
Phone: +43 1 40470 411<br />
Fax: +431 408 7230<br />
E-mail: ambros@ccri.univie.ac.at
70<br />
Therefore, the sampling and storage <strong>of</strong> tumor, blood and bone<br />
marrow should be done in the appropriate way to guarantee<br />
the highest possible quality <strong>of</strong> the results [5]. Furthermore,<br />
quality assessment studies and a uniform nomenclature to<br />
describe the results <strong>of</strong> the genetic/biological studies provide<br />
additional security on the high quality <strong>of</strong> the results [1].<br />
Subgroups <strong>of</strong> neuroblastic tumors based on different<br />
DNA-content<br />
Based on a difference in DNA-content, neuroblastic tumors<br />
can be divided into two major groups (Fig. 1). Slightly more<br />
than half <strong>of</strong> the tumors (55%) have a near-triploid DNA-content<br />
(DNA-index between 1.26 and 1.74) while in approx. 45%<br />
<strong>of</strong> neuroblastic tumors a diploid (or tetraploid or even combined<br />
diploid/tetraploid) DNA content can be observed. Spontaneous<br />
regression or maturation, not triggered by therapy,<br />
and which can <strong>of</strong>ten be found in neuroblastic tumors, is very<br />
likely limited to the near-triploid subgroup [2, 7]. In approx.<br />
15% <strong>of</strong> the cases, however, aggressive tumor behavior can<br />
also be observed in this subgroup (Ambros, unpublished). In<br />
these cases structural chromosome aberrations (MYCN amplification,<br />
1p-deletion) may be found. Most <strong>of</strong> the diploid<br />
tumors, on the other hand, are aggressive even without MYCN<br />
amplification or 1p36.3 aberration, irrespective <strong>of</strong> the patient’s<br />
age at diagnosis or the stage <strong>of</strong> the tumor [19, 21]. Alterations<br />
<strong>of</strong> the genome can be observed in almost all diploid tumors.<br />
Genesis <strong>of</strong> neuroblastic tumors and genetic intratumoral<br />
heterogeneity (focal MYCN amplification)<br />
When focusing on the two different ploidy groups, diploid<br />
versus near-triploid neuroblastic tumors, we can identify different<br />
frequency <strong>of</strong> structural chromosomal aberrations (i.e.<br />
deletions, gains or even amplifications). The majority <strong>of</strong> neartriploid<br />
tumors exclusively have only numerical chromosome<br />
aberrations – which seems to be sufficient for (<strong>of</strong>ten self-limited)<br />
tumor growth. Succeeding secondary changes, as for<br />
example MYCN-amplification or 1p36.3 aberration, lead, on<br />
the other hand, to malignant transformations (Fig. 1). As regards<br />
the diploid (2n) tumor group (without gain <strong>of</strong> additional<br />
chromosomes), the initiating event has not been identified so<br />
far, even though other chromosome aberrations like del11q23,<br />
del3p26 and 17q-gain have been described frequently [10].<br />
What all these diploid tumors have in common, however, is<br />
their aggressive cell growth (Fig.1).<br />
3n<br />
trkA<br />
expression<br />
3n<br />
no NGF<br />
Schwann cell<br />
regression<br />
maturation<br />
(GNB, GN)<br />
neuroblasts<br />
del1p, MNA<br />
progression<br />
2n<br />
LOH 3p, 11q, etc.<br />
progression<br />
Fig. 1 Spontaneous regression and spontaneous maturation are restricted to those tumors with a near triploid (+ 3n) or near pentaploid/hexaploid (+5n/6n)<br />
DNA content. In tumors <strong>of</strong> patients under 1 year <strong>of</strong> age, lack <strong>of</strong> nerve growth factor (NGF) is a common finding [18, 27] and is probably involved in the<br />
phenomenon <strong>of</strong> spontaneous regression. Tumors undergoing spontaneous maturation processes, on the other hand, occur in patients over 1 year <strong>of</strong> age and are<br />
characterized by the presence <strong>of</strong> a reactive, i.e. non neoplastic cell population, namely the Schwann cells, leading to a mixed population <strong>of</strong> near triploid<br />
(penta-, hexaploid) neuroblastic/ganglionic cells and diploid Schwann cells [2]. The tumor cells in both groups are usually characterized by whole chromosome<br />
gains, structural aberrations are found only occasionally. However, aggressive neuroblastomas frequently display diploid tumor cells, which can either<br />
show amplification <strong>of</strong> the MYCN oncogene and/or deletions at the short arm <strong>of</strong> chromosome 1, or display losses at the chromosomal regions 3p, 11q, 14q or<br />
other aberrations and high telomerase activity. 17q gain was found in both groups. Interestingly, also triploid tumors can acquire MYCN amplifications or 1p<br />
deletions, or other aberrations thus transforming this benign tumor into a highly aggressive one (dotted line). (MNA = MYCN amplification, LOH = loss <strong>of</strong><br />
heterozygosity, NGF = nerve growth factor).<br />
Figure modified from the article: 'Neuroblastom' by Peter F. Ambros and Inge M. Ambros in Medizinische Genetik 2:119-124 (2002)
71<br />
Until recently, it has been assumed that the individual neuroblastic<br />
tumors are genetically homogenous and that for this<br />
reason the investigation <strong>of</strong> a very small area <strong>of</strong> the tumor (e.g.<br />
biopsy) is genetically representative <strong>of</strong> the entire tumor. However,<br />
various facts led to quite different results. New and more<br />
sensitive techniques, i.e. serial genetic investigations <strong>of</strong> individual<br />
tumors used according to therapy-protocols and neuroblastoma<br />
screening, discovered also genetically in-homogenous<br />
tumors. Thus it could be shown that in up to 15%<br />
<strong>of</strong> all MYCN-amplified tumors the MYCN-amplification is<br />
focal, i.e. not ubiquitously detectable in the tumor tissue [4].<br />
The discovery <strong>of</strong> the focal MYCN-amplification implies that<br />
this genetic change occurs only in the course <strong>of</strong> tumor progression<br />
– at least with some tumors – and causes, at least<br />
temporarily ,heterogeneous’ cell populations within a tumor.<br />
It may furthermore be assumed that the amplified cells “overgrow”<br />
the non-amplified cells because <strong>of</strong> their advanced proliferation<br />
rate. These observations regarding heterogeneous<br />
tumors may be unexpected for neuroblastic tumors, but are<br />
not at all unusual in other tumor types in which amplified and<br />
non-amplified areas can be found side by side.<br />
Since the first time that the familial neuroblastomas<br />
have been described in the middle <strong>of</strong> the last century, only a<br />
very few cases have been investigated and the involvement <strong>of</strong><br />
the chromosomal region 16p seems to be important [24].<br />
Spontaneous tumor regression<br />
Complete spontaneous regression <strong>of</strong> tumors (even <strong>of</strong> “metastasized”<br />
tumors) without cytotoxic treatment is a phenomenon<br />
which scientists have not yet been able to explain. And even<br />
though spontaneous regression most <strong>of</strong>ten occurs in 4s stage<br />
tumors [12, 14], it is by no means limited to this stage. It can<br />
be observed in localised tumors [41] in 6 month old patients<br />
who have been diagnosed through the urinary mass screening<br />
and even in “classical” stage 4 tumors in the first year <strong>of</strong> life.<br />
In tumors which have the ability to regress spontaneously,<br />
near-triploidy (or polyploidy) was found but no MYCN-amplification<br />
or 1p-deletion [7] (Fig.1) was detected. The latter<br />
two genetic aberrations represent markers <strong>of</strong> aggressive tumor<br />
behavior. Moreover, the telomerase activity in aggressive<br />
neuroblastomas is increased as is the case in many other human<br />
neoplasias [16, 29]. 4s tumors and spontaneously regressing<br />
tumors however had low or absent telomerase activity.<br />
The only exceptions are patients with a stage 4s tumor and<br />
lethal outcome who did actually show an increase in telomerase<br />
activity [16, 29].<br />
Spontaneous tumor maturation<br />
Spontaneous tumor maturation (which is also not induced by<br />
cytotoxic treatment) does not occur in patients younger than<br />
12 months but is observed in patients over one year <strong>of</strong> age.<br />
Fully matured tumors, i.e. ganglioneuromas, are usually only<br />
diagnosed in patients over 3 or 4 years <strong>of</strong> age. The genetic<br />
change consists <strong>of</strong> triploidization <strong>of</strong> the genome (or penta- or<br />
hexaploidization respectively) and a lack <strong>of</strong> chromosome 1p36<br />
and MYCN-amplification [2]. In all ganglioneuroblastomas<br />
and ganglioneuromas a diploid cell population can be found<br />
besides a triploid cell population. Via in situ-hybridization it<br />
could then be shown that this diploid cell population is made<br />
up <strong>of</strong> Schwann cells which usually occur in mature tumors<br />
[2]. Until then, these Schwann cells, the amount <strong>of</strong> which increases<br />
during maturation, were considered to be tumor cells<br />
(like the ganglionic cells in the tumor) which led to the opinion<br />
that neuroblastic tumors evolve from “pluripotent” neural<br />
crest cell [37]. It is however, quite unlikely that a triploid neuroblast<br />
differentiates into a triploid ganglionic cell and a diploid<br />
Schwann cell. According to the current model [3], it is<br />
the neuroblastoma cell which, in the course <strong>of</strong> their cellular<br />
differentiation process, start to express chemotactic, mitogenic<br />
and also differentiation-inducing factors and thus “attract”<br />
Schwann cells, prompting them to proliferate and differentiate<br />
[23, 25, 26]. In addition, Schwann cells have an<br />
antiproliferative effect on NBs while at the same time stimulating<br />
differentiation [3, 4, 30, 34]. These findings confirm<br />
the central role <strong>of</strong> Schwann cells in the maturation process.<br />
Prognostic impact <strong>of</strong> bone marrow clearing in stage 4<br />
patients<br />
Different approaches were used so far to investigate the prognostic<br />
value <strong>of</strong> tumor cell clearing in neuroblastoma patients.<br />
The techniques mainly used are based on immunological detection<br />
<strong>of</strong> GD2 stained cells using different detection systems.<br />
They range from conventional immunohistochemical detection<br />
assays [33], fluorescence microscopy [31] and a combined<br />
approach using fluorescence detection <strong>of</strong> the immunological<br />
target and subsequent FISH <strong>of</strong> unclear results [1,<br />
Modritz et al. in preparation]. Furthermore, RT-PCR was used<br />
to detect TH mRNA [17]. The different reports imply a similarity<br />
to the data in leukemia with their correlation between<br />
rapid bone marrow clearing and an increased probability <strong>of</strong><br />
survival [28, 38]. However, we have to keep in mind that the<br />
ideal time point to obtain insights into the dynamics <strong>of</strong> the<br />
disease has to be determined in large multi-centre studies.<br />
References<br />
1. Ambros IM, Benard J, Boavida M, et al<br />
(2003) Quality assessment <strong>of</strong> genetic<br />
markers used for therapy stratification.<br />
J Clin Oncol 21: 2077-2084<br />
2. Ambros IM, Zellner A, Roald B, et al<br />
(1996) Role <strong>of</strong> ploidy, chromosome 1p,<br />
and Schwann cells in the maturation <strong>of</strong><br />
neuroblastoma [see comments]. N Engl<br />
J Med 334:1505-1511<br />
3. Ambros IM, Ambros PF (2000) The role<br />
<strong>of</strong> Schwann cells in neuroblastoma. In:<br />
Brodeur GM, Sawada T, Tsuchida Y,<br />
Voute PA (eds) Neuroblastoma, Elsevier,<br />
Amsterdam, The Netherlands, pp 229-<br />
239
4. Ambros IM, Attarbaschi A, Rumpler, S,<br />
Luegmayr A, Turk<strong>of</strong> E, Gadner H, Ambros<br />
PF (2001): Neuroblastoma cells provoke<br />
Schwann cell proliferation in vitro. Med<br />
Pediatr Oncol 36:163-168<br />
5. Ambros PF, Ambros IM (2001) <strong>Pathology</strong><br />
and biology guidelines for resectable and<br />
unresectable neuroblastic tumors and bone<br />
marrow examination guidelines. Med<br />
Pediatr Oncol 37:492-504<br />
6. Ambros PF, Ambros IM, Kerbl R, et al<br />
(2001): Intratumoural heterogeneity <strong>of</strong> 1p<br />
deletions and MYCN amplification in neuroblastomas.<br />
Med Pediatr Oncol 36:1-4<br />
7. Ambros PF, Ambros IM, Strehl S, et al<br />
(1995) Regression and progression in<br />
neuroblastoma. Does genetics predict<br />
tumour behaviour Eur J Cancer<br />
31A:510-515<br />
8. Ambros P F, Mehes G, Ambros I M,<br />
Ladenstein R (2003) Disseminated tumor<br />
cells in the bone marrow - chances and<br />
consequences <strong>of</strong> microscopical detection<br />
methods. Cancer Lett 197:29-34<br />
9. Bown, N, Cotterill S, Lastowska M, et<br />
al (1999) Gain <strong>of</strong> chromosome arm 17q<br />
and adverse outcome in patients with<br />
neuroblastoma [see comments]. N Engl<br />
J Med 340:1954-1961<br />
10. Brodeur G M, Ambros PF (2000) Genetic<br />
and biological markers <strong>of</strong> prognosis in<br />
neuroblastoma. In: Brodeur GM, Sawada<br />
T, Tsuchida Y, Voute PA (eds) Neuroblastoma,<br />
Elsevier, Amsterdam, The Netherlands,<br />
pp 355-365<br />
11. Brodeur GM, Seeger RC, Schwab M,<br />
Varmus HE, Bishop JM (1984) Amplification<br />
<strong>of</strong> N-myc in untreated human neuroblastomas<br />
correlates with advanced disease<br />
stage. Science 224:1121-1124<br />
12. D’Angio GJ, Evans AE, Koop CE<br />
(1971) Special pattern <strong>of</strong> widespread<br />
neuroblastoma with a favourable prognosis.<br />
Lancet 1:1046-1049<br />
13. Ejeskar K, Aburatani H, Abrahamsson<br />
J, Kogner P, Martinsson T (1998) Loss<br />
<strong>of</strong> heterozygosity <strong>of</strong> 3p markers in neuroblastoma<br />
tumours implicate a tumoursuppressor<br />
locus distal to the FHIT gene.<br />
Br J Cancer 77:1787-1791<br />
14. Evans AE, Chatten J, D’Angio GJ,<br />
Gerson JM, Robinson J, Schnaufer L<br />
(1980) A review <strong>of</strong> 17 IV-S neuroblastoma<br />
patients at the Children’s Hospital<br />
<strong>of</strong> Philadelphia. Cancer 45: 833-839<br />
15. Guo C, White PS, Weiss MJ, Hogarty<br />
MD, et al (1999) Allelic deletion at<br />
11q23 is common in MYCN single copy<br />
neuroblastomas. Oncogene 18:4948-<br />
4957<br />
16. Hiyama E, Hiyama K, Ohtsu K,<br />
Yamaoka H, Ichikawa T, Shay JW,<br />
Yokoyama T (1997) Telomerase activity<br />
in neuroblastoma: is it a prognostic<br />
indicator <strong>of</strong> clinical behaviour Eur J<br />
Cancer 33:1932-1936<br />
17. Horibe K, Fukuda M, Miyajima Y,<br />
Matsumoto K, Kondo M, Inaba J,<br />
Miyashita Y (2001) Outcome prediction<br />
by molecular detection <strong>of</strong> minimal residual<br />
disease in bone marrow for advanced<br />
neuroblastoma. Med Pediatr<br />
Oncol 36:203-204<br />
18. Kogner P, et al (1994) Trk mRNA and<br />
low affinity nerve growth factor receptor<br />
mRNA expression and triploid DNA content<br />
in favorable neuroblastoma tumors.<br />
Prog Clin Biol Res 385:137-145<br />
19. Ladenstein R, Ambros IM, Potschger U,<br />
et al (2001) Prognostic significance <strong>of</strong><br />
DNA di-tetraploidy in neuroblastoma.<br />
Med Pediatr Oncol 36:83-92<br />
20. Lastowska M, Cotterill S, Bown N, et<br />
al (2002) Breakpoint position on 17q<br />
identifies the most aggressive neuroblastoma<br />
tumors. Genes Chromosomes Cancer<br />
34:428-36<br />
21. Look AT, Hayes FA, Shuster JJ, et al.<br />
(1991) Clinical relevance <strong>of</strong> tumor cell<br />
ploidy and N-myc gene amplification in<br />
childhood neuroblastoma: a Pediatric<br />
Oncology Group study. J Clin Oncol<br />
9:581-591<br />
22. Luttikhuis ME, Powell JE, Rees SA, et<br />
al (2001) Neuroblastomas with chromosome<br />
11q loss and single copy MYCN<br />
comprise a biologically distinct group<br />
<strong>of</strong> tumours with adverse prognosis. Br J<br />
Cancer 85:531-537<br />
23. Marchionni MA, Goodearl AD, Chen<br />
MS, et al (1993) Glial growth factors<br />
are alternatively spliced erbB2 ligands<br />
expressed in the nervous system [see<br />
comments]. Nature 362:312-318<br />
24. Maris JM, Weiss MJ, Mosse Y, et al<br />
(2002) Evidence for a hereditary neuroblastoma<br />
predisposition locus at chromosome<br />
16p12-13. Cancer Res<br />
62:6651-6658<br />
25. Minghetti L, Goodearl AD, Mistry K,<br />
Stroobant P (1996) Glial growth factors<br />
I-III are specific mitogens for glial cells.<br />
J Neurosci Res 43:684-693<br />
26. Morrissey TK, Levi AD, Nuijens A,<br />
Sliwkowski, MX, Bunge RP (1995)<br />
Axon-induced mitogenesis <strong>of</strong> human<br />
Schwann cells involves heregulin and<br />
p185erbB2. Proc Natl Acad Sci USA<br />
92:1431-1435<br />
27. Nakagawara A, et al (1993) Association<br />
between high levels <strong>of</strong> expression <strong>of</strong> the<br />
TRK gene and favorable outcome in<br />
human neuroblastoma. N Engl J Med<br />
328:847-854<br />
28. Panzer-Grumayer ER, Schneider M,<br />
Panzer S, Fasching K, Gadner H (2000)<br />
Rapid molecular response during early<br />
induction chemotherapy predicts a good<br />
outcome in childhood acute lymphoblastic<br />
leukemia. Blood 95:790-794<br />
29. Poremba C, Willenbring H, Hero B, et<br />
al (1999) Telomerase activity distinguishes<br />
between neuroblastomas with<br />
good and poor prognosis [In Process Citation].<br />
Ann Oncol 10:715-721<br />
30. Reynolds ML, Woolf CJ (1993) Reciprocal<br />
Schwann cell-axon interactions.<br />
Curr Opin Neurobiol 3:683-693<br />
31. Saarinen UM, Wikstrom S, Makipernaa<br />
A, et al (1996 In vivo purging <strong>of</strong> bone<br />
marrow in children with poor-risk neuroblastoma<br />
for marrow collection and<br />
autologous bone marrow transplantation.<br />
J Clin Oncol 14:2791-2802<br />
32. Seeger RC, Brodeur GM, Sather H,<br />
Dalton A, Siegel SE, Wong KY,<br />
Hammond D (1985) Association <strong>of</strong><br />
multiple copies <strong>of</strong> the N-myc oncogene<br />
with rapid progression <strong>of</strong> neuroblastomas.<br />
N Engl J Med 313:1111-1116<br />
33. Seeger RC, Reynolds CP, Gallego R,<br />
Stram DO, Gerbing RB, Matthay KK<br />
(2000) Quantitative tumor cell content<br />
<strong>of</strong> bone marrow and blood as a predictor<br />
<strong>of</strong> outcome in stage IV neuroblastoma:<br />
a Children’s Cancer Group Study.<br />
J Clin Oncol 18:4067-4076<br />
34. Snider WD (1994) Functions <strong>of</strong> the<br />
neurotrophins during nervous system<br />
development: what the knockouts are<br />
teaching us. Cell 77:627-638<br />
35. Spitz R, Hero B, Ernestus K, Berthold<br />
F (2003) Deletions in chromosome arms<br />
3p and 11q are new prognostic markers<br />
in localized and 4s neuroblastoma. Clin<br />
Cancer Res 9:52-58<br />
36. Spitz R, Hero B, Ernestus K, Berthold<br />
F (2003) Gain <strong>of</strong> distal chromosome arm<br />
17q is not associated with poor prognosis<br />
in neuroblastoma. Clin Cancer Res<br />
9:4835-4840<br />
37. Tsokos M, Scarpa S, Ross RA, Triche TJ<br />
(1987) Differentiation <strong>of</strong> human neuroblastoma<br />
recapitulates neural crest development.<br />
Study <strong>of</strong> morphology, neurotransmitter<br />
enzymes, and extracellular matrix proteins.<br />
Am J Pathol 128:484-96<br />
38. van Dongen JJ, Seriu T, Panzer-<br />
Grumayer ER, et al (1998) Prognostic<br />
value <strong>of</strong> minimal residual disease in<br />
acute lymphoblastic leukaemia in childhood.<br />
Lancet 352:1731-1738<br />
39. van Roy N, Laureys G, Van, GM, et al<br />
(1997) Analysis <strong>of</strong> 1;17 translocation<br />
breakpoints in neuroblastoma: implications<br />
for mapping <strong>of</strong> neuroblastoma<br />
genes. Eur J Cancer 33:1974-1978<br />
40. Vandesompele J, Van RN, Van GM, et<br />
al (1998) Genetic heterogeneity <strong>of</strong> neuroblastoma<br />
studied by comparative genomic<br />
hybridization. Genes Chromosomes<br />
Cancer 23:141-152<br />
41. Yamamoto K, Hanada R, Kikuchi A, et al<br />
(1998) Spontaneous regression <strong>of</strong> localized<br />
neuroblastoma detected by mass<br />
screening. J Clin Oncol 16:1265-1269
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Neuroblastoma: histoprognostic classification and handling <strong>of</strong><br />
material for biology – a challenge for the pathologist<br />
Klaus Beiske<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
Department <strong>of</strong> <strong>Pathology</strong>,<br />
Rikshospitalet,<br />
Oslo, Norway<br />
Abstract<br />
Peripheral neuroblastic tumors originate from immature elements <strong>of</strong> the sympathetic nerve system and are<br />
characterized by a striking morphological, biological and clinical heterogeneity. For about 100 years, pathologists<br />
could not reach an agreement on a comprehensible and prognostic significant classification system.<br />
This paper summarizes the contributions made by Hiroyuki Shimada, who proposed to link morphological<br />
differentiation and cellular turn-over (measured as the number <strong>of</strong> mitotic and karyorrhectic nuclei) to<br />
the patients age, and describes the further development <strong>of</strong> his system into the International Neuroblastoma<br />
<strong>Pathology</strong> Classification (INPC) <strong>of</strong> 1999 with a recent revision <strong>of</strong> 2003. Pathologists play now a key role in<br />
the handling <strong>of</strong> neuroblastic tumors based on macroscopic inspection. They are responsible for an adequate<br />
sampling and saving <strong>of</strong> material for morphological, biological and genetic investigations, while the results <strong>of</strong><br />
their microscopic assessment create the basis for a histoprognostic categorization beyond the subsets which<br />
presently are defined by biological/genetical markers.<br />
Key words: classification, genetical markers, neuroblastoma, pathology<br />
Introduction<br />
Neuroblastomas belong, together with ganglioneuro-blastomas<br />
and ganglioneuromas, to the group <strong>of</strong> peripheral neuroblastic<br />
tumors (pNTs) derived from sympa-thicoblasts (sympathetic<br />
neuroblasts), i.e. immature precursors <strong>of</strong> the sympathetic<br />
nervous system.<br />
They are considered as embryonic tumors originating<br />
either before or after birth from immature neural crest cells which<br />
are “left over” after normal organogenesis. Thus, the primary<br />
tumors are found in the same anatomical localization as their<br />
normal counterparts, i.e. in the adrenal medulla, and in sympathetic<br />
ganglia and paraganglia.<br />
PNTs are the most common extracranial solid malign<br />
tumors <strong>of</strong> childhood (1/10.000 births) and represent 15%<br />
<strong>of</strong> all malignant neoplasms occurring during the first four<br />
years <strong>of</strong> life [22]. 90% are diagnosed under the age <strong>of</strong> five<br />
years [18].<br />
The challenge <strong>of</strong> heterogeneity<br />
Since the sympathetic neuroblasts <strong>of</strong> embryonic origin display<br />
a restricted maturation capacity in individual tumors,<br />
pNTs are typified by an amazing heterogeneity, both with regard<br />
to the specter <strong>of</strong> histological phenotypes, biological properties<br />
and clinical behavior.<br />
Already the very first reports which were published<br />
during the three last decades <strong>of</strong> the 19 th and the beginning <strong>of</strong><br />
the 20 th century, outlined these neoplasms to comprise features<br />
<strong>of</strong> ganglioneuroma [16], neurocytoma/neuroblastoma<br />
[32] and ganglioneuroblastoma [21]. In 1934, Scherer reported<br />
on fully differentiated ganglioneuromas which contained nodules<br />
<strong>of</strong> either undifferentiated neuroblasts or differentiated<br />
ganglion cells, which he called “development centers” [23].<br />
Thirteen years later, Stout confirmed these observations and<br />
suggested the designation “composite” ganglioneuromas/neuroblastomas<br />
for this variant <strong>of</strong> pNT which today would be<br />
categorized as nodular ganglioneuroblastoma [28].<br />
Address for correspondence<br />
Klaus Beiske, MD, PhD<br />
Department <strong>of</strong> <strong>Pathology</strong><br />
Rikshospitalet<br />
Sognsvannsveien 20<br />
N-0027 Oslo, Norway<br />
Phone: +47 23 07 40 76<br />
Fax: +47 23 07 14 10<br />
E-mail: klaus.beiske@labmed.uio.no
74<br />
Biologically, subsets <strong>of</strong> pNTs, like neuroblastomas <strong>of</strong> stage<br />
4S, can show complete spontaneous regression by massive<br />
apoptosis [10], while others, e.g. those with MYCN amplification,<br />
display aggressive proliferation and are frequently diagnosed<br />
at advanced stages <strong>of</strong> disease [4]. A third variant could<br />
be defined as those which grow slowly achieving more or less<br />
complete maturation. As early as in 1926, Cushing and<br />
Wolbach proposed a sympathetic neuroblastoma to be able to<br />
transform into a ganglioneuroma after comparison <strong>of</strong> tumor<br />
material removed from the same patient with a time interval<br />
<strong>of</strong> 10 years [5]. This idea was later supported by a number <strong>of</strong><br />
reports [6, 7, 12, 30]. Several authors pointed out that more<br />
mature lesions were associated with higher age <strong>of</strong> the patient<br />
[9, 31]. It is not difficult to understand that tumors <strong>of</strong> such<br />
great morphological and biological diversity will present with<br />
various clinical pictures.<br />
Histoprognostic classification <strong>of</strong> neuroblastic tumors<br />
Histopathological classification systems are designed to define<br />
categories and subtypes <strong>of</strong> diseases on the basis <strong>of</strong> commonly<br />
accepted and recognizable morphological features. To<br />
make them applicable to surgical pathology, these categories/<br />
subtypes should ideally be equivalent to clinicopathological<br />
entities implying essential clinical information about prognosis<br />
and appropriate treatment. Considering the above outlined<br />
heterogeneity <strong>of</strong> pNTs, it is obvious that a comprehensible<br />
histoprognostical classification system, based on reproducible<br />
morphological criteria and conveying valuable clinical<br />
information, is not created in a trice for these tumors.<br />
The dilemma <strong>of</strong> ganglioneuroblastomas. Previous attempts<br />
to delimit prognostic categories <strong>of</strong> neuroblastomas and<br />
ganglioneuroblastomas, focused on the differentiation <strong>of</strong><br />
neuroblasts and proposed to list parameters as nuclear and<br />
nucleolar size, relative amount <strong>of</strong> eosinophilic cytoplasm, and<br />
formation <strong>of</strong> clumps, rosettes and/or cytoplasmic (nerve) processes<br />
in an either quantitative [2] or qualitative manner [17].<br />
Although ganglioneuromas were widely accepted as the most<br />
mature form within the specter <strong>of</strong> neuroblastic tumors, the<br />
relative amount <strong>of</strong> Schwannian stroma was not appreciated as<br />
a parameter <strong>of</strong> differentiation for less mature tumors like<br />
ganglioneuroblastomas before the early eighties <strong>of</strong> the 20th<br />
century. Nodules <strong>of</strong> undifferentiated neuroblasts or differentiated<br />
ganglion cells had indeed been recognized in<br />
ganglioneuroblastomas (see above), but rather vague designations<br />
as “development centers” or “composite” tumors indicated<br />
that the maturational relationship <strong>of</strong> these nodules to<br />
the surrounding ganglioneuromatous tissue was poorly understood.<br />
Some were even interpreted as a sign <strong>of</strong> focal partial<br />
or focal complete differentiation [2]. The search for a basic<br />
agreement to the entity <strong>of</strong> ganglioneuroblastoma was further<br />
hampered by a lack <strong>of</strong> commonly accepted histological<br />
criteria for this tumor: Some included neuroblastomas with a<br />
high degree <strong>of</strong> gangliocytic differentiation, while others required<br />
a substantial amount <strong>of</strong> ganglioneuromatous tissue<br />
between foci <strong>of</strong> differentiating neuroblasts [12]. Thus, a<br />
histoprognostic classification <strong>of</strong> ganglioneuroblastomas fell<br />
between two stools, i.e. immature neuroblastomas on one side<br />
and mature ganglioneuromas on the other.<br />
The Shimada Classification<br />
The credit for the first histoprognostical classification system<br />
which includes all peripheral neuroblastic tumors, goes to<br />
Hiroyuki Shimada [26].<br />
Histomorphological differentiation and MKI<br />
Shimada recognized the amount <strong>of</strong> Schwannian stroma in neuroblastic<br />
tumors as a major criterium to distinguish between<br />
immature (i.e. Schwannian stroma-poor) and mature (i.e.<br />
Schwannian stroma-rich) lesions.<br />
The stroma-poor group was further subdivided into undifferentiated<br />
and differentiating tumors depending on whether<br />
the tumor contains less or more than 5% gangliocytic differentiated<br />
neuroblasts. This distinction represented a modification<br />
<strong>of</strong> the prognostic system originally proposed by Beckwith<br />
and Martin for neuroblastic tumors. As a measure <strong>of</strong> aggressive<br />
behavior <strong>of</strong> tumor cells in the stroma-poor group, Shimada<br />
proposed to analyse the mitosis-karyorrhexis index (MKI),<br />
i.e. the percentage <strong>of</strong> mitotic and karyorrhectic nuclei per 5000<br />
tumor cells. He found that an MKI <strong>of</strong> 4% as high. Mitotic and<br />
karyorrhectic cells were summed up in one index because it<br />
was not always possible to distinguish between both phenomena<br />
on light microscopic grounds (Fig. 1).<br />
The stroma-rich group contained three subgroups: (a)<br />
stroma-rich well differentiated tumors consisting mainly <strong>of</strong><br />
ganglioneuromatous tissue with few immature neuroblastic<br />
cells, (b) stroma-rich intermixed tumors with nests <strong>of</strong> variably<br />
differentiated neuroblastic cells, and (c) stroma-rich nodular<br />
tumors with <strong>of</strong>ten grossly visible, hemorrhagic nodules <strong>of</strong><br />
stroma-poor neuroblastoma displaying microscopically pushing<br />
borders towards the surrounding stroma-rich tissue.<br />
Shimada pointed out that his stroma-poor group overlaps with<br />
tumors called by others “classical neuroblastoma” and “diffuse<br />
ganglioneuroblastoma”, while the stroma-rich group corresponds<br />
to tumors previously called “ganglioneuroblastoma” and<br />
“immature ganglioneuroma”.<br />
Fig. 1 Undifferentiated neuroblastoma with area <strong>of</strong> high MKI. Karyorrhectic<br />
cells <strong>of</strong>ten show condensed eosinophilic cytoplasm and hyperchromatic,<br />
fragmented nuclei. Round nuclei with a regular outer border might be lymphocytes<br />
and are not accepted as karyorrhectic.
75<br />
Age<br />
In his original paper <strong>of</strong> 1984, Shimada applied these morphological<br />
criteria on histological sections from 295 neuroblastomas<br />
and ganglioneuroblastomas recruited from two American,<br />
one Japanese and one British center. When looking at the<br />
distribution <strong>of</strong> the stroma-poor and stroma-rich groups and<br />
subgroups according to the patients age at diagnosis, he found<br />
that stroma-rich tumors had their debut at a relatively higher<br />
age, i.e. the stroma-rich intermixed and nodular ones mainly<br />
between two and five years, and stroma-rich well differentiated<br />
ones at the age <strong>of</strong> five years and older. These findings<br />
confirmed previous observations (see above) and supported<br />
the idea that the immature elements in the non-aggressive variants<br />
<strong>of</strong> these embryonic tumors have the capability to mature<br />
into benign ganglioneuromas over a certain number <strong>of</strong> years.<br />
On the other hand, a disturbance (e.g. delay) <strong>of</strong> this<br />
“normal” sequence <strong>of</strong> maturation could probably forebode a<br />
tumor which because <strong>of</strong> its restricted maturation capacity will<br />
persist at an immature, biologically more aggressive stage.<br />
Shimada found strong support also for this hypothesis when<br />
he compared the age distribution <strong>of</strong> patients with stroma-poor<br />
tumors to MKI and clinical outcome. The majority <strong>of</strong> undifferentiated<br />
and differentiated stroma-poor tumors with low<br />
MKI diagnosed under the age <strong>of</strong> 1,5 year had a favorable outcome,<br />
while almost all undifferentiated tumors with low MKI<br />
diagnosed at >1,5 years killed the patients. Stroma-poor tumors<br />
with high MKI had a bad outcome, and the majority<br />
occurred in children older than 1,5 year. All children with<br />
stroma-poor tumors diagnosed at >5 years died.<br />
The stroma-rich intermixed and well differentiated subgroups<br />
occurred in children older than 2 and 5 years, respectively,<br />
and almost all showed a favorable outcome. In contrast,<br />
most <strong>of</strong> the stroma-rich nodular tumors had an unfavorable<br />
prognosis, irrespective <strong>of</strong> their occurrence at the “correct”<br />
age <strong>of</strong> 2-5 years. It seemed probable that the stromapoor<br />
nodules could represent a malignant outgrowth <strong>of</strong> biologically<br />
more aggressive clones within an otherwise maturing<br />
stroma-rich tumor.<br />
Taken together, Shimada was the first to prove the usefulness<br />
<strong>of</strong> a classification based on a combination <strong>of</strong><br />
histomorphology (i.e. the relative amount <strong>of</strong> Schwannian<br />
stroma and gangliocytic differentiation), MKI and age at diagnosis<br />
and concluded that<br />
“1) the prognosis <strong>of</strong> the patients under 1,5 years old is directly<br />
influenced by the MKI regardless <strong>of</strong> the degree <strong>of</strong> maturation,<br />
2) the prognosis <strong>of</strong> the patients between 1,5 and 5 years old is<br />
influenced both by the degree <strong>of</strong> maturation and the MKI,<br />
3) the prognosis <strong>of</strong> the patients over 5 years old is poor regardless<br />
<strong>of</strong> the degree <strong>of</strong> maturation and/or the MKI.”<br />
Modifications <strong>of</strong> the Shimada classification<br />
In 1992, Joshi [12] searched to combine the conventional (pre-<br />
Shimada) terminology <strong>of</strong> neuroblastic tumors with the prognostic<br />
categories <strong>of</strong> the Shimada classification and suggested<br />
the following changes/additions:<br />
(1) The stroma-poor tumors <strong>of</strong> Shimada should be called<br />
neuroblastomas and defined as tumors with a neuroblastic<br />
component <strong>of</strong> >50% <strong>of</strong> the total tumor area.<br />
(2) Shimadas stroma-poor differentiated tumors should be<br />
splitted up into poorly differentiated neuroblastomas<br />
(containing neuropil and 5% differentiated<br />
neuroblasts).<br />
(3) Shimadas stroma-rich tumors should be called<br />
ganglioneuroblastoma, nodular, intermixed and borderline<br />
and should be defined as tumors containing >50%<br />
ganglioneuromatous tissue. The borderline type was<br />
meant to replace Shimadas stroma-rich well differentiated<br />
type.<br />
(4) Tumors with equal amounts <strong>of</strong> neuroblastic and<br />
ganglioneuromatous components should be called “transitional<br />
neuroblastic tumors”. The term “unclassifiable<br />
neuroblastic tumor” should be reserved for tumors where<br />
the histological assessment was hampered by necrosis,<br />
hemorrhage, calcification, crush artifacts, cystic changes,<br />
and poor fixation/processing.<br />
Interestingly, Joshi also performed a histoprognostic categorization<br />
<strong>of</strong> the nodules in nine nodular ganglioneuroblastomas<br />
(see below), without being able to show any significant impact<br />
on the survival <strong>of</strong> these few patients.<br />
In other publications, he proposed a histological grading<br />
system based on the presence/absence <strong>of</strong> calcification and<br />
level <strong>of</strong> mitotic rate (MR) [13] which he later modified by<br />
replacing MR with MKI [15]. By combining these (modified)<br />
histological grades with the patients age, he defined (modified)<br />
low and high risk groups independent <strong>of</strong> the morphological<br />
differentiation.<br />
The International Neuroblastoma <strong>Pathology</strong><br />
Classification (INPC)<br />
In 1994, the International Neuroblastoma <strong>Pathology</strong> Committee<br />
was established with the goal to achieve a “standardization<br />
<strong>of</strong> terminology and morphologic criteria <strong>of</strong> neuroblastic<br />
tumors and establishment <strong>of</strong> a morphologic classification that<br />
is prognostically significant, biologically relevant, and reproducible”<br />
[24]. Both Shimada and Joshi were members <strong>of</strong> this<br />
committee, and the proposed classification represents by and<br />
large the original Shimada system <strong>of</strong> 1984 with a few modifications,<br />
some proposed previously by Joshi (see above), and<br />
some performed by the committee.<br />
Morphological categorization<br />
The following categories and subtypes <strong>of</strong> peripheral neuroblastic<br />
tumors were listed:<br />
1. Neuroblastoma (Schwannian Stroma-Poor)<br />
Definition: PNT with 50% or less Schwannian stroma<br />
a. undifferentiated subtype<br />
consists <strong>of</strong> small-to-medium sized neuroblasts without<br />
neuritic processes (neuropil) or gangliocytic<br />
differentiation (Fig. 2). Scattered or foci <strong>of</strong> large or<br />
pleomorphic-anaplastic cells occur infrequently.
76<br />
The diagnosis <strong>of</strong> this subtype <strong>of</strong> pNT may pend on ancillary<br />
techniques as e.g. immunohistology (NSE, CD56, tyrosine<br />
hydroxylase, synaptophysin, chromogranin A and markers to<br />
exclude myogenic tumors, primitive neuroectodermal tumors/<br />
Ewing sarcoma and lymphomas), cytogenetics and elevated<br />
urinary levels <strong>of</strong> metabolites <strong>of</strong> catecholamine synthesis.<br />
b. poorly differentiated subtype<br />
consists <strong>of</strong> neuroblasts and neuropil. Less than 5% <strong>of</strong><br />
neuroblasts show gangliocytic differentiation (Fig. 3).<br />
Scattered or foci <strong>of</strong> large or pleomorphic-anaplastic<br />
cells occur infrequently.<br />
c. differentiating subtype<br />
consists <strong>of</strong> neuroblasts and neuropil. 5% or more <strong>of</strong><br />
neuroblasts show synchronous gangliocytic<br />
differentiation (Fig. 4), i.e. enlarged, eccentric nucleus,<br />
vesicular chromatin pattern, prominent nucleolus and<br />
increased amount <strong>of</strong> cytoplasm (total cell diameter<br />
larger than twice the nuclear diameter). Areas <strong>of</strong><br />
Schwannian stroma can be seen at the periphery <strong>of</strong> tumor<br />
(transitional zone), but do not exceed 50% <strong>of</strong> the<br />
tumor area.<br />
2. Ganglioneuroblastoma, intermixed (Schwannian<br />
Stroma-Rich)<br />
Definition: pNT with >50% ganglioneuromatous tissue which<br />
includes sharply defined nests <strong>of</strong> neuroblastic tissue (Fig. 5)<br />
containing neuropil and a mixture <strong>of</strong> differentiating neuroblasts<br />
and and maturing ganglion cells (Fig. 6).<br />
3. Ganglioneuroma (Schwannian Stroma-Dominant)<br />
a. Ganglioneuroma, maturing subtype<br />
consists <strong>of</strong> >50% ganglioneuromatous tissue with scattered<br />
differentiating neuroblasts, maturing and mature<br />
ganglion cells which never lie in sharply demarcated<br />
nests (Fig. 7). This subtype corresponds to Shimadas<br />
stroma-rich, well differentiated [26] and Joshis<br />
ganglioneuroblastoma, borderline.<br />
b. Ganglioneuroma, mature subtype<br />
consists <strong>of</strong> mature Schwannian stroma with fascicular<br />
neuritic processes and mature ganglion cells<br />
(Fig. 8). Neuroblasts are no longer present.<br />
Fig. 2 The undifferentiated subtype <strong>of</strong> neuroblastoma consists <strong>of</strong> small-tomedium<br />
sized cells without neuritic processes or gangliocytic differentiation.<br />
Fig. 3 In the poorly differentiated subtype, the neuroblasts are surrounded by<br />
a fibrillary meshwork <strong>of</strong> neuritic processes (neuropil). A few cells (50% Schwannian<br />
stroma which includes sharply defined nests <strong>of</strong> neuroblastic tissue.
77<br />
4. Ganglioneuroblastoma, Nodular (Composite Schwannian<br />
Stroma-Rich/Stroma-Dominant and Stroma-<br />
Poor)<br />
Definition: pNT with a stroma-rich (like in ganglioneuro-blastoma,<br />
intermixed) or strom-dominant (like in ganglioneuroma,<br />
maturing) component which surrounds macroscopically visible,<br />
<strong>of</strong>ten hemorrhagic nodules <strong>of</strong> a neuroblastic, stroma-poor<br />
component (Fig. 9 a and b), regarded as a more aggressive<br />
clone. The nodule(s) show either pushing borders (Fig. 10) or<br />
a more infiltrative pattern towards the stroma-rich component.<br />
It is important to be aware <strong>of</strong> the possibility that a surgical<br />
biopsy may only contain a small rim <strong>of</strong> stroma-rich tissue<br />
around the nodule, i.e. the stroma-rich part will not necessarily<br />
make up >50% <strong>of</strong> the visible tumor area.<br />
5. Terminology for not completely classifiable pNTs<br />
a. Neuroblastoma (Schwannian Stroma-Poor), NOS<br />
is reserverd for tumors which clearly belong to the category<br />
<strong>of</strong> Schwannian stroma-poor pNT, but which can<br />
not be allocated to any subtype because <strong>of</strong> poor quality<br />
<strong>of</strong> the sections, bleeding, cystic degeneration, necrosis,<br />
crush artifact or diffuse calcification.<br />
Fig. 6 The neuroblastomatous nests <strong>of</strong> ganglioneuroblastoma, intermixed,<br />
contain differentiating neuroblasts, maturing ganglion cells and neuropil.<br />
b. Ganglioneuroblastoma, NOS<br />
is applied to a stroma-rich tumor which extensive calcification<br />
which may obscure a stroma-poor nodule.<br />
c. Neuroblastic tumor, unclassifiable<br />
is recommended for a pNT which cannot be allocated<br />
to any <strong>of</strong> the categories listed above. This may e.g apply<br />
to very small biopsies.<br />
Prognostic categorization<br />
In order to (1) test the consensus between the committee members<br />
to recognize the above listed morphological categories<br />
and (2) identify the most powerful system for prognostic<br />
categorization, the committee reviewed 227 cases <strong>of</strong> pNTs<br />
[25] and compared the original Shimada system (based on<br />
morphology, MKI and age) with Joshi’s histological grades<br />
(based on MR and calcification), risk groups (based on histological<br />
grade and age) and their modifications replacing MR<br />
with MKI, which can only be used for prognostic analysis <strong>of</strong><br />
stroma-poor tumors. The combination <strong>of</strong> morphology, MKI<br />
and age, originally proposed by Shimada, had the strongest<br />
impact on prognosis, measured as event free survival (EFS).<br />
The statistical analysis also confirmed the age <strong>of</strong> 1,5 years as<br />
the borderline <strong>of</strong> greatest prognostic significance. Beyond the<br />
age <strong>of</strong> 5 years, all stroma-poor tumors had a bad outcome.<br />
Consequently, the International Neuroblastoma <strong>Pathology</strong><br />
Committee included age and MKI, but not MR and calcification<br />
as relevant prognostic data for stroma-poor tumors<br />
into the new classification.<br />
The MKI can be determined applying a method previously<br />
proposed by Joshi [14] It is based on the initial estimation<br />
<strong>of</strong> cell density in different areas <strong>of</strong> a given tumor (Low:<br />
100-300, Moderate: 300-600, High: 600-900 cells per high<br />
power field (HPF) <strong>of</strong> 400x magnification) and the subsequent<br />
definition <strong>of</strong> the number HPFs which are required to evaluate<br />
5000 tumor cells. The MKI is reported as one <strong>of</strong> three classes<br />
(low, intermediate, high) according to the definitions originally<br />
given by Shimada [26].<br />
Fig. 7 Ganglioneuroma, maturing subtype, contains >50% Schwannian stroma<br />
and single or small aggregates <strong>of</strong> differentiating neuroblasts, and maturing/mature<br />
ganglion cells, but no neuropil.<br />
Fig. 8 Ganglioneuroma, mature subtype, consists <strong>of</strong> abundant Schwannian<br />
stroma and scattered mature ganglion cells.
78<br />
Fig. 9 In ganglioneuroblastoma,<br />
nodular, a ganglioneuromatous<br />
component surrounds nodule(s) <strong>of</strong><br />
neuroblastic stroma-poor tumor<br />
tissue (a). Note lack <strong>of</strong> protein S-<br />
100-positive Schwannian stroma<br />
innside the nodule (b).<br />
Fig. 10 The neuroblastic nodule (left) shows pushing borders by compressing<br />
the surrounding ganglioneuromatous tissue (right).<br />
Table 1 shows the prognostic allocation <strong>of</strong> the morphological<br />
categories and subtypes <strong>of</strong> pNTs as recommended in the INPC.<br />
The process <strong>of</strong> reaching a final histoprognostic conclusion<br />
according to differentiation, MKI and age may appear confusing<br />
to the inexperienced. For newcomers, it can be recommended<br />
to learn the favorable categories by heart because their<br />
number is quite low: poorly differentiated and differentiating<br />
tumors with low and intermediate MKI below 1,5 years, and<br />
differentiating neuroblastoma with low MKI between 1,5 and<br />
5 years. All other neuroblastomas are actually unfavorable.<br />
Similar to the Shimada classification <strong>of</strong> 1984, Schwannian<br />
stroma-rich and dominant tumors have a favorable prognosis<br />
unrelated to the patient’s age, except for nodular<br />
ganglioneuroblastomas which all are ascribed an unfavorable<br />
outcome.<br />
Revision <strong>of</strong> the International Neuroblastoma <strong>Pathology</strong><br />
Classification (INPC)<br />
Both Joshi [12] and the International Neuroblastoma <strong>Pathology</strong><br />
Committee [24, 25] mentioned the possibility <strong>of</strong> performing<br />
a prognostic grading <strong>of</strong> nodular ganglioneuroblastoma<br />
(GNBn) on the basis <strong>of</strong> the stroma-poor nodule(s) since this<br />
component <strong>of</strong> the tumor had been regarded as the malignant<br />
one already many years ago [28]. However, the number <strong>of</strong><br />
GNBns in their reviews was too small.<br />
Umehara et al. [29] were the first to review 70 GNBns<br />
and to perform a prognostic categorization by analyzing the<br />
nodule(s) according to the above detailed criteria <strong>of</strong> the INPC<br />
for neuroblastomatous tumors (morphology and MKI) and<br />
relating their data to the patients’ age. These authors also described<br />
GNBns with single or multiple nodules and variant<br />
forms which (1) consisted mainly <strong>of</strong> the stroma-poor component<br />
surrounded only by a thin, microscopically visible rim<br />
<strong>of</strong> stroma-rich/-dominant tissue, and (2) only showed<br />
ganglioneuromatous tissue in the primary tumor (probably due<br />
to poor sampling), but a neuroblastomatous component at the<br />
metastatic site. Depending on the presence <strong>of</strong> nodule(s) <strong>of</strong> the<br />
favorable or unfavorable category, favorable (32,4%) and unfavorable<br />
(67,7%) subsets <strong>of</strong> GNBn were established which<br />
showed statistically significant differences in event free survival<br />
and survival, quite similar to neuroblastic tumors.<br />
In 2003, The International Neuroblastoma <strong>Pathology</strong> Committee<br />
reviewed the same cohort <strong>of</strong> tumors and confirmed these<br />
results [20]. A revision <strong>of</strong> the INPC was proposed including<br />
the following terms: GNBn, classic, containing one nodule;<br />
and variant forms containing either multiple nodules, large<br />
nodules or no nodule, but a metastatic stroma-poor tumor.<br />
Unfavorable prognosis was defined by the demonstration <strong>of</strong><br />
at least one nodule displaying features <strong>of</strong> the unfavorable INPC<br />
categories <strong>of</strong> neuroblastomatous tumors.<br />
The acceptance <strong>of</strong> a large nodule as a variant <strong>of</strong> GNBn<br />
touches on one <strong>of</strong> the principles <strong>of</strong> the former INPC, which<br />
claimed that a tumor belonging to the stroma-rich or -dominant<br />
category has to be made up by >50% Schwannian stroma<br />
(see above). It is important for pathologists to be aware <strong>of</strong> all<br />
variants <strong>of</strong> GNBn because they were two times more frequent<br />
than the classic form among the cases reviewed by Umehara<br />
and Peuchmaur.<br />
The greatest advantage <strong>of</strong> this INPC revision, however,<br />
is brought by the recognition <strong>of</strong> a subset (about 30%)<br />
<strong>of</strong> nodular ganglioneuroblastomas which, in contrast to previous<br />
thinking, belong to a prognostic favorable category<br />
which might benefit from a milder therapeutic regime.
79<br />
Table 1<br />
International Neuroblastoma <strong>Pathology</strong> Classification (INPC). Assignment <strong>of</strong> morphological categories/subtypes to prognostic<br />
categories according to MKI and age (modified from Shimada et al. [25])<br />
Neuroblastoma<br />
Schwannian stroma-poor<br />
favorable<br />
5 yrs all tumors<br />
Ganglioneuroblastoma, intermixed<br />
favorable independent from age<br />
Ganglioneuroma<br />
maturing<br />
mature<br />
favorable independent from age<br />
Ganglioneuroblastoma, nodular<br />
Figure 11 shows the morphologic and prognostic categories<br />
<strong>of</strong> the revised INPC.<br />
Handling <strong>of</strong> tumor material for biological investigations<br />
Schwannian stroma-rich<br />
Schwannian stroma-dominant<br />
composite Schwannian stroma-rich/<br />
stroma-dominant and stroma-poor<br />
Independent from the above outlined endeavor <strong>of</strong> pathologists<br />
towards a clinically informative histoprognostic classification<br />
system for pNTs, a growing number <strong>of</strong> biological and genetic<br />
alterations has been discovered in these tumors during the past<br />
two decades which today allow an assignment to low-, intermediate-<br />
and high-risk groups [3]. The prognostic most important<br />
ones are still MYCN/1p status and ploidy. It is not<br />
possible to enter a child with a neuroblastic tumor into any <strong>of</strong><br />
the current European clinical protocols without at least knowledge<br />
about MYCN, analyzed by Southern blot and/or fluorescence<br />
in situ hybridization (FISH).<br />
Since many <strong>of</strong> these investigations either require or<br />
are most easily performed on unfixed tumor tissue, additional<br />
tasks have to be assumed by pathologists who usually are the<br />
first in the hospital to receive fresh tumor tissue from the operating<br />
theatre.<br />
The various procedures for handling samples <strong>of</strong> neuroblastic<br />
tumors were in detail described by Ambros PF and<br />
Ambros IM [1], and will not be repeated here. The most central<br />
functions <strong>of</strong> the pathologist can be summed up in the following<br />
three key words: sampling, saving and microscopical<br />
evaluation.<br />
Sampling. Taking into account the great morphological<br />
heterogeneity <strong>of</strong> these tumors, it is obvious that the pathologist,<br />
prior to any fixation, should cut the tumor into slices<br />
searching for e.g. nodules or hemorrhagic areas. It is important<br />
to take samples from every macroscopic variant, and this<br />
should proceed under sterile conditions if some <strong>of</strong> the material<br />
is planned to be used for culturing.<br />
The further sub-sampling <strong>of</strong> any macroscopic area,<br />
being <strong>of</strong> interest for special investigations, follows a back-toback<br />
principle, i.e. a representative piece designated for paraffin<br />
embedding should be used to produce at least 10 imprints<br />
from a fresh cut surface (for e.g. FISH or static ploidy<br />
analysis) before fixation in formalin. The two most closely<br />
neighbored (“opposite”) tissue slices should be snap frozen<br />
(for e.g. extraction <strong>of</strong> DNA, RNA and proteins, immunohistology<br />
requiring unfixed tissue and interphase cytogenetics if<br />
imprints were not freshly taken) and put into a sterile culture<br />
medium (for e.g flow cytometry, conventional cytogenetics<br />
and culturing), respectively.<br />
Saving. The adequate saving <strong>of</strong> the samples depends<br />
on the individual pathologists knowledge about the techniques<br />
which are required for the most essential biological investigations.<br />
Thus, imprints should be air dried over night and then<br />
kept frozen in air-tight containers at -80º. Snap frozen tissue<br />
should also be stored at -80º, or in liquid nitrogen if preservation<br />
<strong>of</strong> RNA is intended. Frozen tissue cannot be used for<br />
conventional cytogenetics. Tissue planned to be analyzed by<br />
cytogenetics and flow cytometry, should be brought as soon<br />
as possible in phosphate buffered saline or culture medium to<br />
analysis, although it is possible to recover nuclei for FISH<br />
and flow cytometry from paraffin embedded tissue if fresh<br />
material is not available.
80<br />
Fig. 11 International Neuroblastoma <strong>Pathology</strong> Classification (INPC) (revised form). Morphological and prognostic categories. FH: favorable histology; UH:<br />
unfavorable histology; GNBn: ganglioneuroblastoma, nodular; MKI: mitosis-karyorrhexis index. The prognostic categorization <strong>of</strong> GNBn is performed by<br />
evaluating the neuroblastomatous component in the nodule(s) according to the criteria for neuroblastomas (modified from Peuchmaur et al., 2003).<br />
Microscopical evaluation. The pathologist should not only<br />
analyze morphology and MKI for the histoprognostic classification,<br />
but also use the microscope for estimation <strong>of</strong> the tumor<br />
cell content in the material designed for biological investigations.<br />
Thus, microscoping a paraffin section from the tissue<br />
sample which was used for imprinting prior to fixation,<br />
will provide important information about the possible percentage<br />
<strong>of</strong> tumor cells, non-tumor cells (e.g. lymphocytes or<br />
stroma) and necrosis which might influence the representativity<br />
<strong>of</strong> the imprint. A microscopic analysis <strong>of</strong> the tumor cell content<br />
performed on frozen sections from the material which is<br />
intended to be used e.g. for PCR <strong>of</strong> the 1p36.3 region, is even<br />
more demanded because the correct interpretation <strong>of</strong> the PCR<br />
result requires a tumor cell content <strong>of</strong> at least 70%.<br />
It is obvious that the pathologist who is in charge <strong>of</strong><br />
handling samples from neuroblastic tumors, plays a central<br />
role in providing adequate material for biological analyses.<br />
Prognostic categorization by INPC and biological<br />
markers – competing or complementary systems<br />
It has been known for many years that MYCN amplification<br />
in neuroblastomas is a strong indicator <strong>of</strong> aggressive tumor<br />
behavior [4], and <strong>of</strong>ten associated with undifferentiated morphology<br />
and increased MKI [27]. One might therefore be<br />
tempted to ask whether the histoprognostic categorization provided<br />
by the INPC could be replaced by the analysis <strong>of</strong> MYCN.<br />
The correlation between INPC categorization and<br />
MYCN status was investigated by Goto et al. [8] in a large<br />
cohort <strong>of</strong> 628 patients with neuroblastic tumors. As expected,<br />
97,7% <strong>of</strong> tumors with favorable histology (FH) were MYCN<br />
non-amplified, while 93,2% <strong>of</strong> MYCN amplified tumors<br />
showed an unfavorable histology (UH). However, the comparison<br />
<strong>of</strong> MYCN status and INPC categories revealed a third<br />
and surprisingly large group <strong>of</strong> tumors with UH but without<br />
MYCN amplification. As shown in Fig. 12, the prognosis <strong>of</strong><br />
this group was intermediate to FH/non-amplified and UH/<br />
amplified tumors, and the difference in EFS between all three<br />
groups was statistically significant.<br />
The majority <strong>of</strong> UH, non-amplified tumors were observed<br />
at stage 3 and 4 in children older than one year. The<br />
results <strong>of</strong> this investigation demonstrate that the<br />
histoprognostic INPC categorization is able to identify a substantial<br />
number <strong>of</strong> patients who, in spite <strong>of</strong> normal MYCN<br />
status, belong to a group <strong>of</strong> inferior prognosis, and it appears<br />
relevant to ask whether this category <strong>of</strong> patients should be<br />
<strong>of</strong>fered a modified form <strong>of</strong> therapy.<br />
Further support to this notion comes from the recently<br />
completed histopathological review <strong>of</strong> 124 stage 2A and 2B<br />
MYCN non-amplified trial patients who were treated with<br />
surgery alone according to the LNESG (Localised Neuroblastoma<br />
European Study Group) protocol 94.01 (Navarro et al.,<br />
in preparation). The review was performed according to the<br />
INPC by the seven members <strong>of</strong> the SIOP European Neuroblastoma<br />
(SIOPEN) <strong>Pathology</strong> Reference Panel (Gabriele<br />
Amann, Klaus Beiske, Catherine Cullinane, Emanuele<br />
D’Amore, Claudio Gambini, Sam Navarro, Michel<br />
Peuchmaur), and assigned 20% <strong>of</strong> these MYCN-negative tumors<br />
to the unfavorable category. The difference in event free<br />
and overall survival between the favorable and unfavorable<br />
subset was statistically significant and underlines the importance<br />
<strong>of</strong> the INPC as a valuable tool for prognostic categorization<br />
<strong>of</strong> localized, MYCN non-amplified tumors.<br />
In the forthcoming LNESG2 study, these results have<br />
already influenced the therapeutic design in case <strong>of</strong> relapse <strong>of</strong><br />
the localized tumor. It has been decided that the relapse will
81<br />
receive chemotherapy if the histoprognostic categorization <strong>of</strong><br />
the primary tumor was unfavorable, while the relapse <strong>of</strong> a<br />
histologically favorable tumor will be treated with surgery<br />
alone. However, according to the new protocol, the primary<br />
tumor’s histoprognostic category will only be implied into<br />
therapeutic decisions for a relapse, if the histological slides <strong>of</strong><br />
the primary have been reviewed by one <strong>of</strong> the members <strong>of</strong> the<br />
SIOPEN <strong>Pathology</strong> Reference Panel within six weeks after<br />
the local pathologist finished his/her report. It is mandatory<br />
that the decision about favorable or unfavorable histoprognosis<br />
<strong>of</strong> the localized tumor is based on at least two pathologists<br />
from different institutions. If the local pathologist can not agree<br />
to the conclusion made by the first reviewer, another member<br />
<strong>of</strong> the SIOPEN <strong>Pathology</strong> Reference Panel will be contacted<br />
for a third opinion.<br />
Summary<br />
Pathologists are today ascribed a key role in the diagnostic<br />
work up <strong>of</strong> pNTs:<br />
1. After macroscopic inspection, pathologists are responsible<br />
for an adequate sampling, saving and quality control <strong>of</strong> tumor<br />
material for morphological, biological and genetic investigations.<br />
2. The result <strong>of</strong> the pathologist’s microscopic analysis assigns<br />
a tumor to one <strong>of</strong> five morphological categories which in case<br />
<strong>of</strong> stroma-rich/-dominant tumors (except for nodular<br />
ganglioneuroblastomas) render the analysis <strong>of</strong> biological markers<br />
irrelevant.<br />
The determination <strong>of</strong> morphological differentiation and<br />
MKI enables the pathologist to categorize the<br />
neuroblastomatous tumors and nodular ganglioneuroblastoma<br />
into favorable or unfavorable subsets which will influence the<br />
choice <strong>of</strong> therapy <strong>of</strong> a possible relapse in those patients who<br />
are enrolled into the forthcoming European protocol for localized,<br />
non- MYCN amplified peripheral neuroblastic tumors.<br />
Finally, the great importance <strong>of</strong> obtaining biopsy material,<br />
which is adequate for histoprognostic assessment, cannot<br />
be stressed enough. Cytological specimens <strong>of</strong> tumor cells,<br />
produced from fine needle aspirates, can be used for biological<br />
analyses - provided that a pathologist has controlled their<br />
tumor cell content -, but such samples preclude any<br />
histoprognostic evaluation. The biological information <strong>of</strong> a<br />
MYCN non-amplified status, obtained from cytological<br />
samples, should not make the clinician live in the belief that<br />
this is a tumor <strong>of</strong> good prognosis. Data by Goto et al [8] and<br />
Navarro et al [19], summarized in this paper, provide clear<br />
evidence that MYCN non-amplified tumors may “hide” a<br />
considerable proportion <strong>of</strong> cases with unfavorable outcome.<br />
Fig. 12 Event free survival for patients grouped according to FH (favorable<br />
histology), UH (unfavorable histology) and MYCN status (modified from<br />
Goto et al., 2001).<br />
References<br />
1. Ambros PF, Ambros IM (2001) <strong>Pathology</strong><br />
and biology guidelines for respectable<br />
and unresectable neuroblastic<br />
tumors and bone marrow examination<br />
guidelines. Med Pediatr Oncol<br />
37:492-504<br />
2. Beckwith JB, Martin RF(1968) Observations<br />
on the histopathology <strong>of</strong> neuroblastoma.<br />
J Pediatr Surg 3:106-110<br />
3. Brodeur GM (2003) Neuroblastoma:<br />
biological insights into a clinical<br />
enigma. Nat Rev Cancer 3(3):203-216<br />
4. Brodeur GM, Seeger RC, Schwab M,<br />
Varmus HE, Bishop JM (1984) Amplification<br />
<strong>of</strong> N-myc in untreated human<br />
neuroblastomas correlates with advanced<br />
stage <strong>of</strong> disease. Science<br />
224:1121-1124<br />
5. Cushing H, Wolbach SB (1927) Transformation<br />
<strong>of</strong> malignant paravertebral<br />
sympathicoblastoma into benign ganglioneuroma.<br />
Am J Pathol 3:203-216<br />
6. Everson TC (1964) Spontaneous regression<br />
<strong>of</strong> cancer. Ann N Y Acad Sci<br />
114:767-770<br />
7. Fox F, Davidson J, Thomas LB (1959)<br />
Maturation <strong>of</strong> sympathicoblastoma into<br />
ganglioneuroma. Report <strong>of</strong> two patients<br />
with 20- and 46-year survicals, respectively.<br />
Cancer 12:108-116<br />
8. Goto S, Umehara S, Gerbing RB, et al<br />
(2001) Histopathology (International<br />
Neuroblastoma <strong>Pathology</strong> classification)<br />
and MYCN status in patients with<br />
peripheral neuroblastic tumors. Cancer<br />
92:2699-2708<br />
9. Grosfeld JL, Skinner MA, Rescorla FJ,<br />
West KW, Scherer LR (1994) Mediastinal<br />
tumors in children: experience with<br />
196 cases. Ann Surg Oncol 1:121-127<br />
10. Haas D, Albin AR, Miller C, Zoger S,<br />
Matthay KK (1988) Complete pathologic<br />
maturation and regression <strong>of</strong> stage<br />
IV-S neuroblastoma without treatment.<br />
Cancer 62:818-825<br />
11. Horn RC, Koop CE, Kiesenwetter WB<br />
(1956) Neuroblastoma in childhood.<br />
Lab Invest 5:106-119<br />
12. Joshi VV, Cantor AB, Altshuler G, Larkin<br />
EW, Neill JSA, Shuster JJ, Holbrook CT,<br />
Hayes FA, Castleberry RP (1992) Recommendations<br />
for modification <strong>of</strong> terminology<br />
<strong>of</strong> neuroblastic tumors and prognostic<br />
significance <strong>of</strong> Shimada classification:<br />
a clinicopathologic study <strong>of</strong> 213<br />
cases from the Pediatric Oncology<br />
Group. Cancer 69:2183-2196
13. Joshi VV, Cantor AB, Altshuler G,<br />
Karkin EW, Neill JSA, Shuster JJ,<br />
Holbrook CT, Hayes FA, Nitschke R,<br />
Duncan MH, Shochat SJ, Talbert J,<br />
Smith EI, Castleberry RP (1992) Agelinked<br />
prognostic categorization based<br />
on a new histologic grading system <strong>of</strong><br />
neuroblastomas. Cancer 69:2197-221<br />
14. Joshi VV, Chatten J, Sather HN,<br />
Shimada H (1991) Evaluation <strong>of</strong><br />
Shimada classification in advanced neuroblastoma<br />
with special reference to the<br />
mitosis karyorrhexis index: a report<br />
from the Children’s Cancer Study<br />
Group. Mod Pathol 4:139-147<br />
15. Joshi VV, Rao PV, Cantor AB, Altshuler<br />
G, Shuster JJ, Castleberry RP (1996)<br />
Modified histologic grading <strong>of</strong> neuroblastoma<br />
by replacement <strong>of</strong> mitotic rate<br />
with mitosis karyorrhexis index: a clinicopathologic<br />
study <strong>of</strong> 223 cases from<br />
the Pediatric Oncology Group. Cancer<br />
77:1582-1588<br />
16. Loretz W. Ein Fall von gangliosem<br />
Neurom (Gangliom) (1870) Arch Pathol<br />
Anat Physiol Klin Med 49:435-437<br />
17. Mäkinen J (1972) Microscopic patterns<br />
as a guide to prognosis <strong>of</strong> neuroblastomas<br />
in childhood. Cancer 29:1637-1646<br />
18. Monforte-Munoz H, Kawakami T,<br />
Stram D, Gerbing R, Matthay KK,<br />
Lukens J et al (1997) Neuroblastoma in<br />
children over 5 years <strong>of</strong> age: recognition<br />
<strong>of</strong> a rare and aggressive subset with<br />
“unconventional” morphology. Mod<br />
Pathol 10:4P<br />
19. Navarro S, Amann G, Beiske K,<br />
Cullinane C, D’Amore E, Gambini C,<br />
Mosseri V, De Bernardi B, Michon J,<br />
Peuchmaur M (2004) Prognostic value<br />
<strong>of</strong> International Neuroblastoma <strong>Pathology</strong><br />
Committee Classification in<br />
localised resectable peripheral neuroblastic<br />
tumors. In preparation<br />
20. Peuchmaur M, d’Amore ESG, Joshi VV,<br />
et al (2003) Revisión <strong>of</strong> the International<br />
Neuroblastoma <strong>Pathology</strong> Classification.<br />
Confirmation <strong>of</strong> favorable and unfavorable<br />
prognostic subsets in<br />
Ganglioneuroblastoma nodular. Cancer<br />
298:2274-2281<br />
21. Robertson HE (1915) Das Ganglioneuroblastom,<br />
ein besonderer Typus im<br />
System der Neurone. Virchows Arch<br />
[Pathol Anat] 63:147-168<br />
22. Ross JA, Severson RK, Pollock BH,<br />
Robison LL (1996) Childhood cancer in<br />
the United States: a geographic analysis<br />
<strong>of</strong> cases from the Pediatric Cooperative<br />
Clinical Trials Group. Cancer<br />
77:201-207<br />
23. Scherer HJ (1934) Bemerkungen zur<br />
Empfindlichkeit der Ganglienzelle.<br />
Virchows Arch Path Anat 293:429-437<br />
24. Shimada H, Ambros IM, Dehner LP,<br />
Hata J, Joshi VV, Roald B (1999) Terminology<br />
and morphologic criteria <strong>of</strong><br />
neuroblastic tumors: recommendations<br />
by the International Neuroblastoma <strong>Pathology</strong><br />
Committee. Cancer 86:349-363<br />
25. Shimada H, Ambros IM, Dehner LP, et<br />
al (1999) The International Neuroblastoma<br />
<strong>Pathology</strong> Classification (the<br />
Shimada system). Cancer 86:364-372<br />
26. Shimada H, Chatten J, Newton WA Jr,<br />
Sachs N, Hamoudi AB, Chiba T,<br />
Marsden HB, Misugi K (1984) Histopathologic<br />
prognostic factors in neuroblastic<br />
tumors: definition <strong>of</strong> subtypes <strong>of</strong><br />
ganglioneuroblastoma and an age-linked<br />
classification <strong>of</strong> neuroblastomas. J Natl<br />
Cancer Inst 73:405-416<br />
27. Shimada H, Stram DO, Chatten J, et al<br />
(1995) Identification <strong>of</strong> subsets <strong>of</strong> neuroblastomas<br />
by combined histopathologic<br />
and N-myc analysis. J Natl Cancer<br />
Inst 187:1470-1476<br />
28. Stout AP (1947) Ganglioneuroma <strong>of</strong> the<br />
sympathetic nervous system. Surg<br />
Gynecol Obstet 84:101-110<br />
29. Umehara S, Nakagava A, Matthay KK,<br />
Lukens JN, Seeger RC, Stram DO,<br />
Gerbing RB, Shimada H (2000) Histopathology<br />
defines prognostic subsets <strong>of</strong><br />
ganglioneuroblastoma, nodular. Cancer<br />
89:1150-1161<br />
30. Visfeldt J (1963) Transformation <strong>of</strong><br />
sympathicoblastoma into ganglioneuroma.<br />
Acta Path Microbiol Scand<br />
158:414-428<br />
31. Wahl HR (1914) Neuroblastoma: with<br />
study <strong>of</strong> a case illustrating the three types<br />
that arise from the sympathetic nervous<br />
system. J Med Res 30:205-260<br />
32. Wright JH (1910) Neurocytoma or neuroblastoma,<br />
a kind <strong>of</strong> tumor not generally<br />
recognized. J Exper Med xii:556
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Intracranial ependymomas in children: correlation <strong>of</strong> selected<br />
factors and event-free survival in the group <strong>of</strong> 142 consecutive<br />
patients treated at one institution.<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
S³awomir Barszcz 1 , Wies³awa Grajkowska 2 , Danuta Perek 3 , Marcin Roszkowski 1 , Monika<br />
Drogosiewicz 3 , Marta Perek-Polnik 3 , El¿bieta Jurkiewicz 4 , Pawe³ Daszkiewicz 1<br />
1<br />
Department <strong>of</strong> Neurosurgery,<br />
2<br />
Department <strong>of</strong> <strong>Pathology</strong>,<br />
3<br />
Department <strong>of</strong> Oncology,<br />
4<br />
Department <strong>of</strong> Radiology,<br />
The Children’s Memorial Health Institute,<br />
Warsaw, Poland<br />
Abstract<br />
Ependymomas are among the most frequent intracranial tumors in children. Nevertheless, the identification<br />
<strong>of</strong> risk factors and the role <strong>of</strong> various treatment modalities are still far from standarization. The aim <strong>of</strong> this<br />
study was to evaluate the impact <strong>of</strong> patients’ age, tumor location, extent <strong>of</strong> surgical resection, degree <strong>of</strong><br />
histological malignancy, type <strong>of</strong> radiotherapy (RT), and chemotherapy (CHT) on event free survival in the<br />
group <strong>of</strong> 142 consecutive patients treated at one institution. Retrospective analysis and comparisons <strong>of</strong> eventfree<br />
survival (EFS) probabilities were done in subgroups <strong>of</strong> patients selected on the basis <strong>of</strong> various treatemt<br />
protocols. For the entire group, age <strong>of</strong> patients, extent <strong>of</strong> surgical resection, and histological malignancy<br />
significantly affected EFS. Extent <strong>of</strong> surgical resection significantly influenced EFS in benign tumors and<br />
did not in anaplastic ependymomas. Neuroaxis RT did not improve EFS for anaplastic lesions. Treatment<br />
results were better after 1997 in anaplastic ependymomas (potential role <strong>of</strong> CHT) and finally CHT significantly<br />
improved control <strong>of</strong> small tumor residues<br />
Key words: chemotherapy, ependymoma, prognosis, radiotherapy, surgery<br />
Introduction<br />
Ependymomas are among the most frequent intracranial tumors<br />
in children, accounting for approximately 10% <strong>of</strong> primary<br />
central nervous system neoplasms [35]. Treatment <strong>of</strong><br />
patients with ependymomas includes neurosurgical resection,<br />
radiotherapy (RT), chemotherapy (CHT), and radiosurgery<br />
[16, 33]. Despite introduction <strong>of</strong> various treatment regimens,<br />
treatment outcomes are still unsatisfactory [27, 31, 36].<br />
The aim <strong>of</strong> the study was to analyse the influence <strong>of</strong><br />
selected factors on event-free survival (EFS) in the group <strong>of</strong><br />
intracranial ependymomas treated at our institution.<br />
Material and methods<br />
In the years since 1981 thru 2003, a total number <strong>of</strong> 154 children<br />
suffering from intracranial ependymomas were treated<br />
at the Children’s Memorial Health Institute in Warsaw. Twelve<br />
patients were lost to follow-up, and the remaining group <strong>of</strong>142<br />
children (74 boys and 68 girls) were used for further analysis.<br />
Retrospective analysis <strong>of</strong> the data was performed to<br />
evaluate the influence <strong>of</strong> patients’age, tumor location, extent<br />
<strong>of</strong> surgery, tumor malignancy, type <strong>of</strong> radiotherapy (RT) and<br />
use <strong>of</strong> chemotherapy (CHT) on event-free survival (EFS),<br />
according to various treatmet protocols. The group <strong>of</strong> patients<br />
was heterogenous (various treatment protocols, mainly before<br />
and after 1997). Age <strong>of</strong> patients, extent <strong>of</strong> resection, and tumor<br />
malignancy were the main factors influencing selection<br />
Address for correspondence<br />
S³awomir Barszcz, MD, PhD<br />
Department <strong>of</strong> Neurosurgery<br />
Children's Memorial Health Institute<br />
Al. Dzieci Polskich 20<br />
04-853 Warsaw, Poland<br />
Phone: +48 22 8157560<br />
E-mail: slawomirbarszcz@wp.pl
84<br />
<strong>of</strong> treatment options. In such circumstances the mentioned<br />
factors with potential influence on survival were not independent<br />
verieties, and multivariate analysis could not be performed.<br />
We made a 2-step statistical analysis. First, comparability<br />
<strong>of</strong> the subgroups <strong>of</strong> benign and anaplastic ependymomas<br />
was ascertained, according to age, extent <strong>of</strong> surgery, type<br />
<strong>of</strong> RT, and use <strong>of</strong> CHT. Then, we made a few separate comparisons<br />
for comparable subgroups <strong>of</strong> patients in order to<br />
analyse the potential influence <strong>of</strong> risk factors on actuarial EFS.<br />
EFS probability curves were drawn, and their stratification<br />
was studied using the log-rank test.<br />
We did not study overall survival (OS), because recurrences<br />
<strong>of</strong> tumors as well as their treatments were not analysed.<br />
Results<br />
Age <strong>of</strong> the patients ranged from 5 months to 18 years and 6<br />
months (median 5 years 0 months). In 63 patients ependymomas<br />
were located in the infratentorial space, and in 59 children<br />
supratentorial tumors were found. In 61 patients the tumors<br />
were totally, in 38 subtotally, and in 38 children partially<br />
resected. In the remaining 5 cases only biopsies were<br />
performed. In the years since 1981 thru 1999, the extent <strong>of</strong><br />
surgical tumor removal was evaluated on the basis <strong>of</strong> surgical<br />
reports and postoperative control CTs. Since 1999, the intraoperative<br />
estimation as well as postoperative MRI studies have<br />
been used to determine the extent <strong>of</strong> surgical resection. All<br />
pathological specimens were reviewed and devided into two<br />
subgroups <strong>of</strong> 89 benign and 53 malignant (anaplastic) ependymomas.<br />
Anaplastic tumors matched the following critera:<br />
marked nuclear pleomorphism, high mitotic activity, necrosis,<br />
vascular proliferation. 118 patients were treated with radiotherapy.<br />
Radiotherapy significanty changed over the described<br />
period <strong>of</strong> time, due to the developement <strong>of</strong> cobalttherapy<br />
and linac technology as well as introduction <strong>of</strong> new<br />
treatment protocols. To simplify the variety <strong>of</strong> problems concerning<br />
radiotherapy, for further analysis we defined only two<br />
main subgroups: 1. “local” radiotherapy (29 patients) and 2.<br />
neuroaxis radiotherapy (89 patients). Untill 1996, irrespective<br />
<strong>of</strong> the extent <strong>of</strong> surgical resection, all patients underwent<br />
whole neuroaxis irradiation. Since1996 thru 2000, patients<br />
after total removal <strong>of</strong> benign ependymomas were treated with<br />
“local” radiotherapy. In 2000 the “wait and see” approach was<br />
introduced after total removal <strong>of</strong> benign tumors. Partial resections<br />
<strong>of</strong> benign ependymomas were followed by chemotherapy<br />
and “local” RT. Anaplastic ependymomas after surgery were<br />
treated with adjuvant chemotherapy followed by tumor bed<br />
and ventricles irradiation, and maintenance chemotherapy. Two<br />
different treatment approaches were tailored for children under<br />
3 years <strong>of</strong> age. Total resection <strong>of</strong> benign ependymoma<br />
was the only treatment modality. The rest <strong>of</strong> patients below 3<br />
years <strong>of</strong> age (partial resection <strong>of</strong> benign tumor and all patients<br />
with anaplastic ependymomas) were treated with 18-months’<br />
chemotherapy without RT. The use <strong>of</strong> the whole neuroaxis<br />
RT was reserved only for disseminated tumors. Chemotherapy<br />
was used for the treatment <strong>of</strong> 58 patients. The median followup<br />
period was 3 years and 2 months (ranging from 2 months<br />
to 18 years and 6 months).<br />
In the study group there were no significant differences<br />
between patients with benign and anaplastic tumors according<br />
to age and extent <strong>of</strong> resection. The use <strong>of</strong> neuroaxis vs. local RT<br />
were close to the limit <strong>of</strong> signifficance (Table 1). The entire<br />
study group was devided into 3 age-dependent subgroups. There<br />
were 41 children below 3 years <strong>of</strong> age. In 75 patients, age ranged<br />
from 3 to 10 years, and 26 patients were older than 10 years.<br />
The list <strong>of</strong> subsequent comparisons <strong>of</strong> potential risk factors,<br />
outcomes and statistical analysis are shown in Table 2.<br />
The study revealed that age <strong>of</strong> patients significantly influenced<br />
EFS.The lower the age, the worse the prognosis (Fig.<br />
1). No differences were found concernig event-free survival<br />
probabillities for the group <strong>of</strong> 83 patients with infratentorial<br />
tumors vs. 59 patients with supratentorial ependymomas. Primary<br />
tumor location did not influence EFS. Diagnosis <strong>of</strong> malignant<br />
(anaplastic) ependymoma according to the mentioned<br />
morphologic criteria was a marker <strong>of</strong> poor prognosis in the study<br />
group (Fig. 2). Event-free survival probability for the group <strong>of</strong><br />
99/142 patients after total and subtotal tumor resection was better<br />
than for the group <strong>of</strong> 43/142 patients after partial resection and<br />
biopsy. Extent <strong>of</strong> surgical resection significantly influenced EFS<br />
for the entire study group. Extent <strong>of</strong> surgical removal significantly<br />
influenced EFS for benign tumors. The prognosis was<br />
better for patients after total and subtotal resection <strong>of</strong> benign<br />
ependymomas (Fig. 3). Event-free survival probability after total<br />
and subtotal resection <strong>of</strong> grade III ependymomas was slightly<br />
better than after less radical resection, but stratification <strong>of</strong> survival<br />
curves was not significant. The comparison <strong>of</strong> EFS probabilities<br />
for benign ependymomas treated with neuroaxis and<br />
“local” RT revealed that EFS was better for the subgroup after<br />
whole neuroaxis irradiation. It is rather confusing, taking into<br />
account everyday clinical practice. Before 1996, all the cases<br />
<strong>of</strong> intracranial ependymomas irrespective histological malignancy<br />
and extent <strong>of</strong> surgical resection received whole neuroaxis<br />
RT, whereas after 1996 neuroaxis irradiation was reserved for<br />
disseminated lesions only. There was no statistically significant<br />
difference between EFS probabilities for neuroaxis vs. “local”<br />
(tumor bed or tumor bed + ventricles) RT for the patients<br />
with malignant ependymomas. It was shown that introduction<br />
(1997) <strong>of</strong> the standardized treatment protocols including: surgery,<br />
adjuvant chemotherapy, tumor bed or tumor bed + ventricles<br />
radiotherapy, and finally maintenance chemotherapy significantly<br />
improved EFS probability for malignant ependymomas<br />
(Fig. 4). Statistically significant stratification <strong>of</strong> EFS curves<br />
for the patients treated with chemotherapy vs. patients treated<br />
without chemotherapy after total or subtotal tumor removals<br />
indicates that chemotherapy improved control <strong>of</strong> small tumor<br />
residues (Fig. 5).<br />
Discussion<br />
Identification <strong>of</strong> clinical and pathological factors influencing<br />
survival has a key role in improvement <strong>of</strong> treatment outcomes<br />
in children suffering from intracranial ependymomas. Various<br />
risk factors were proposed, and because <strong>of</strong> relatively small<br />
and heterogenous groups <strong>of</strong> patients and different treatemt<br />
protocols, the results <strong>of</strong> numerous studies differ considerably
85<br />
Table 1<br />
Comparison between ependymoma grade I - II and ependymoma grade III patients according to: age, extent <strong>of</strong> surgery, type <strong>of</strong><br />
RT, and use <strong>of</strong> CHT (NS=not significant)<br />
Table 2<br />
Feature Benign vs. anaplastic (ch 2 ) Significance<br />
Age P > 0.05 NS<br />
Surgery P> 0.05 NS<br />
RT (CNS vs. local) P = 0.06 +/-<br />
CHT P < 0.0005 ∗∗∗<br />
List <strong>of</strong> comparisons <strong>of</strong> the studied factors, and their significance (NS=not significance, * , ** , *** = degrees <strong>of</strong> statistical<br />
significance)<br />
Comparisons <strong>of</strong> EFS probabilities for the studied parameters Log-rank Significance<br />
Three age groups p= 0.0039 ∗∗<br />
Infratentorial vs. supratentorial ependymomas p=0.37 NS<br />
Benign vs. anaplastic ependymomas. p=0.0037 ∗∗<br />
Total and subtotal resections vs. partial resections and biopsies<br />
p=0.0001<br />
∗∗∗<br />
(entire study group).<br />
Total and subtotal resections vs. partial resections and biopsies<br />
p=0.00005<br />
∗∗∗<br />
(benign ependymomas).<br />
Total and subtotal resections vs. partial resections and biopsies<br />
p=0.15<br />
NS<br />
(anaplastic ependymomas).<br />
Neuroaxis RT vs. “local” RT<br />
(benign ependymomas)<br />
p=0.007<br />
∗∗<br />
Neuroaxis RT vs. “local” RT<br />
(anaplastic ependymomas)<br />
p=0.6326<br />
Anaplastic ependymomas treated before 1997 vs. after 1997. p=0.043 ∗<br />
Totally and subtotally removed tumors CHT (+) vs. CHT (-) p=0.047 ∗<br />
NS<br />
[2, 6, 9, 19, 25]. Lower age <strong>of</strong> patients was found to be a poor<br />
prognostic factor in most series [3]. It was not clear wheather<br />
poorer prognosis in very young children was due to different<br />
tumor biology, different treatement protocols, higher morbidity<br />
and poorer response to various treatment modalities especially<br />
radiotherapy [34]. Our results confirmed that observation.<br />
EFS probabilities were lower for the subgroups <strong>of</strong><br />
younger children. The influence <strong>of</strong> primary tumor location on<br />
survival was difficult to evaluate reliably. Predominance <strong>of</strong><br />
infratentorial ependymomas in the first decade <strong>of</strong> life and<br />
higher frequency <strong>of</strong> supratentorial tumors in adolescents and<br />
adults as well as precise tumor location have led to different<br />
treatment outcomes in particular subgroups <strong>of</strong> patients. No<br />
differences were found in the study group concerning two main<br />
localization groups <strong>of</strong> supra- and infratentorial ependymomas.<br />
However, it should be remembered that surgical mortality and<br />
morbidity as well as extent <strong>of</strong> surgical resection are more favorable<br />
in supratentorial extraaxial and midline posterior fossa<br />
ependymomas as compared to midline supratentorial and posterior<br />
fossa paramedian (cerebellopontine angle) tumors [4,<br />
20]. Extent <strong>of</strong> surgical resection was the most consistent and<br />
strongest prognostic factor in almost all <strong>of</strong> series as well as in<br />
our group <strong>of</strong> patients [24, 35]. The main problem in tailoring<br />
treatment and predicting prognosis is to define reliable features<br />
in the diagnosis <strong>of</strong> malignant (anaplastic) ependymomas.<br />
Uncritical use <strong>of</strong> the morfologic criteria <strong>of</strong> histologic<br />
malignancy accepted for astrocytomas is doubtful. In our group<br />
<strong>of</strong> patients, actuarial event-free survival was significantly better<br />
for the so called benign ependymomas, but a lot <strong>of</strong> authors<br />
indicate that there is no strict correlation between tumor morphology<br />
and prognosis in ependymomas [11, 29, 30]. Much<br />
time and effort were spent to study various immunohistochemical<br />
and genetic features as well as their correlations with tumor<br />
biology, but there are still no reliable markers <strong>of</strong> malig-
86<br />
Fig. 1 Statistically significant stratification <strong>of</strong> event-free survival probability<br />
curves for various age groups <strong>of</strong> patients (log-rank: p= 0.0039)<br />
Fig. 2 Significant stratification <strong>of</strong> EFS probabnility curves for benign (B - 89<br />
patients) and anaplastic (A- 53 patients) tumors (log-rank: p=0.0037)<br />
Fig. 3 Significantly higher EFS after total and subtotal resections (T+ST) vs.<br />
partial resections and biopsies (P+B) <strong>of</strong> benign ependymomas (log-rank:<br />
p=0.00005)<br />
Fig. 4 Significant improvement <strong>of</strong> treatment outcome <strong>of</strong> anaplastic ependymomas<br />
after 1997 (introduction <strong>of</strong> complex treatment protocols: surgery +<br />
adjuvant CHT + RT + maintenance CHT; log-rank: p=0.043)<br />
Fig. 5 Better EFS after chemotherapy (CH +) in patients in whom total or<br />
subtotalal tumor resections were performed (log-rank: p=0.047)
87<br />
nancy in ependymomas [7, 21]. Opinions on adjuvant therapy<br />
differ from series to series. It is generally accepted that radiotherapy<br />
and chemotherapy can delay tumor recurrence but their<br />
influence on overall survival is still unclear [1, 5, 23, 28]. The<br />
rationale for agressive removal <strong>of</strong> ependymomas in certain<br />
locations is debatable. Devastating late complications <strong>of</strong><br />
neuroaxis radiotherapy, especially in the youngest age group<br />
are well known [17, 18, 32]. That is why there is a trend to<br />
eliminate radiotherapy in children under 3 years <strong>of</strong> age and<br />
after total removal <strong>of</strong> histologically benign tumors. The fields<br />
<strong>of</strong> irradiation were restricted to tumor bed or tumor bed and<br />
ventricles for partially resected benign and anaplastic lesions<br />
respectively. The neuroaxis irradiation is usually reserved for<br />
disseminated ependymomas [12, 26]. This tendency is supported<br />
by the observations that reccurences are limited to primary<br />
tumor location in almost all cases and CSF dissemination<br />
is relatively rare [13]. Patterns <strong>of</strong> failure indicate, that<br />
final treatment outcome depends mostly on the local control<br />
<strong>of</strong> disease. These statements were the reason for the concept<br />
<strong>of</strong> “second-look” surgery, whenever reoperation was possible<br />
in cases <strong>of</strong> residual disease [8]. Chemotherapy was introduced<br />
in the treatment <strong>of</strong> children under 3 years to delay or<br />
eliminate the need for radiotherapy as well as in the treatment<br />
<strong>of</strong> malignant lesions and tumor recurrences and disseminations<br />
and finally in the treatment <strong>of</strong> partially resected benign<br />
lesions [15, 37]. Variable response rates to the same treatment<br />
protocols created the need for potential identification <strong>of</strong> subpopulations<br />
sensitive or resistent to chemotherapy,<br />
developement <strong>of</strong> novel drugs and intensification <strong>of</strong> treatment<br />
with subsequent bone marrow reconstruction [10, 14, 22]. As<br />
mentioned above, in our series neuroaxis irradiation correleated<br />
with better actuarial EFS for benign ependymomas. Significant<br />
change <strong>of</strong> treatment protocols over the years resulted in<br />
fairly confusing data. Before 1996, all cases were treated with<br />
neuroaxis irradiation; after 1996, RT was reserved only for<br />
disseminated ependymomas. It was clearly shown that<br />
neuroaxis RT did not improve EFS in anaplastic ependymomas<br />
in our series. An introduction <strong>of</strong> standarized treatment<br />
protocols (including chemotherapy) in 1997 improved treatment<br />
outcomes in malignant tumors. Chemotherapy also improved<br />
control <strong>of</strong> small tumor residues after surgery. Treatment<br />
response <strong>of</strong> tiny remnants seems to be an interesting<br />
clinical model for evaluation <strong>of</strong> CHT efficacy in the treatment<br />
<strong>of</strong> ependymomas.<br />
Conclusions<br />
1. For the entire group <strong>of</strong> patients, age, extent <strong>of</strong> surgical<br />
resection, and histological malignancy, significantly influenced<br />
EFS;<br />
2. Extent <strong>of</strong> surgical resection significantly influenced EFS in<br />
benign tumors and did not influence EFS in anaplastic<br />
ependymomas;<br />
3. Neuroaxis RT did not influence EFS in patients with anaplastic<br />
ependymomas;<br />
4. Treatment results in anaplastic ependymomas improved after<br />
1997 (a potential role <strong>of</strong> CHT);<br />
5. CHT significantly improved control <strong>of</strong> small tumor residues.<br />
References<br />
1. Bouffet E, Foreman N (1999) Chemotherapy<br />
for intracranial ependymomas<br />
(review). Child’s Nerv Syst 15:563-323<br />
2. Bouffet E, Perilongo G, Canete A, et al<br />
(1998) Intracranial ependymomas in<br />
children: a critical review <strong>of</strong> prognostic<br />
factors and a plea for cooperation. Medical<br />
and Pediatric Oncology 30:319-331<br />
3. Duffner PK, Krischer JP, Sanford RA,<br />
et al (1998) Prognostic factors in infants<br />
and very young children with intracranial<br />
ependymomas. Pediatr Neurosurg<br />
28:215-222<br />
4. Ernestus R, Schroder R, Stutzer H, et al<br />
(1996) Prognostic relevance <strong>of</strong> localization<br />
and grading in intracranial ependymomas<br />
<strong>of</strong> childhood. Child’s Nerv Syst<br />
12:522-526<br />
5. Evans AE, Anderson JR, Lefkowitz-<br />
Boudreaux IB, et al (1996) Adjuvant<br />
chemotherapy <strong>of</strong> childhood posterior<br />
fossa ependymoma: caraniospinal irradiation<br />
with or without adjuvant CCNU,<br />
vincristine, and prednisone: a Childrens<br />
Cancer Group study. Med Pediatr Oncol<br />
27:8-14<br />
6. Figarella-Branger D, Civatte M, Bouvier-Labit<br />
C, et al (2000) Prognostic factors<br />
in intracranial ependymomas in<br />
children. J Neurosurg 93:605-613<br />
7. Figarella-Branger D, Gambarelli D,<br />
Dollo C, et al (1991) Infratentorial<br />
ependymomas <strong>of</strong> childhood. Correlation<br />
between histological features, immunohistological<br />
fenotype, silver nucleolar<br />
staining values and post-operative survival<br />
in 16 cases; Acta Neuropathol<br />
82:208-216<br />
8. Foreman NK, Love S, Gill SS, Coakham<br />
HB (1997) Second-look surgery for incompletely<br />
resected fourth ventricle<br />
ependymomas: technical case report.<br />
Neurosurgery 40:856-860<br />
9. Foreman NK, Love S, Thorne R (1996)<br />
Intracranial ependymomas: analysis <strong>of</strong><br />
prognostic factors in a population-based<br />
series. Pediatr Neurosurg 24:119-125<br />
10. Geddes JF, Vowles GH, Ashmore SM<br />
(1994) Detection <strong>of</strong> multidrug resistance<br />
gene product (P-glycoprotein) expression<br />
in ependymomas. Neuropathol<br />
Appl Neurobiol 20(2):118-121<br />
11. Gerszten PC, Pollack IF, Martinez AJ<br />
(1996) Intracranial ependymomas <strong>of</strong><br />
childhood. Lack <strong>of</strong> correlation <strong>of</strong> histopathology<br />
and clinical outcome. Path<br />
Res Pract 192:515-522<br />
12. Goldwein JW, Corn BW, Finlay JL, et<br />
al (1991) Is craniospinal irradiation required<br />
to cure children with malignant<br />
(anaplastic) intractranial ependymomas<br />
Cancer 67:2766-2771<br />
13. Goldwein JW, Glause TA, Packer RJ,<br />
et al (1990) Recurrent intracranial<br />
ependymomas in children. Survival,<br />
patterns <strong>of</strong> feilure, and prognostic factors.<br />
Cancer 66: 557-563<br />
14. Grill J, Kalifa C, Doz F, et al (1996) A<br />
high-dose busulfan thiotepa combination<br />
followed by autologous bone marrow<br />
transplantation in childhood recurrent<br />
ependymoma. A phase II study.<br />
Pediatr Neurosurg 25:7-12<br />
15. Grill J, LeDeley MC, Gambarelli D, et<br />
al (2001) Postoperative chemotherapy<br />
without irradiation for ependymoma in<br />
children under 5 years <strong>of</strong> age: a<br />
multicenter trial <strong>of</strong> the French Society<br />
<strong>of</strong> Pediatric Oncology. J Clin Oncol<br />
19:1288-1296
16. Grill J, Pascal C, Chantal K (2003)<br />
Childhood ependymoma a systemic review<br />
<strong>of</strong> treatment options and strategies.<br />
Paediatr Drugs 5(8):533-543<br />
17. Grill J, Renaux VK, Bulteau C, et al<br />
(1999) Long-term intellectual outcome<br />
in children with posterior fossa tumors<br />
according to radiation dose and volumes.<br />
Int J Radiation Oncology Biol<br />
Phys 45:137-145<br />
18. Hoppe-Hirsch E, Brunet L, Laroussinie<br />
F, et al (1995) Intellectual outcome in<br />
children with malignant tumors <strong>of</strong> posterior<br />
fossa: influence <strong>of</strong> the field <strong>of</strong> irradiation<br />
and quality <strong>of</strong> surgery. Child’s<br />
Nerv Syst 11(6):340-345<br />
19. Horn B, Heideman R, Geyer R, et al<br />
(1999) A multiple-institutional retrospective<br />
study <strong>of</strong> intracranial ependymomas<br />
in children: identification <strong>of</strong> risk<br />
factors. J Pediatr Hematol Oncol<br />
21:203-211<br />
20. Ikezaki K, Matsushima T, Inoue T, et al<br />
(1993) Correlation <strong>of</strong> microanatomical<br />
localization with postoperative survival<br />
in posterior fossa ependymomas. Neurosurgery<br />
32(1):38-44<br />
21. Kordek R, Liberski PP (2001)<br />
Nowotwory gleju wyœció³kowego. Pol<br />
J Pathol 53, 4 (suppl):39-53 (in Polish)<br />
22. Mason WP, Goldman S, Yates AJ, et al<br />
(1998) Survival following intensive chemotherapy<br />
with bone marrow reconstruction<br />
for children with recurrent intracranial<br />
ependymoma – a report <strong>of</strong> the<br />
Children’s Cancer Group. J Neurooncol<br />
37:135-143<br />
23. McLaughlin MP, Marcus RB, Buatti<br />
JM, et al (1998) Ependymoma: results<br />
prognostic factors and treatment recommendations.<br />
Int J Radiation Oncology<br />
Biol Phys 40:845-850<br />
24. Palma L, Celli P, Mariottini A (2000)<br />
The importance <strong>of</strong> surgery in supratentorial<br />
ependymomas. Child’s Nerv Syst<br />
16:170-175<br />
25. Paulino AC, Bouffet E, Perilongo G, et<br />
al (1998) Intracranial ependymomas in<br />
children: a critical review <strong>of</strong> prognostic<br />
factors and a plea for cooperation. Medical<br />
and Pediatric Oncology 30:319-331<br />
26. Paulino AC (2001) The local field in<br />
infratentorial ependymoma: does the<br />
entire posterior fossa need to be treated<br />
Int J Radiation Oncology Biol Phys<br />
49:757-761<br />
27. Pollack IF, Gerszten PC, Martinez AJ,<br />
et al (1995) Intracranial ependymomas<br />
<strong>of</strong> childhood: long-term outcome and<br />
prognostic factors. Neurosurgery<br />
37(4):655-666<br />
28. Robertson PL, Zeltzer PM, Boyett JM,<br />
et al (1998) Survival and prognostic factors<br />
following radiation therapy and chemotherapy<br />
for ependymomas in children:<br />
a report <strong>of</strong> the Children’s Cancer Group.<br />
J Neurosurg. 88:695-703<br />
29. Rorke LB (1987) Relationship <strong>of</strong> morphology<br />
<strong>of</strong> ependymomas in children to<br />
prognosis. Prog Exp Tumor Res 30:170-<br />
174<br />
30. Ross GW, Rubinstein LJ (1989) Lack<br />
<strong>of</strong> histopathological correlation <strong>of</strong> malignant<br />
ependymomas with postoperative<br />
survival. J Neurosurg 70:31-36<br />
31. Schiffer D, Giordana MT (1998) Prognosis<br />
<strong>of</strong> ependymoma. Child’s Nerv<br />
Syst 14:357-361<br />
32. Seaver E, Geyer R, Sulzbacher S, et al<br />
(1994) Psychosocial adjustment in longterm<br />
survivors <strong>of</strong> childhood<br />
meduloblastoma and ependymoma<br />
treated with craniospinal irradiation.<br />
Pediatr Neurosurg 20(4):248-253<br />
33. Smyth MD, Horn BN, Russo C, et al<br />
(2000) Intracranial ependymomas <strong>of</strong><br />
childhood: current management strategies.<br />
Pediatr Neurosurg 33:138-150<br />
34. Suc E, Kalifa C, Brauner R, et al (1990)<br />
Brain tumors under the age <strong>of</strong> tree. The<br />
price <strong>of</strong> survival. Acta Neurochir<br />
106:93-98<br />
35. Sutton LN, Goldwein JW, Schwartz D<br />
(1999) Ependymoma. In: Albright AL,<br />
Pollack IF, Adelson PD (eds) Principles<br />
and practice <strong>of</strong> pediatric neurosurgery.<br />
Thieme, New York, Stuttgart, pp 609-<br />
628<br />
36. Teo Ch, Nakaji P, Symons P, et al (2003)<br />
Ependymoma. Child’s Nerv Syst<br />
19:270-285<br />
37. White L, Johnston H, Jones R, et al<br />
(1993) Postoperative chemotherapy<br />
without radiation in young children with<br />
malignant non-astrocytic brain tumors.<br />
A report from the Australia and New<br />
Zeland Childhood Cancer Study Group<br />
(ANZCCSG). Cancer Chemoter<br />
Pharmacol 32(5):403-406
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
<strong>Pathology</strong> <strong>of</strong> fatty liver in children with LCHAD deficiency<br />
Katarzyna Iwanicka 1 , Janusz Ksi¹¿yk 2 , Monika Pohorecka 3 , Maciej Pronicki 1<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
1<br />
Department <strong>of</strong> <strong>Pathology</strong>,<br />
2<br />
The Clinic <strong>of</strong> Pediatrics,<br />
3<br />
Department <strong>of</strong> Metabolic Diseases,<br />
The Children’s Memorial Health Institute,<br />
Warsaw, Poland<br />
Abstract<br />
Deficiency <strong>of</strong> long chain 3-hydroksyacyl-CoA dehydrogenase (LCHADD) impairs the process <strong>of</strong> mitochondrial<br />
beta-oxidation <strong>of</strong> fatty acids. LCHADD may be clinically benign up to the moment <strong>of</strong> first symptoms,<br />
i.e. fasting inducing the first acute life-threatening episode (ALTE). Patients present vomiting, lethargy, convulsions,<br />
arrhytmia and hypoketotic hypoglycemia, which is essential for established a diagnosis. Thus, after<br />
fasting, healthy looking child may die with serious symptoms <strong>of</strong> acute illness. The aim <strong>of</strong> this study was the<br />
histopathological assessment <strong>of</strong> liver in our own LCHADD patients with particular attention to characteristic<br />
changes including intensity, type and localization <strong>of</strong> liver steatosis. Seven liver samples were assessed: 3<br />
biopsies and 4 autopsy specimens obtained from 6 patients, aged from 3 months to one year. In 3 autopsies<br />
we found severe macrovacuolar fatty liver, in one biopsy moderate mixed steatosis, and in remaining 3 cases<br />
mild fatty liver <strong>of</strong> macrovacuolar and mixed character. All samples but one displayed diffuse distribution <strong>of</strong><br />
steatotic hepatocytes. In 4 cases steatosis was accompanied by fibrosis and cirrhosis, in 3 by inflammatory<br />
infiltrates. Intensity <strong>of</strong> steatosis was related to the severity <strong>of</strong> clinical symptoms. Fibrosis was another morphological<br />
feature characteristic for LCHAD deficiency. The results showed that liver steatosis found during<br />
autopsy <strong>of</strong> patients who died <strong>of</strong> unexplained reason should attract attention to LCHADD as a possible cause<br />
<strong>of</strong> death.<br />
Key words: LCHAD deficiency, liver steatosis<br />
Introduction<br />
Clinical symptoms <strong>of</strong> long chain 3-hydroksyacyl-CoA dehydrogenase<br />
(LCHAD) deficiency usually appear after prolonged<br />
fasting or could be evoked by upper respiratory tract infections,<br />
vaccination, physical exercises and other stress. Clinically<br />
healthy child presents hypoketotic hypoglycemia, which<br />
may be accompanied by vomiting, abdominal pain, convulsion,<br />
muscle weakness and cardiomegaly. In the course <strong>of</strong> the<br />
disease sensorimotor neuropathy and pigmentary retinopathy<br />
develop [5, 9, 11]. The age <strong>of</strong> onset ranges from one day to 40<br />
months. Treatment involves the diet with long chain fatty acids<br />
restriction and increased supply <strong>of</strong> carbohydrates.<br />
Fatty acids are the most important source <strong>of</strong> energy<br />
during fasting [5, 11]. They are transported into the inner<br />
membrane <strong>of</strong> mitochondria to be used in beta-oxidation process<br />
[5, 9, 11]. This process has especially important value<br />
for muscle, heart and liver cells as their own source <strong>of</strong> energy.<br />
Beta-oxidation process has two steps: transport and following<br />
oxidation. Three enzymes take parts in transport <strong>of</strong> fatty<br />
acids into the mitochondria, creating the pathway called carnitine<br />
transporting system [2, 3, 5, 12]. Proper beta-oxidation<br />
pathway depends on activity <strong>of</strong> several enzymes (four for long,<br />
four <strong>of</strong> medium and four for short chain fatty acids). The names<br />
<strong>of</strong> appropriate enzymes differ only by the name <strong>of</strong> length <strong>of</strong><br />
the chain. The basis <strong>of</strong> beta-oxidation process is shortening <strong>of</strong><br />
fatty acid chain by cutting acetyl-CoA to introduce it to tricarboxylic<br />
acids cycle. Deficiency <strong>of</strong> 3-hydroksyacyl-CoA dehydrogenase<br />
(LCHAD) impairs the process and leads to toxic<br />
accumulation <strong>of</strong> fatty acids and their acylcarnitines derivatives<br />
[2, 5, 7, 9, 11]. Accumulation <strong>of</strong> lipids in the cells may<br />
be a site effect <strong>of</strong> this metabolic decompensation.<br />
Address for correspondence<br />
Iwanicka Katarzyna<br />
Department <strong>of</strong> <strong>Pathology</strong><br />
The Children's Memorial Health Institute<br />
Aleja Dzieci Polskich 20,<br />
04-736 Warsaw, Poland<br />
Phone: +48 22 815 16 14<br />
E-mail: kasiai@yahoo.com
90<br />
Since 1994, twenty two unrelated children with LCHAD deficiency<br />
have been identified in Poland. Diagnosis was done<br />
on the analysis <strong>of</strong> GC-MS organic acid pr<strong>of</strong>ile in urine and<br />
than confirmed by genetic investigation. Common protocol<br />
<strong>of</strong> treatment and monitoring (CPTM) has been introduced in<br />
2000. There were 8 LCHAD-deficient children identified before<br />
CPTM. Diagnosis was markedly delayed in all cases,<br />
rarely established at first acute life-threatening episode<br />
(ALTE), frequently post mortem. Five <strong>of</strong> them died, only three<br />
patients were in good condition. In second period (since 2000)<br />
14 new LCHAD deficient cases were identified. The diagnosis<br />
was established usually at first ALTE, only in 4 patients<br />
too late (post mortem or post-episodic neurological sequels).<br />
As in the literature there are only few reports concerning<br />
histological pattern <strong>of</strong> the liver from patients with LCHAD<br />
deficiency [5, 7, 9, 11], the aim <strong>of</strong> our study was to analyse<br />
morphological findings in the liver <strong>of</strong> 6 patients with LCHAD<br />
deficiency to establish the spectrum <strong>of</strong> morphological changes<br />
and compare our results with the described reports.<br />
Results<br />
Case No 1<br />
The liver specimen has been obtained on autopsy. It revealed<br />
the diffused localization <strong>of</strong> mixed pattern <strong>of</strong> steatosis concerning<br />
<strong>of</strong> 100 % <strong>of</strong> hepatocytes. Apart <strong>of</strong> congection any<br />
other pathological change was not detected in the liver. Steatosis<br />
<strong>of</strong> cardiomyocytes and lipid accumulation in renal proximal<br />
tubules was observed as well (Fig. 1).<br />
Material and methods<br />
Material consists <strong>of</strong> seven liver samples obtained from six<br />
LCHAD deficient patients (4 boys and 2 girls). One <strong>of</strong> the<br />
patients underwent liver biopsy at the age <strong>of</strong> 3 months and<br />
post mortem examination at 6 months. There were three biopsy<br />
samples obtained from the LCHAD-deficient boys and<br />
four autopsy specimens derived from affected patients (two<br />
boys and two girls). Patients were aged from 3 to 12 months.<br />
Clinical diagnosis <strong>of</strong> LCHAD deficiency was based on urine<br />
organic acid pr<strong>of</strong>ile analysis using GC-MS method (Dept <strong>of</strong><br />
Laboratory <strong>Diagnostic</strong>s, CMHI), and confirmed by molecular<br />
study.<br />
The liver samples obtained during biopsies were prepared<br />
for light and electron microscopy. Slides were stained<br />
with hematoxylin and eosin, PAS, diastase digested PAS, for<br />
collagen and reticulin fibres – AZAN and Gomori stains, respectively.<br />
Semi-thin slides <strong>of</strong> plastic embedded (epon) liver<br />
samples post fixed in osmium tetroxide and stained with toluidine<br />
blue were used for steatosis detection. Liver tissue samples<br />
obtained during autopsies were processed routinely for histology<br />
and stained with hematoxylin and eosin.<br />
During microscopical assessment we assumed three<br />
grades <strong>of</strong> steatosis intensity: mild, moderate and severe, when<br />
lipid droplets comprised up to 30%, 30-70%, and over 70%<br />
<strong>of</strong> liver parenchyma, respectively. Two types <strong>of</strong> distribution<br />
<strong>of</strong> steatotic hepatocytes were recorded: diffuse or focal. Type<br />
<strong>of</strong> steatosis included three categories: macrovacuolar,<br />
microvacuolar, and mixed. Semi-thin slides are very helpful<br />
in correct lipid detection, especially <strong>of</strong> microvacuolar type.<br />
Accompanying inflammatory infiltrates and fibrosis were assessed<br />
according to routine grading and staging system.<br />
Fig. 1 Liver biopsy <strong>of</strong> patient no 1 reveals severe mixed steatosis. Presence<br />
<strong>of</strong> lipid accumulation in renal proximal tubules (<strong>of</strong> patient no 1).<br />
Case No 2<br />
The liver specimen has been obtained on autopsy. It revealed<br />
the typical pattern <strong>of</strong> fatty liver. Macrovesicular lipid droplets<br />
are present in almost all hepatocytes. Mild fibrosis was present<br />
only in periportal areas. Inflammatory infiltrates and<br />
cholestasis were not detected. There was found vacuolisation<br />
corresponding probably to lipid accumulation in proximal renal<br />
tubules (Fig. 2).
91<br />
Fig. 2 Liver biopsy <strong>of</strong> patient no 2 shows severe diffuse macrovesicular steatosis.<br />
Liver biopsy <strong>of</strong> patient no 3 shows diffuse, moderate, mixed steatosis.<br />
Mild intralobular inflamatory infiltrates <strong>of</strong> lymphoid cells and single necrotic<br />
hepatocytes are observed.<br />
Case No 3<br />
The liver tissue obtained during biopsy showed fatty changes<br />
in approximately 60 % <strong>of</strong> hepatocytes. They revealed diffuse<br />
distribution. Lipid droplets in hepatocytes were <strong>of</strong> mixed pattern:<br />
macrovacuoles and microvacuoles were present. The mild<br />
intralobular and portal inflamatory infiltrates <strong>of</strong> lymphoid cells<br />
were found. Single necrotic hepatocytes were observed. Fibrosis<br />
and cholestasis were not detected (Fig. 2).<br />
Case No 4<br />
The liver biopsy specimen obtained prior to autopsy revealed<br />
precirrhotic pattern <strong>of</strong> liver injury. Macrovesicular steatotis were<br />
seen in 30 % <strong>of</strong> hepatocytes. Their localization was rather focal,<br />
within some <strong>of</strong> the nodules. Severe portal inflammatory<br />
infiltrates were present. Cholestasis was not found (Fig. 3).<br />
Case No 5 (the same patient as above)<br />
Subsequent liver specimen obtained during autopsy revealed<br />
cirrhosis. Severe macrovesicular fatty changes concerned all<br />
hepatocytes. Mild portal inflammatory infiltrates remained<br />
similar to those <strong>of</strong> the biopsy specimen. No cholestasis was<br />
present (Fig. 3).<br />
Fig. 3 Precihrrotic pattern <strong>of</strong> moderate, focal, macrovesicular steatosis <strong>of</strong><br />
patient 4. Subsequent, post mortem examination <strong>of</strong> the same patient reveals<br />
severe, macrovesicular fatty changes.<br />
Case No 6<br />
The liver biopsy differed substantially from other patients.<br />
Diffuse, mixed steatotic changes were seen only in about 5-<br />
10% <strong>of</strong> hepatocytes. No inflammatory infiltrates, fibrosis or<br />
cholestasis were detected in the liver.<br />
Case No 7<br />
The girl was referred to autopsy examination with diagnosis<br />
<strong>of</strong> cardiac insufficiency due to hypertrophied cardiomyopathy.<br />
Appropriate diagnosis was established retrospectively,<br />
some years after death on the basis on genetic family study. It<br />
was performed after her younger brother was diagnosed to<br />
have LCHAD deficiency. On autopsy examination features <strong>of</strong><br />
excentric hypertrophy <strong>of</strong> left cardiac ventricle with accompanying<br />
signs <strong>of</strong> mitral insufficiency and endocardial thickening<br />
was observed. Steatosis <strong>of</strong> the liver was also reported in<br />
autopsy protocol, but no morphological characteristic was<br />
made. Microscopically, macrovesicular steatosis <strong>of</strong> diffuse localization<br />
consisted <strong>of</strong> 10 % <strong>of</strong> hepatocytes accompanied by<br />
mild fibrosis was found. No inflammation and cholestasis was<br />
observed.
92<br />
Summary<br />
Liver steatosis <strong>of</strong> severe degree involving 100% <strong>of</strong> liver parenchyma<br />
was found in three patients (No 1, 2, and 5) who<br />
died during ALTE. Moderate steatosis involving approximately<br />
60% <strong>of</strong> liver was present in one biopsy ( No 3). Mild steatosis<br />
affecting 30% and 15% <strong>of</strong> liver parenchyma was found in two<br />
biopsies coming from cases 4 and 6, respectively. In one autopsy<br />
sample liver steatosis involved 10% <strong>of</strong> parenchyma (No<br />
7). Steatosis was macrovacuolar or mixed. The first type was<br />
found in two sequential examinations <strong>of</strong> the same patient (biopsy<br />
– No 4 and autopsy – No 5) and in two autopsies (samples<br />
No 2 and 7). Macrovacuolar steatosis was severe in two cases<br />
(No 2 and 5) and mild in two others (No 4 and 7). Mixed<br />
steatosis was seen in two biopsies (No 3 and 6) and one autopsy<br />
(No 1). Its degeree was mild (sample No 6), moderate<br />
(sample No 3), and severe (sample No 1). None <strong>of</strong> the patients<br />
had pure microvacuolar fatty liver. In six cases distribution<br />
<strong>of</strong> steatotic hepatocytes was diffuse, in one focal (sample<br />
No 4). Inflammation was present in three cases. It was mild<br />
(cases No 3 and 5) or severe (case No 4). Fibrosis was disclosed<br />
in four examined samples derived from three patients:<br />
in two cases its intensity was mild (No 2 and 7) in two severe<br />
(samples No 4 and 5). Liver biopsy samples available for assessment<br />
from the same patient disclosed progression from<br />
precirrhosis to cirrhosis. Data concerning patients and their<br />
liver morphology are presenting in Table 1.<br />
Discussion<br />
It is known that the process <strong>of</strong> mitochondrial fatty acid oxidation<br />
can be divided in two stages. First involves transport<br />
through mitochondrial membrane, the second consists <strong>of</strong> cutting<br />
<strong>of</strong>f two-carbon moieties from fatty acid chain by several<br />
enzymes for long, medium, and short chain fatty acids, respectively<br />
[5, 9, 11]. Fatty liver may develop in both patients<br />
with defects <strong>of</strong> the first stage involving carnitine dependent<br />
transport [2, 3, 12], and with defects <strong>of</strong> the proper beta-oxidation<br />
[2, 4, 6-8, 10, 11]. Baldridge in his study <strong>of</strong> 82 patients<br />
with liver steatosis reported only one child in whom the<br />
LCHAD deficiency was established [1]. Our group comprises<br />
six patients with this diagnosis. Roe and Coates provided general<br />
description <strong>of</strong> liver morphology in LCHAD deficiency<br />
[9]. They pointed lipid accumulation and sometimes accompanying<br />
fibrosis as characteristic features <strong>of</strong> this disorder. Our<br />
findings are consistent with this observation. However, they<br />
have not provided particulars concerning intensity, type, and<br />
distribution <strong>of</strong> steatosis. Gilbert-Barness and Barness have<br />
presented more detailed description <strong>of</strong> liver microscopical<br />
pathology in LCHAD deficient patients [5]. They considered<br />
diffuse or zonal macrovacuolar severe fatty liver to be characteristic<br />
<strong>of</strong> the majority <strong>of</strong> LCHAD-deficient patients. In our<br />
group this type <strong>of</strong> morphological pattern was found in three<br />
patients always when the liver biopsy was performed at the<br />
acute clinical presentation.<br />
In a number <strong>of</strong> described patients with LCHAD deficiency<br />
the liver discloses only focal steatosis <strong>of</strong> mild intensity<br />
[5]. We observed focal fatty changes only in one case out <strong>of</strong><br />
seven (sample No 4). In remaining patients the degree <strong>of</strong> steatosis<br />
was mild to moderate and was almost invariably diffusely<br />
distributed.<br />
Moore described morphology <strong>of</strong> the liver in six months<br />
old girl with LCHAD deficiency [7]. There were mixed steatosis<br />
accompanied by mild cholestasis. Author has not provided<br />
data concerning intensity and localization <strong>of</strong> fatty<br />
changes. In our series <strong>of</strong> seven cases we did not find any case<br />
with the features <strong>of</strong> cholestasis.<br />
Tyni described liver morphology including microscopical<br />
findings <strong>of</strong> 16 patients coming from 12 families, who died<br />
with diagnosis <strong>of</strong> LCHAD deficiency [11]. All patients in her<br />
study had features <strong>of</strong> macrovacuolar fatty liver. In our patients<br />
steatosis was not only macrovacuolar, but also mixed. Tyni<br />
concluded that steatosis was typical for fatty acid beta oxidation<br />
defects, and emphasized that accompanying fibrosis was<br />
Table 1<br />
Details <strong>of</strong> morphological changes <strong>of</strong> the liver in patients with LCHADD<br />
Type <strong>of</strong><br />
examination<br />
Sample<br />
No<br />
Age<br />
(mo)<br />
Intensity <strong>of</strong><br />
steatosis (%)<br />
Type <strong>of</strong><br />
steatosis<br />
Localization<br />
<strong>of</strong> steatosis<br />
Inflammation<br />
Fibrosis Cholesta<br />
A 3299 4 100 mixed diffuse no no no<br />
A 3289 3 100 macro diffuse no mild no<br />
B 30573 12 60 mixed diffuse mild no no<br />
B 30760 3 30 macro focal severe precirrhosis no<br />
A 2701 6 100 macro diffuse mild cirrhosis no<br />
B 51605 7 15 mixed diffuse no no no<br />
A 3070 6 10 macro diffuse no mild no
93<br />
especially typical for LCHAD deficiency [11]. In our series<br />
the fibrosis was found in four out <strong>of</strong> seven liver samples (obtained<br />
from three children). Tyni suggested presence <strong>of</strong> relationship<br />
between the severity <strong>of</strong> clinical course and the intensity<br />
<strong>of</strong> morphological changes in the liver [11]. Our observations<br />
are in agreement with this statement.<br />
Our observations strongly underline that liver steatosis<br />
<strong>of</strong> any degree detected at autopsy <strong>of</strong> a child died without<br />
clearly established diagnosis obliges to include fatty acids<br />
oxidation disorders into the differential diagnosis [2]. One <strong>of</strong><br />
our patient, died many years ago with the diagnosis <strong>of</strong> hypertrophied<br />
cardiomyopathy, was detected just recently as<br />
LCHAD-deficient during genetic family study, after establishing<br />
LCHAD deficiency in her younger brother. Lack <strong>of</strong> acute<br />
life threatening episode in her medical history and only mild<br />
degree <strong>of</strong> liver steatosis in her post mortem examination, preliminarily<br />
did not paid our attention and missed from correct<br />
diagnosis.<br />
In general our results are consistent with observations <strong>of</strong> other<br />
authors and warrant drawing the following conclusions:<br />
1. Fatty liver is characteristic <strong>of</strong> LCHAD deficiency.<br />
2. Intensity <strong>of</strong> steatosis is related to severity <strong>of</strong> clinical symptoms<br />
3. In patients with mitochondrial beta-oxidation defects liver<br />
steatosis may be accompanied by fibrosis which is suggestive<br />
<strong>of</strong> LCHAD deficiency.<br />
4. Fatty liver found in a patient who died <strong>of</strong> undiagnosed disease<br />
should suggest the possibility <strong>of</strong> LCHAD deficiency<br />
as a cause <strong>of</strong> death.<br />
5. Semi-thin plastic embedded tissue section postfixed in osmium<br />
tetroxide and stained with toluidine blue is very helpful<br />
in reliable assessment <strong>of</strong> liver steatosis<br />
Acknowledgments<br />
The study was supported by a statutory grant No S 86 <strong>of</strong> The<br />
Children’s Memorial Health Institute<br />
References<br />
1. Baldridge AD, Perez-Atayde AR<br />
Graeme-Cook F, Higgins L, Lavine JE<br />
(1995) Idiopathic steatohepatitis in<br />
childchood A multicenter study. J<br />
Pediatr 127:700-704<br />
2. Chace DH, DiPerna JC, Mitchell BL,<br />
Sgroi B, H<strong>of</strong>man LF, Naylor EW (2001)<br />
Electrospray Tandem Mass Spectrometry<br />
or Analysis <strong>of</strong> Acylcarnitines in Dried<br />
Postmortem Blood Spcimens Collcted at<br />
Autopsy from Infants with Unexplained<br />
Cause <strong>of</strong> Death. Clin Chemist<br />
47(7):1166-1182<br />
3. Chalmers RA, Stanley CA, English N,<br />
Wigglesworth JS (1997) Mitochondrial<br />
carnitine-acylcarnitine translocase deficiency<br />
presenting as sudden neonatal<br />
death. J Pediatr 131:220-225<br />
4. Dawson DB, Waber L, Hale DE,<br />
Bennett MJ (1995) Transient organic<br />
aciduria and persistent lacticacidemia in<br />
a patient with short-chain acyl-coenzyme<br />
A dehydrogenase deficiency. J<br />
Pediatr 126:69-71<br />
5. Gilbert-Barness and Barness (2000)<br />
Fatty acids beta-oxidation defects. In:<br />
Gilbert-Barness and Barness (eds)<br />
Metabolic Diseases Eaton Publishing,<br />
Natick, pp113-136<br />
6. Iafolla AK, Thompson RJ, Roe CR<br />
(1994) Medium-chain acyl-coenzyme A<br />
dehydrogenase deficiency: Clinical<br />
course in 120 affected children. J Pediatr<br />
124:409-415<br />
7. Moore R, Glasgow JFT, Bingham MA,<br />
Dode JA, Pollitt RJ,Olpin SE, Middleton<br />
B, Carpentier K (1993) Long chain 3-<br />
hydroxyacyl-coenzyme A dehydrogenase<br />
deficiency – diagnosis,<br />
plasmacarnitine fractions and management<br />
in a further patient. Eur J Pediatr<br />
152:433-6<br />
8. Roe CR Millington DS, Maltby DA<br />
Kinnebrew P (1986) Recognition <strong>of</strong> medium-chain<br />
acyl-CoA dehydrogenase<br />
deficiency in asymptomatic siblings <strong>of</strong><br />
children dying <strong>of</strong> sudden infant death<br />
or Reye-like syndromes. J Pediatr<br />
108:13-18<br />
9. Roe CR, Coates PM (1995) Mitochondrial<br />
fatty acids oxidation disorders. In:<br />
Scriver CR, Beaudet AL, Sly WS, Valle<br />
D (eds) The metabolic and molecular<br />
basis <strong>of</strong> inherited disease. McGraw-Hill,<br />
New York, pp 1501-1535<br />
10. Santer R, Schmidt-Sommerfeld E,<br />
Leung YK, Fischer JE, Lebental E<br />
(1990) Medium-chain acyl-CoA dehydrogenase<br />
deficiency: electron microscopic<br />
differentiation from Reye syndrome.<br />
Eur J Pediatr 150:111-114<br />
11. Tyni T, Rapola J, Paetau A, Palotie A,<br />
Pihko H (1997) Patology <strong>of</strong> long chain<br />
3-hydroxyacyl-CoA dehydrogenase deficiency<br />
causes by the G1528C mutation.<br />
Ped Path Lab Med 17:427-447<br />
12. Winter SC, Szabo-Aczel S, Curry CJR,<br />
Hutchinson HT, Hogue R, Shug A<br />
(1987) Plasma carnitine deficiency<br />
Clinical Observations in 51 Pediatric<br />
Patients. AJDC 141:660-665
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Isolation <strong>of</strong> urothelial cells for tissue engineered<br />
bladder augmentation<br />
Tomasz Drewa 1, 2 , Przemys³aw Galazka 1, 3 , Zbigniew Wolski 2 , Andrzej I. Prokurat 3 , Jan Sir 4<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
1<br />
Department <strong>of</strong> Biology,<br />
2<br />
Department <strong>of</strong> Urology,<br />
3<br />
Department <strong>of</strong> Pediatric Surgery,<br />
The L. Rydygier Medical University in Bydgoszcz,<br />
Bydgoszcz, Poland<br />
4<br />
Department <strong>of</strong> <strong>Pathology</strong>,<br />
Oncological Center in Bydgoszcz,<br />
Bydgoszcz, Poland<br />
Abstract<br />
Objectives. In case <strong>of</strong> certain human congenital anomalies such as bladder extrophies, there may not be<br />
enough residual bladder for closure. Tissue engineering is a promising method for bladder augmentation.<br />
The aim <strong>of</strong> our study was to compare isolation efficiency <strong>of</strong> various digestive mixtures and establish isolation<br />
and cell culture methodology <strong>of</strong> urothelium. Different variants <strong>of</strong> growth media and their influence on proliferative<br />
capacity was assessed. Methods. Primary Rabbit Urothelial Cells (PRUC) culture was established<br />
from 8 months old male rabbit urinary bladder wall. 5 different digesting mixtures for isolation <strong>of</strong> urothelial<br />
cells were tested. Cells obtained from 0.1% collagenase I digestion after 1 and 4 hours were checked for their<br />
growth potential in 3 different media. Results. The best digestion solution for urothelial cells isolation was<br />
0.1% collagenase I. It can be noticed that the cell number <strong>of</strong> all secondary cultures was higher after 4 h<br />
digestion than after 1 h. The medium substrates also influenced total cell number in urothelial subcultures.<br />
The best foetal bovine serum (FBS) supplementation was 5%, when the medium was additionally enriched<br />
with micro-supplements. Conclusions. Despite <strong>of</strong> enzymes used for isolation, the digestion time and medium<br />
enriched with properly amount <strong>of</strong> serum both deeply influence on the outcome <strong>of</strong> cell therapy. Autologous<br />
cells could be used for urinary tract reconstruction using tissue engineering methods.<br />
Key words: tissue engineering, urinary tract reconstruction, urothelial cells<br />
Introduction<br />
In case <strong>of</strong> certain human congenital anomalies such as bladder<br />
extrophies, there may not be enough residual bladder for closure<br />
[7]. The autologous materials and techniques have been<br />
proposed for bladder augmentation with small and large bowel,<br />
stomach [1, 13]. Unfortunately none <strong>of</strong> used materials has been<br />
enough satisfactory [9, 17]. A number <strong>of</strong> biomaterials have been<br />
used in experimental models including acellular tissue matrix<br />
grafts, synthetic biodegradable or non-biodegradable polymers<br />
[2]. Many reports revealed failure <strong>of</strong> these attempts because <strong>of</strong><br />
recurrent urinary tract infections, marked contracture <strong>of</strong> the graft<br />
or graft rejection and stones formation [5, 12, 15, 17].<br />
Tissue engineering is a promising method for bladder augmentation<br />
[7]. The use <strong>of</strong> an autologous cultured urothelium for<br />
bladder reconstruction could prevent many <strong>of</strong> the problems associated<br />
with applied materials [4]. Tissue engineered bladder<br />
wall consisting <strong>of</strong> a adequate shaped biodegradable polymer<br />
used as a scaffold, can deliver autologous urothelial cells [11].<br />
This device may restore bladder capacity more effective than<br />
biomaterials alone. Atala et al demonstrated that urothelial cells<br />
seeding on the bioabsorbable scaffold can allow creation <strong>of</strong> new<br />
functional urinary bladder wall [3].<br />
Address for correspondence<br />
Tomasz Drewa, MD, PhD<br />
Dpt. <strong>of</strong> Medical Biology,<br />
the L. Rydygier Medical University in Bydgoszcz<br />
Ul. Karlowicza 24<br />
85-094 Bydgoszcz, Poland<br />
E-mail: tomaszdrewa@wp.pl
96<br />
The aim <strong>of</strong> our study was to compare isolation efficiency <strong>of</strong><br />
various digestive mixtures and establish proper isolation methodology<br />
<strong>of</strong> urothelial cells. Also different variants <strong>of</strong> growth<br />
medium and its influence on proliferative capacity <strong>of</strong> growing<br />
cells was assessed. In the future these cells can be used for urinary<br />
tract reconstruction using tissue engineering methods.<br />
Methods<br />
Primary Rabbit Urothelial Cells (PRUC) culture was established<br />
from 8 months old male rabbit urinary bladder wall.<br />
After ketamine (25 mg/kg m.c. i.m.) and scoline (50 mg/kg)<br />
overdosage bladder wall sample (5 x 5 cm) was obtained. Fragment<br />
was immersed in sterile Phosphate Buffered Saline (PBS,<br />
Biomed). In the next step urinary mucosa was mechanically<br />
separated from muscle layer. At this stage samples were cut<br />
into 12 equal sized parts (1 cm 2 each). Mucosa samples were<br />
cut into 2 mm 3 pieces.<br />
First <strong>of</strong> all 5 different digesting mixtures for isolation<br />
<strong>of</strong> urothelial cells were tested. Incubation time was 4 hours.<br />
Digesting solutions were as follow:<br />
1. 0.125% trypsin and 0.01% EDTA<br />
2. 0.08 % trypsin and 0.006% EDTA<br />
3. 0.06 % trypsin and 0.005% EDTA<br />
4. 0.05% trypsin and 0.02% EDTA<br />
5. 0.1% collagenase-I<br />
After incubation time the cell pellet was centrifuged<br />
(800 g/5 min), resuspended in each <strong>of</strong> the tested culture media<br />
and seeded on 25 cm 2 culture dishes (Greiner). Cells were<br />
identified as epithelial cells by morphological criteria as well<br />
as presence <strong>of</strong> cytokeratins (Anti-Cytokeratin, Clone: MNF<br />
116, DAKO), after three passages.<br />
In the next step 2 nd PRUC was established using the<br />
most efficient digestive solution: 0.1% collagenase I. Digestion<br />
efficiency was assessed using two incubation times (1<br />
and 4 hours). Cells obtained from 0.1% collagenase I digestion<br />
after 1 and 4 hours were checked for their growth potential<br />
in 3 different media:<br />
I- DMEM supplemented with 10% FBS and antibiotics: penicillin<br />
(100 IU/ml) (Polfa) and streptomycin (100 ug/ml) (Polfa)<br />
II- 3:1 DMEM and F-12 mixture supplemented with 5% FBS,<br />
epidermal growth factor (EGF, Sigma), bovine pituary extract<br />
(Sigma), cholera toxin (30 ng/ml) (Sigma), penicillin (100<br />
IU/ml) (Polfa) and streptomycin (100 ug/ml) (Polfa)<br />
III- 1:1 DMEM and F-12 mixture supplemented with 2.5%<br />
FBS, epidermal growth factor (EGF, Sigma), bovine pituary<br />
extract (Sigma), cholera toxin (30 ng/ml) (Sigma), penicillin<br />
(100 IU/ml) (Polfa) and streptomycin (100 ug/ml) (Polfa).<br />
Cells were seeded on 25 cm 2 culture dishes (Greiner)<br />
and grown in 37 o C in a humidified atmosphere with 5% CO 2<br />
.<br />
Cells were counted using trypan blue exclusion test after four<br />
days <strong>of</strong> cultivation. Neubauer«s cytologic chamber was used<br />
for counting. Morphology was examined under inverted microscope.<br />
Photographic documentation was done.<br />
Mean values (+/-SD) from 10 counts for each culture were<br />
compared to each other. The Student test was used for statistical<br />
analysis. A p value
97<br />
3<br />
2<br />
1<br />
0<br />
x10 6 cells<br />
1 hour 4 hours<br />
Fig. 2 Digestion efficiency using 0.1% collagenase I solution was assessed<br />
using two incubation times (1 and 4 hours)<br />
4<br />
3<br />
2<br />
1<br />
0<br />
x10 6 cells<br />
A B C D E F<br />
Fig. 3 Cells obtained from 0.1% collagenase I digestion after 1 hour (a,b,c)<br />
and 4 hours (d,e,f) were checked for their growth potential in 3 different<br />
media as: - DMEM with 10% FBS (a,d); - 3:1 DMEM and F-12 mixture<br />
enriched with microsupplements and 5% FBS (b,e); - 1:1 DMEM and F-12<br />
mixture enriched with microsupplements and 2.5% FBS (c,f). Cells were<br />
counted after 4 days <strong>of</strong> culturing (A vs D, p
References<br />
1. Adams MC, Mitchell ME, Rink RC<br />
(1882) Gastrocystoplasty: an alternative<br />
solution to the problem <strong>of</strong> urological reconstruction<br />
in the severely compromised<br />
patient. J Urol 140:1152-1156<br />
2. Atala A (1997) Tissue engineering in<br />
the genitourinary system. In: Tissue engineering,<br />
Atala A, Mooney D (eds)<br />
Birhauser Press, Boston, MA, pp. 149-<br />
164<br />
3. Atala A (2002) Future trends in bladder<br />
reconstructive surgery. Semin Pediatr<br />
Surg 11:134-142<br />
4. Atala A, Vacanti JP, Peters CA, Mandell<br />
J, Retik AB, Freeman MR (1992) Formation<br />
<strong>of</strong> urothelial structures in vivo<br />
from dissociated cells attached to biodegradable<br />
polymer scaffolds in vitro.J<br />
Urol 148:658-662<br />
5. Cain MP, Casale AJ, Kaefer M, Yerkes<br />
E, Rink RC (2002) Percutaneous<br />
cystolithotomy in the pediatric augmented<br />
bladder. J Urol 168(4 Pt<br />
2):1881-1882<br />
6. Drewa T, Wolski Z, Galazka P, Sir J,<br />
WoŸniak A, Czaplewski A (2004) Preliminary<br />
study on alginate scaffold application<br />
for chondrocytes transplantation<br />
into the rat bladder wall.<br />
Biotechnologia 3(66):213-224<br />
7. Fauza DO, Fishmann SJ, Mehegan K,<br />
Atala A (1998) Videoscopically assisted<br />
fetal tissue engineering: bladder augmentation.<br />
J Ped Surg 33(1):7-12<br />
8. Follmann W, Guhe C, Weber S, Birkner<br />
S, Mahler S (2000) Cultured porcine urinary<br />
bladder epithelial cells as a screening<br />
model for genotoxic effects <strong>of</strong> aromatic<br />
amines: characterisation and application<br />
<strong>of</strong> the cell culture model. Altern<br />
Lab Anim 28(6):833-854<br />
9. Gough DC (2001) Enterocystoplasty.<br />
BJU 88(7):739-743<br />
10. Hobbiesiefken J, Ehlers ME, Behrens<br />
P, Wunsch L (2003) Urothelial mesh- a<br />
new technique <strong>of</strong> cell culture on<br />
biomaterials. Eur J Pediatr Surg<br />
13(6):361-366<br />
11. Kim BS, Baez CE, Atala A (2000)<br />
Biomaterials for tissue engineering.<br />
World J Urol 18(1):2-9<br />
12. Mingin GC, Stock JA, Hanna MK<br />
(1999) Gastrocystoplasty: long-term<br />
complications in 22 patients. J Urol<br />
162(3 Pt 2):1122-1125<br />
13. Motley RC, Montgomery BT, Zollman<br />
PE, Holley KE, Kramer SA (1990) Augmentation<br />
cystoplasty utilizing de-epithelialized<br />
sigmoid colon: a preliminary<br />
study. J Urol 143:1257-1260<br />
14. Rebel JM, De Boer WI, Thijssen CD,<br />
Vermey M, Zwarth<strong>of</strong>f EC, Van der<br />
Kwast TH (1994) An in vitro model <strong>of</strong><br />
urothelial regeneration: effects <strong>of</strong><br />
growth factors and extracellular matrix<br />
proteins. J Pathol. 173(3):283-291<br />
15. Sugasi S, Lesbros Y, Bisson I, Zhang YY,<br />
Kucera P, Frey P (2000) In vitro engineering<br />
<strong>of</strong> human stratified urothelium: analysis<br />
<strong>of</strong> its morphology and function. J Urol<br />
164(3 Pt 2):951-957<br />
16. Wechselberger G, Schoeller T, Stenzl A,<br />
Ninkovic M, Lille S, Russell RC (1998)<br />
Fibrin glue as a delivery vehicle for autologous<br />
urothelial cell transplantation<br />
onto a prefabricated pouch. J Urol<br />
160(2):583-586<br />
17. Woodhouse CR, Redgrave NG (1996)<br />
Late failure <strong>of</strong> the reconstructed exstrophy<br />
bladder. Br J Urol 77(4):590-592<br />
18. Zhang YY, Ludwikowski B, Hurst R,<br />
Frey P (2001) Expansion and long-term<br />
culture <strong>of</strong> differentiated normal rat<br />
urothelial cells in vitro. In Vitro Cell Dev<br />
Biol Anim 37(7):419-429
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Status <strong>of</strong> oral hygiene and dentition in children<br />
exposed to anticancer treatment<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
Dorota Olczak-Kowalczyk 1 , Marta Daszkiewicz 1 , Barbara Adamowicz-Klepalska 2 , El¿bieta Czarnowska 3 ,<br />
Agnieszka Sowiñska 3 , Bo¿ena Dembowska-Bagiñska 4 , Danuta Perek 4 , Pawe³ Daszkiewicz 5<br />
1<br />
Department <strong>of</strong> Oral <strong>Pathology</strong>,<br />
3<br />
Department <strong>of</strong> <strong>Pathology</strong>,<br />
4<br />
Department. <strong>of</strong> Oncology,<br />
5<br />
Department <strong>of</strong> Neurosurgery,<br />
The Children’s Memorial Health Institute,<br />
Warsaw, Poland<br />
2<br />
Department <strong>of</strong> Developmental Age Stomatology,<br />
Medical Academy,<br />
Gdañsk, Poland<br />
Abstract<br />
Background: Deleterious effects <strong>of</strong> radiation and chemotherapy on oral cavity tissues are well known, but<br />
little data exist on the effect <strong>of</strong> combined anticancer treatment on developing teeth. Additionally, there are no<br />
established standards for dental care in children undergoing complex anticancer treatment. The aim <strong>of</strong> study:<br />
Evaluation <strong>of</strong> oral hygiene and dentition status in children subjected to combined anticancer treatment. Material<br />
and method: 88 children (age range 3-18 years), who underwent combined chemo-radiotherapy or<br />
chemotherapy alone due to a malignant neoplasm, were included to the study. Follow-up time was from 6<br />
months to 5 years. Patients were assessed in the dental out-patients’ clinic and their medical documentation<br />
reviewed. Results and conclusions: An inadequate oral hygiene was found in all patients as well as a severe<br />
caries and an increased incidence <strong>of</strong> non-caries-mediated enamel defects. A deleterious effect <strong>of</strong> combined<br />
chemo-radiotherapy on mineralized tooth tissues was found, both in primary and in permanent teeth. Ionizing<br />
radiation had a stronger negative impact than chemotherapy alone. In all children analyzed, there was a<br />
discrepancy between actual requirements for dental care and currently performed dental treatment.<br />
Key words: children, chemotherapy, enamel structure, oral hygiene, permanent dentition, primary dentition,<br />
radiotherapy<br />
Introduction<br />
Anticancer treatment, including chemotherapy and radiotherapy<br />
<strong>of</strong> the facial region, may enhance both the development<br />
<strong>of</strong> dental caries and also <strong>of</strong> non-caries dependant lesions<br />
on smooth surfaces <strong>of</strong> teeth [4-6, 10, 11]. The etiology <strong>of</strong> these<br />
phenomena is multi-factorial and still poorly understood. Both<br />
chemo- and radiotherapy increase the susceptibility <strong>of</strong> teeth<br />
to noxious factors and affect adversely the ecosystem <strong>of</strong> oral<br />
cavity [9, 10]. In patients undergoing combined anticancer<br />
treatment, these adverse effects may enhance each other [7].<br />
In general opinion, the direct effect <strong>of</strong> ionizing radiation<br />
on teeth leads to denaturation <strong>of</strong> protein matrix <strong>of</strong> the dentin<br />
and to damage <strong>of</strong> its structure due to degeneration and dysfunction<br />
<strong>of</strong> dental pulp. On the other hand, there is much less<br />
information concerning the pathogenesis <strong>of</strong> enamel lesions in<br />
Address for correspondence<br />
Dorota Olczak-Kowalczyk<br />
Department <strong>of</strong> Oral <strong>Pathology</strong><br />
The Children's Memorial Health Institute<br />
Al. Dzieci Polskich 20<br />
04-736 Warsaw, Poland<br />
Phone : +4822 815 13 15; +4822 815 16 31<br />
E-mail : dok.@bobas.czd.pl
100<br />
available literature. Enamel is described as poorly mineralized,<br />
less hard and more brittle, or as more susceptible to damage by<br />
acids while preserving normal hardness. Independent on the<br />
mechanism <strong>of</strong> radiation-induced lesions in mineralized tissues<br />
<strong>of</strong> teeth, they become more susceptible to harmful factors [5].<br />
There is little data concerning the effects <strong>of</strong> chemotherapy not<br />
combined with radiotherapy on teeth. Nevertheless, they show<br />
its deleterious effect on the function <strong>of</strong> dental pulp, thereby<br />
increasing susceptibility <strong>of</strong> teeth to various pathologic processes<br />
[10]. The effect <strong>of</strong> particular cytostatics on tooth pulp is difficult<br />
to ascertain. This is due to general use <strong>of</strong> multi-drug chemotherapy<br />
regimens. Toxic effects <strong>of</strong> vincristin are known the<br />
best. Histopathologic examination <strong>of</strong> teeth extracted from patients<br />
undergoing multi-drug chemotherapy revealed linear lesions,<br />
most probably resulting from disturbed production <strong>of</strong><br />
collagen matrix by odontoblasts. An important point is finding<br />
<strong>of</strong> correlation between the number and distribution <strong>of</strong> these lines<br />
and chemotherapy cycles, when one <strong>of</strong> administered drugs was<br />
vincristin [6]. It is also well known that colchicin and vinblastin<br />
block dentin formation in incisors in rats, while trethanomelamin<br />
and cyclophosphamide delay cutting <strong>of</strong> molars in these animals<br />
[6, 7].<br />
Adverse change <strong>of</strong> oral eco-system in patients undergoing<br />
anticancer treatment is caused mainly by qualitative and<br />
quantitative disturbances <strong>of</strong> salivary secretion [9]. Facial irradiation<br />
<strong>of</strong>ten leads to dysfunction <strong>of</strong> serous cells <strong>of</strong> parotid<br />
gland. Depending on total absorbed dose <strong>of</strong> radiation (over<br />
60 Gy), this may lead to total (irreversible) or partial (reversible)<br />
xerostomia and to qualitative change <strong>of</strong> saliva, such as<br />
increased viscosity, decreased buffering properties and decreased<br />
IgA level. A decreased volume <strong>of</strong> secreted saliva may<br />
accompany administration <strong>of</strong> many cytostatic drugs [2, 4, 9].<br />
Increased acidity <strong>of</strong> oral cavity may be further enhanced by<br />
vomiting, which <strong>of</strong>ten accompanies chemotherapy. An extremely<br />
unfavorable aspect <strong>of</strong> chemotherapy is its prolonged<br />
administration, ranging from 6 months to 3 years, depending<br />
on the kind <strong>of</strong> neoplasm.<br />
Unfavorable alteration <strong>of</strong> oral eco-system in patients undergoing<br />
oncologic treatment may enhance demineralization<br />
<strong>of</strong> teeth, thus increasing the susceptibility <strong>of</strong> teeth to cariespromoting<br />
bacteria, leading to the development <strong>of</strong> caries and<br />
erosion <strong>of</strong> enamel. Particular form <strong>of</strong> pathologic process (caries<br />
and/or erosion) depends mainly on acid pH and duration <strong>of</strong><br />
its contact with mineralized tissues <strong>of</strong> teeth [2]. Increased susceptibility<br />
<strong>of</strong> teeth to the influence <strong>of</strong> deleterious factors (chemical,<br />
bacterial and mechanical) may be an important factor particularly<br />
in children and adolescents, where it is caused not only<br />
by the neoplasm itself and anti-cancer therapy, but also by morphologic<br />
and functional immaturity <strong>of</strong> teeth [15, 16].<br />
When discussing the etiology <strong>of</strong> damage to mineralized<br />
tissues <strong>of</strong> teeth observed in patients undergoing anti-cancer<br />
treatment, we must also take into account the effect <strong>of</strong><br />
neurologic deficits, e.g. weakness <strong>of</strong> chewing muscles leading<br />
to “lazy” chewing and compromising self-purification <strong>of</strong><br />
oral cavity. Other important factors are: co-existing stomatitis,<br />
disturbed taste, lack <strong>of</strong> appetite and general malaise, leading<br />
to hygienic neglect and dietary mistakes.<br />
There is no published data concerning the pr<strong>of</strong>ile <strong>of</strong> structural<br />
changes in mineralized tissues <strong>of</strong> teeth, developing in children<br />
undergoing chemotherapy combined with facial irradiation.<br />
Aim <strong>of</strong> the study<br />
The aim <strong>of</strong> this study was clinical assessment <strong>of</strong> lesions in<br />
mineralized tissues <strong>of</strong> teeth in children subjected to chemotherapy<br />
combined with radiotherapy to the facial region and<br />
an electron-microscopic analysis <strong>of</strong> structure <strong>of</strong> atypical defects<br />
present on smooth surface <strong>of</strong> primary teeth.<br />
Material and method<br />
Patients. The study included 88 children (57 boys and 31 girls)<br />
aged from 3 to 18 years, who underwent combined anti-cancer<br />
treatment. Time since completion <strong>of</strong> oncologic treatment<br />
ranged from 6 months to 5 years. Patients’ characteristics concerning<br />
basic diagnosis, total dose <strong>of</strong> radiation and location<br />
<strong>of</strong> irradiated area (face or neurocranium), are presented in Table<br />
1. Children included in the study have been subdivided into 3<br />
subgroups: those with primary dentition, those with mixed<br />
dentition and those with permanent dentition (Table 2).<br />
Stomatologic assessment <strong>of</strong> dentition. Dental examinations<br />
were performed in the setting <strong>of</strong> a dental <strong>of</strong>fice, using<br />
a shadowless lamp, dental probe and dental mirror. Primary<br />
assessed parameters included: oral hygiene and dental status,<br />
presence <strong>of</strong> caries, fillings, non-caries-mediated enamel defects<br />
and missing teeth. At the same time, prophylactic and<br />
therapeutic requirements were defined and secondary endpoints<br />
were assessed, such as frequency and severity <strong>of</strong> caries,<br />
treatment index and incidence <strong>of</strong> atypical non-caries-mediated<br />
defects.<br />
Oral hygiene. Oral hygiene was assessed using the<br />
“Oral Hygiene Index” according to Green and Vermillion<br />
(OHI-S). Dental plaque stained with eosin was evaluated on<br />
buccal/labial and palatal/lingual surfaces <strong>of</strong> 6 representative<br />
teeth: 55 (15), 53 (13), 51 (11), 75 (36), 73 (13), 71 (31). If<br />
the desired tooth was missing, the adjacent tooth was examined.<br />
On the basis <strong>of</strong> mean values <strong>of</strong> the OHI-S index, oral<br />
hygiene was considered good if the score was 0-1,0; adequate<br />
if the score was >1,0-2,0 and poor if the score was >2,0-3,0.<br />
Severity <strong>of</strong> caries. Evaluation was performed according<br />
to the DMF index for permanent teeth and the dmf index for<br />
primary teeth. The following lesions <strong>of</strong> mineralized tooth tissues<br />
were considered as atypical: white smooth stains, white or<br />
rusty rough stains, enamel defect within a white or a rusty stain.<br />
Structure <strong>of</strong> defect surface. Teeth were cut along the longitudinal<br />
axis and transversely at the defect level. They were<br />
fixed in 4 % glutaraldehyde solution (Serva) in 0.1 M cacodyle<br />
buffer with pH value <strong>of</strong> 7.3 (BDH Chemicals Ltd, Poole, England)<br />
and next they were dehydrated using increasing concentrations<br />
<strong>of</strong> ethyl alcohol and acetone. Tooth fragments were attached<br />
to brass rods with silver paste (AGAR, England) and<br />
vacuum-coated with charcoal and gold powder and finally analyzed<br />
using a scanning electron microscope (JSM 35C, Jeol).
101<br />
Table 1<br />
Diagnosis, mean total dose and field <strong>of</strong> radiation in patients subjected to combined chemo-radiotherapy. Radiation fields<br />
included teeth and teeth buds<br />
Diagnosis<br />
Number <strong>of</strong><br />
children (N)<br />
Mean dose <strong>of</strong><br />
radiation (cGy)<br />
Irradiated field<br />
Medulloblastoma 18 3500<br />
4500<br />
Neural axis (brain and spinal cord)<br />
Posterior fossa<br />
Brainstem tumors 7 5400 Tumor site<br />
Ependymoma 5 5400 Tumor site<br />
Astrocytoma III 5 5400 Tumor site<br />
Glioblastoma multiforme 2 5400 Tumor site<br />
Carcinoma plexus chorioidei 3 5400 Tumor site<br />
Nasopharyngeal<br />
9 5400 Tumor site<br />
rhabdomyosarcoma<br />
Non-Hodgkin lymphoma 1 2400 Neural axis<br />
Neuroblastoma stage IV 1 4500 Brain metastases<br />
Retinoblastoma 1 4500 Lymph node metastases in head and<br />
Table 2<br />
Distribution <strong>of</strong> dentition types in the analyzed population <strong>of</strong><br />
children subjected to anti-cancer treatment<br />
Dentition type<br />
Primary dentition 10<br />
Mixed dentition 30<br />
Permanent dentition 25<br />
Total 65<br />
Results<br />
Number <strong>of</strong> children (N)<br />
Clinical evaluation<br />
The incidence <strong>of</strong> caries in the studied population <strong>of</strong> children<br />
after combined chemo-radiotherapy was high and approached<br />
100 %. Oral hygiene in the whole group studied was considered<br />
adequate (mean OHI-S score = 1,88), while in the subgroup<br />
<strong>of</strong> children with primary teeth oral hygiene was poor<br />
(mean OHI-S score = 2,25) (Table 3).<br />
An analysis <strong>of</strong> severity <strong>of</strong> caries is presented in Table<br />
4. The mean dmf score was 14,6; 7,06 and 6,0 in subgroups <strong>of</strong><br />
children with primary, mixed and permanent teeth respectively,<br />
indicating extremely severe caries both in primary and in permanent<br />
dentition. In all subgroups, the proportion <strong>of</strong> primary<br />
and permanent teeth with active caries were a significant component<br />
<strong>of</strong> the mean score <strong>of</strong> dmf and DMF indices.<br />
An analysis <strong>of</strong> treatment indices, both for primary and<br />
for permanent teeth, showed significant neglect concerning<br />
both treatment and prevention (Table 5). Obtained values were<br />
very small, ranging from 0,02 to 0,43, depending on sex and<br />
type <strong>of</strong> dentition.<br />
In the area <strong>of</strong> dental therapeutic requirements (Table 6), the<br />
need for conservative treatment significantly outnumbered all<br />
other parameters. On the basis <strong>of</strong> proportion <strong>of</strong> teeth with active<br />
caries, need for conservative treatment was observed in<br />
71,42 % <strong>of</strong> teeth in the subgroup <strong>of</strong> children with primary dentition,<br />
in 48,82 % <strong>of</strong> primary teeth and 89.,10 % <strong>of</strong> permanent<br />
teeth in the subgroup with mixed dentition and in 95,22 % <strong>of</strong><br />
teeth in the subgroup <strong>of</strong> children with permanent dentition.<br />
In the subgroup <strong>of</strong> children with primary dentition, the<br />
mean number <strong>of</strong> teeth with active caries was 13,3 out <strong>of</strong> 20,0<br />
teeth examined, where the mean number <strong>of</strong> teeth qualifying<br />
for extraction was 3,8 (Table 7). In children with permanent<br />
dentition, the mean number <strong>of</strong> teeth with caries was 10,88 out<br />
<strong>of</strong> 26,88 teeth examined and the mean number <strong>of</strong> teeth qualified<br />
for extraction was 0,52. In the subgroup <strong>of</strong> children with<br />
mixed dentition, mean numbers <strong>of</strong> teeth with active caries and<br />
teeth qualified for extraction were elevated too. Interpretation<br />
<strong>of</strong> results obtained in this subgroup is difficult due to on-going<br />
process <strong>of</strong> exchange <strong>of</strong> dentition.<br />
Non-caries-mediated enamel defects were noted in 49<br />
children (75,38 % <strong>of</strong> the whole group) (Table 8). The proportion<br />
<strong>of</strong> children with non-caries-mediated enamel defects were<br />
70,0 %, 76,6 % and 76,0 % in the subgroups <strong>of</strong> children with<br />
primary, mixed and permanent dentition, respectively. Noncaries-mediated<br />
enamel defects were located on buccal or labial<br />
surfaces, in pericervical area or encompassed more than<br />
one tooth surface. However, most non-caries-dependant defects<br />
were localized on labial or buccal surfaces, taking the<br />
form <strong>of</strong> white-smooth (173 out <strong>of</strong> 229 lesions seen in 39 subjects)<br />
or rusty-rough patches (156 out <strong>of</strong> 254 lesions seen in<br />
33 subjects). Enamel defects were noticed in 22 patients. Labial<br />
or buccal location <strong>of</strong> lesions was seen in 104 out <strong>of</strong> 182<br />
lesions (Table 8).
102<br />
Table 3<br />
Correlation <strong>of</strong> oral hygiene with age and sex in children subjected to chemio- and radiotherapy (OHI-S mean value)<br />
Dentition type Sex N (children) OHI-S (mean value)<br />
Primary dentition Boys 7 2,51<br />
Girls 3 1,63<br />
Total 10 2,25<br />
Mixed dentition Boys 19 1,90<br />
Girls 11 2,01<br />
Total 30 1,94<br />
Permanent dentition Boys 17 1,70<br />
Girls 8 1,55<br />
Total 25 1,65<br />
Total Boys 43 1,92<br />
Table 4<br />
Girls 22 1,79<br />
Total 65 1,88<br />
Correlation <strong>of</strong> Severity <strong>of</strong> caries, sex and type <strong>of</strong> dentition in children subjected to chemotherapy combined with radiotherapy<br />
(mean scores <strong>of</strong> dmf and DMF indices)<br />
N (teeth)<br />
Indem sc<br />
Dentition<br />
type<br />
Sex<br />
with caries removed filled dmf D<br />
N<br />
(children) d D m M f F<br />
primary boys 7 105 - 0 - 2 - 15,20 -<br />
girls 3 28 - 0 - 11 - 13.0 -<br />
total 10 133 - 0 - 13 - 14.6 -<br />
mixed boys 19 104 102 13 0 20 15 7,21 6.<br />
girls 11 66 54 2 0 7 9 6,81 5,<br />
total 30 170 156 15 0 27 24 7,06 6,<br />
permanent boys 17 - 191 - 1 - 106 - 17<br />
girls 8 - 81 - 3 - 62 - 20<br />
total 25 - 272 - 4 - 168 - 17<br />
d/D - caries in primary /permanent dentition<br />
m/M - removed primary teeth/permanent<br />
f/F - filled primary teeth/permanent<br />
duf/DUF - dental caries severity index in primary/permanent dentition
103<br />
Table 5<br />
Correlation <strong>of</strong> teeth-treatment index, dentition type and sex in children subjected to combined chemo-radiotherapy<br />
Teeth-treatment index<br />
Dentition type Sex N (children) Primary Permanent<br />
Primary boys 7 0,02 -<br />
girls 3 0,28 -<br />
total 10 0,09 -<br />
Mixed boys 19 0,16 0,12<br />
girls 11 0,09 0,14<br />
total 30 0,14 0,13<br />
permanent boys 17 - 0,36<br />
girls 8 - 0,43<br />
total 25 - 0,38<br />
Table 6<br />
Correlation <strong>of</strong> requirement for conservative and surgical treatment with sex and dentition type in children subjected to chemotherapy<br />
combined with radiotherapy<br />
Dentition<br />
type<br />
Sex<br />
N<br />
(children)<br />
examined<br />
N (teeth)<br />
with caries<br />
n=100% For conservative treatment For extraction<br />
M S M S M S M S<br />
n % n % n % n %<br />
Primary boys 7 140 - 105 - 71 67,6 - - 34 32,4 - -<br />
girls 3 60 - 28 - 24 85,7 - - 4 14,28 - -<br />
total 10 200 - 133 - 95 71,42 - - 38 28,57 - -<br />
Mixed boys 19 163 271 104 102 53 50,96 94 92,15 51 49,03 8 7,84<br />
girls 11 102 155 66 54 30 45,45 45 83,33 36 54,54 9 16,66<br />
total 30 265 426 170 156 83 48,82 139 89,10 87 51,17 17 10,89<br />
Perma-nent boys 17 - 451 - 191 - - 180 94,24 - - 11 5,75<br />
girls 8 - 221 - 81 - - 79 97,53 - - 2 2,46<br />
total 25 - 672 - 272 - - 259 95,22 - - 13 4,77<br />
M- primary teeth<br />
S- permanent teeth
104<br />
Table 7<br />
Total mean number <strong>of</strong> teeth with caries and total mean number <strong>of</strong> teeth requiring conservative and surgical treatment depending<br />
on dentition type<br />
Dentition<br />
type N Examined with caries<br />
N (teeth) (mean value)<br />
requiring<br />
conservative<br />
treatment<br />
requiring<br />
extraction<br />
M S M S M S M S<br />
Primary 10 20 - 13,30 - 9,50 - 3,80 -<br />
Mixed 30 8,83 14,20 5,66 5,20 2,76 4,63 2,90 0,56<br />
Permanent 25 - 26,88 - 10,88 - 10,36 - 0,52<br />
Table 8<br />
Non-caries-dependent enamel defects in children subjected to chemo- and radiotherapy dependent on dentition type (w-labial/<br />
buccal surface, sz-cervical area)<br />
White smooth stain Rough stain Enamel defects within s<br />
Dentition<br />
Nt Nt Nt<br />
type Nc Nc w sz >1 total Nc w sz >1 total Nc w sz >1<br />
Primary 7 2 2 4 - 6 6 35 8 - 43 5 49 - 15<br />
Mixed 23 21 106 1 27 134 16 77 3 35 115 6 19 - 6<br />
Perma-nent 19 16 65 1 24 89 13 40 4 58 96 11 36 36 21<br />
Total 49 39 173 6 51 229 33 156 15 93 254 22 104 36 42<br />
Nc = number <strong>of</strong> children<br />
Nt = number <strong>of</strong> teeth<br />
Fig. 1 Scanning electron microscopic view <strong>of</strong> tooth surface with cracked<br />
enamel and altered enamel prisms within an area <strong>of</strong> enamel defect. Microscopical<br />
magnification x 1100<br />
Fig. 2 Scanning electron microscopic view <strong>of</strong> the tooth dentin canals. Microscopical<br />
magnification x 1500
105<br />
Electron-microscopic examination<br />
Scanning electron microscopical analysis <strong>of</strong> the enamel <strong>of</strong> teeth<br />
showed its lack or crack in number <strong>of</strong> areas. Derangement <strong>of</strong><br />
enamel prisms and their clump was observed (Fig.1). No alterations<br />
<strong>of</strong> the pattern <strong>of</strong> dentin canals were noticed (Fig.2).<br />
Discussion<br />
Intensification <strong>of</strong> chemotherapy and it’s combination with<br />
surgery and/or radiotherapy have made possible an increasingly<br />
effective treatment <strong>of</strong> head and neck malignancies [1,<br />
2]. However, such an aggressive treatment is associated with<br />
an increased risk <strong>of</strong> many adverse side-effects, concerning<br />
many different components <strong>of</strong> the chewing apparatus. Particularly<br />
severe complications may accompany anticancer<br />
treatment <strong>of</strong> children and adolescents. Anticancer treatment<br />
proves effective in a growing number <strong>of</strong> patients, resulting in<br />
longer survival time. This in turn contributes to an increased<br />
incidence <strong>of</strong> late adverse effects <strong>of</strong> therapy, e.g. destruction <strong>of</strong><br />
mineralized tissues <strong>of</strong> teeth and various developmental abnormalities<br />
<strong>of</strong> chewing apparatus [3, 4, 5]. Therefore, oral care<br />
pr<strong>of</strong>essionals will be increasingly <strong>of</strong>ten confronted by such<br />
problems. Unfortunately, available literature provides little data<br />
concerning dental problems in patients undergoing anticancer<br />
treatment in childhood or guidelines for their effective<br />
prophylactic, therapeutic and rehabilitative management.<br />
Results <strong>of</strong> clinical trials indicate significant hygienic<br />
neglect and poor dentition status <strong>of</strong> children subjected to chemotherapy<br />
combined with radiotherapy. We noticed alarmingly<br />
high incidence <strong>of</strong> caries and it’s extreme severity. In our<br />
study, the mean dmf score was 14,6, largely exceeding values<br />
observed in children in the risk group for infectious endocarditis,<br />
where dmf score was 9,25 and DMF score was 10,42, as<br />
well as in children undergoing chemotherapy alone, where it<br />
equaled to 2,5 and 14,1 respectively [13]. We have noticed a<br />
large disproportion between requirements for dental treatment<br />
and dental treatment actually carried out. Values <strong>of</strong> treatment<br />
indices in children after anticancer treatment and those in the<br />
risk group for infectious endocarditis were similar, in the range<br />
<strong>of</strong> 0-0,34 and 0,03-0,34 respectively.<br />
An analysis <strong>of</strong> the scope <strong>of</strong> required dental treatment<br />
in children after chemotherapy combined with radiotherapy<br />
revealed significant needs in the area <strong>of</strong> conservative treatment<br />
and relatively smaller needs in the field <strong>of</strong> surgical treatment,<br />
possibly indicating high speed <strong>of</strong> development <strong>of</strong> new<br />
caries-dependent defects.<br />
In 69 % <strong>of</strong> children analyzed we observed atypical noncaries<br />
dependent enamel lesions in the form <strong>of</strong> patches and<br />
enamel defects. They occurred twice as <strong>of</strong>ten than in children<br />
undergoing chemotherapy alone. Children after chemotherapy<br />
combined with radiotherapy presented mostly white, rusty or<br />
rough patches, while children after chemotherapy alone had<br />
usually white lesions.<br />
Deleterious effect <strong>of</strong> radiotherapy on dentition is well known<br />
since a long time. The so-called “post-radiation caries” in patients<br />
undergoing radiotherapy in the area <strong>of</strong> head and neck,<br />
is a phenomenon well established in the literature [2, 3, 5, 8,<br />
11, 12, 14]. Observed thereby enamel defects are at the beginning<br />
probably non-bacterial in nature and are caused by chemical<br />
and mechanical factors acting upon a primarily more susceptible<br />
enamel. It would seem, that subsequent development<br />
<strong>of</strong> caries in these patients is secondary to the above described<br />
phenomena.<br />
Conclusions<br />
1. High incidence and severity <strong>of</strong> caries and atypical non-caries<br />
mediated enamel defects observed in patients subjected to<br />
chemotherapy combined with radiotherapy in the facial region,<br />
support the thesis about deleterious effect <strong>of</strong> anti-cancer<br />
on dentition.<br />
2. Significant disproportion between requirements for dental<br />
treatment and actually performed conservative and surgical<br />
treatment indicate, that dental prophylactic and therapeutic<br />
management should be instituted as early as possible in these<br />
patients.<br />
References<br />
1. Cioch M (2001) Uszkodzenie bariery<br />
sluzówkowej (Mucosal barier injury-<br />
MBI) w nastêpstwie intensywnego<br />
leczenia cytostatycznego. Onkol Pol 4,2:<br />
85-89 (in Polish)<br />
2. Darczuk D (1999) Zmiany w jamie<br />
ustnej wywo³ane napromienianiem<br />
nowotworów g³owy i szyi. Stomat<br />
Wspó³czesna 6,1:23-25 (in Polish)<br />
3. Groetz KA, Wagner W, Duschner H<br />
(2001) Chronische Strahlenfolgen an<br />
den<br />
Zahnhartgeweben<br />
(“Strahlenkaries”). Klassifikation und<br />
Behandlungsansaetze. Strahlentherapie<br />
und Onkologie-Abstract 177,2 :96-10<br />
4. Jaffe N, Toth BB, Hoar RE, Ried HL,<br />
Sullivan MP, McNeese M (1984) Dental<br />
and maxill<strong>of</strong>acial abnormalites in<br />
long-term survivors <strong>of</strong> childhood cancer:<br />
effects <strong>of</strong> treatment with chemotherapy<br />
and radiation to the head and<br />
neck. Pediatrics 73,6:816-823<br />
5. Jankowska K (1992) Próchnica<br />
popromienna (opis przypadku).<br />
Wroc³awska Stomatologia 235-238 (in<br />
Polish)<br />
6. Macleod RI, Welbury RR, Soames J<br />
(1987) Effects <strong>of</strong> cytotoxic chemotherapy<br />
on dental development. J Royal<br />
Soc Med 80:207-209<br />
7. Maguire A, Welbury R (1996) Long-term<br />
Effects <strong>of</strong> antineoplastic chemotherapy<br />
and radiotherapy on dental development.<br />
Dental Update 23 (5):188-194<br />
8. Manguire A, Craft AW, Evans RGB,<br />
Amineddine H, Kehrnahan J, Macleod<br />
RI (1987) Long-term effects <strong>of</strong> treatment<br />
on the dental condition <strong>of</strong> children<br />
surviving malignant disease. Cancer<br />
60:2570-2575<br />
9. Markitziu A, Zafiropolos G, Tsalikis L,<br />
Cohen L (1992) Gingival health and salivary<br />
function in head- and neck–<br />
irradited patients. Oral Surg Oral Med<br />
Oral Pathol 73:427-433
10. Nunn JH, Welbury RR, Gordon PH,<br />
Kernahan J, Craft AW (1991) Dental<br />
caries and dental anomalies in children<br />
treated by chemotherapy for malignant<br />
disease: a study in the north <strong>of</strong> England.<br />
Int J Paediatr Dent 1:131-135<br />
11. Olczak-Kowalczyk D, Dobies K,<br />
Daszkiewicz M (2002) Zastosowanie<br />
lakieru Seal & Protect w pr<strong>of</strong>ilaktyce<br />
próchnicy popromiennej u dzieci po<br />
przebytej terapii przeciwnowotworowej.<br />
Magazyn Stomatologiczny<br />
11,133,12:10-13 (in Polish)<br />
12. Olczak-Kowalczyk D, Daszkiewicz M<br />
(2002) Wspó³czesne metody<br />
pr<strong>of</strong>ilaktyki próchnicy w grupie<br />
wysokiego ryzyka jej wystêpowania.<br />
Standardy Medyczne 4,6 (32):402-411<br />
(in Polish)<br />
13. Olczak-Kowalczyk D, Bedra B (2003)<br />
Stan zdrowia jamy ustnej i<br />
stomatologiczne potrzeby lecznicze w<br />
badanej populacji dzieci z ryzykiem<br />
infekcyjnego zapalenia wsierdzia. Nowa<br />
Stomat 3,25:111-119 (in Polish)<br />
14. Olczak-Kowalczyk D, Perek D,<br />
Daszkiewicz M, Adamowicz-Klepalska<br />
B, Dembowska-Baginska B,<br />
Daszkiewicz P (2003) Problemy<br />
stomatologiczne u dzieci z chorobami<br />
nowotworowymi. Doœwiadczenia<br />
wlasne. Nowa Stomat 4;26:175-179 (in<br />
Polish)<br />
15. Rosenberg SW, Kolodney H, Wong<br />
GY, Murphy ML (1987) Altered dental<br />
root development in long-term survivors<br />
<strong>of</strong> pediatric acute lymphoblastic<br />
leukemia. A review <strong>of</strong> 17 cases.<br />
Cancer 59:1640-1648<br />
16. Welbury RR, Craft AW, Murray JJ,<br />
Kehrnahan J (1984) Dental health <strong>of</strong> survivors<br />
<strong>of</strong> malignant disease. Archiv Dis<br />
Child 59:1186-1188
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4): 106-110<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Preliminary review <strong>of</strong> the treatment results <strong>of</strong> hepatoblastoma and<br />
hepatocarcinoma in children in Poland in the period 1998-2002<br />
Czes³aw Stoba 1 , Katarzyna Nierzwicka 1 , Piotr Czauderna 1 , Barbara Skoczylas-Stoba 2 ,<br />
Stefan Popadiuk 3 , Jolanta Bonar 4 , Krystyna Sawicz-Birkowska 5 , Hanna Kaczmarek-Kanold 6 ,<br />
Przemys³aw Mañkowski 7 , Krzyszt<strong>of</strong> K¹tski 8 , Wojciech Madziara 9 , Magdalena Rych³owska 10 ,<br />
Anna Sitkiewicz 11 , Anna Szo³kiewicz 12 , Sabina Szymik-Kantorowicz 13 , Violetta Œwi¹tkiewicz 14<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
1<br />
Department <strong>of</strong> Pediatric Surgery,<br />
3<br />
Department <strong>of</strong> Pediatrics, Gastroenterology and Oncology<br />
12<br />
Department <strong>of</strong> Pediatric Oncology<br />
Medical University <strong>of</strong> Gdansk, Gdansk,Poland<br />
2<br />
Department <strong>of</strong> Anesthesiology and Intensive Therapy,<br />
Regional Copernicus Hospital, Gdansk, Poland<br />
4<br />
Department <strong>of</strong> Pediatrics, Hematology, Oncology<br />
and Endocrinology,<br />
5<br />
Department <strong>of</strong> Pediatric Surgery,<br />
Medical University <strong>of</strong> Wroclaw, Wroclaw, Poland<br />
6<br />
Department <strong>of</strong> Pediatric Hematology and Oncology,<br />
7<br />
Department <strong>of</strong> Pediatric Surgery,<br />
Medical University <strong>of</strong> Poznan, Poznan, Poland<br />
8<br />
Department <strong>of</strong> Pediatric Hematology and Oncology,<br />
Medical University <strong>of</strong> Lublin, Lublin, Poland<br />
9<br />
Department <strong>of</strong> Pediatric Surgery,<br />
Medical University <strong>of</strong> Katowice, Katowice, Poland<br />
10<br />
Department <strong>of</strong> Pediatric Surgery and Oncology,<br />
Institute <strong>of</strong> Mother and Child, Warszawa, Poland<br />
11<br />
Department <strong>of</strong> Pediatric Surgery and Oncology,<br />
Medical University <strong>of</strong> Lodz, Lodz, Poland<br />
13<br />
Department <strong>of</strong> Pediatric Surgery,<br />
Medical University <strong>of</strong> Krakow, Krakow, Poland<br />
14<br />
Department <strong>of</strong> Hematology and Oncology,<br />
Medical University <strong>of</strong> Bydgoszcz, Bydgoszcz, Poland<br />
Abstract<br />
Address for correspondence<br />
Objectives: Hepatoblastoma (HB) and hepatocellular carcinomas (HCC) are most common <strong>of</strong> all primary<br />
malignant liver tumors in children. This series <strong>of</strong> HB and HCC represents a preliminary report <strong>of</strong> treatment in<br />
11 Polish pediatric oncology centers. Treatment protocols were based on two consecutive SIOPEL group<br />
studies: 2 and 3. Material and methods: From 1998 to 2002 there were 34 children with HB and HCC<br />
diagnosed (28 were HB and 6 were HCC). All HB and HCC patients received preoperative chemotherapy<br />
based on SIOPEL 3 protocols (CDDP alone, PLADO or SuperPLADO). Among HB 23 tumors were unifocal<br />
and 5 multifocal. Eight HB cases were qualified to the high risk group according to the SIOPEL protocol<br />
definition. Alphafetoprotein (AFP) was elevated in all cases. Lung metastases were present in one HB and in<br />
three HCC cases. In 5 cases diagnosis was made on the clinical ground, in most <strong>of</strong> the patients initial biopsy<br />
was performed. Standard risk tumor were treated either Cisplatin monotherapy or PLADO regimen. High<br />
risk group was treated with SuperPLADO regimen. Twenty-one HB cases were operated in a delayed setting.<br />
Five tumor resections were incomplete: 3 macroscopically and 2 microscopically. In 4 cases information on<br />
surgery is missing. Results: Among 28 HB patient 19 are alive with no evidence <strong>of</strong> disease, 2 are alive with<br />
disease, 6 children died and one is lost to follow-up. Thus 3-year overall survival <strong>of</strong> HB patient was 75%,<br />
while 3-year event-free-survival was 64%. Median follow-up time is 40 mouths. Overall survival among<br />
standard risk group was 90% in comparison with 66% in the high risk group. All children with macroscopic<br />
residuum post resection died. Overall survival in HCC cases at 3 years is 33%, but <strong>of</strong> the two alive patients<br />
one currently experienced recurrence. Conclusions: Reported treatment for hepatoblastoma are similar to<br />
those achieved by other study groups and constitute an improvement in comparison with our retrospective<br />
series (OS=75% vs. 44%). High risk HB patients require modification <strong>of</strong> the current treatment strategy due to<br />
inferior survival than in standard risk HB. Treatment results <strong>of</strong> HCC (OS=33%) were clearly inferior to HB<br />
being in line with experience <strong>of</strong> other international study groups. Importance <strong>of</strong> the complete tumor resection,<br />
both in HB and HCC was confirmed.<br />
Keywords: children, hepatoblastoma, hepatocellular carcinoma, surgery, treatment<br />
Piotr Czauderna, PhD<br />
Dept. <strong>of</strong> Pediatric Surgery,<br />
Medical University <strong>of</strong> Gdansk,<br />
Ul. Nowe Ogrody 1-6,<br />
80-803 Gdansk, Poland.<br />
Phone/fax: +48 58 302 64 27<br />
E-mail: pedsurg@amg.gda.pl
108<br />
Introduction<br />
In the last 15 years a steady increase in survival in pediatric<br />
liver tumors has been noted. First observations on improvement<br />
in survival with the use <strong>of</strong> adjuvant chemotherapy came<br />
from Children’s Cancer Study Group (CCSG) and Pediatric<br />
Oncology Group (POG) in the late 70’s. Later in unresectable<br />
cases neoadjuvant chemotherapy was applied [3, 9]. In 1986<br />
Belgian and Canadian centers introduced in hepatoblastoma<br />
standard pre- and postoperative chemotherapy consisting <strong>of</strong><br />
cisplatin and adriamycin. This chemotherapy protocol, called<br />
later PLADO, has become a golden standard <strong>of</strong><br />
hepatoblastoma (HB) treatment in many centers, including<br />
Mother and Child Memorial Hospital in Warsaw. Efficacy <strong>of</strong><br />
further modified protocols was tested by the multinational<br />
SIOPEL group in three subsequent trials: SIOPEL 1-3 [9-11].<br />
It was shown that cisplatin alone is as effective as PLADO in<br />
standard risk HB [9, 10].<br />
Despite chemotherapy progress complete tumor resection<br />
remains a goal <strong>of</strong> treatment and prerequisite for cure. If it<br />
cannot be achieved it is better to abandon any surgical attempt<br />
and resort to another treatment modality and/or consult the<br />
case with referral center. Our remarks on principles <strong>of</strong> the<br />
surgical treatment <strong>of</strong> liver tumors were presented during Surgical<br />
Workshop in Szklarska Porêba, Poland in 2002 [13]. It<br />
was reported that progress in surgical management <strong>of</strong> liver<br />
tumors had been associated with better knowledge <strong>of</strong> its<br />
anatomy, improved surgical technique and equipment (ultrasonic<br />
and water-jet dissectors, argon beam coagulation,<br />
thrombostatic materials), as well as new imaging techniques,<br />
new method <strong>of</strong> anesthesia and improved perioperative care.<br />
Presented results emerged from multicenter cooperation<br />
<strong>of</strong> 13 Polish institutions within the study devoted to surgical<br />
treatment <strong>of</strong> malignant epithelial tumors <strong>of</strong> childhood<br />
including patients’ stratification according to risk groups in<br />
cooperation with the International Childhood Liver Tumors<br />
Strategy Group (SIOPEL). This study is coordinated in Poland<br />
by the Department <strong>of</strong> Pediatric Surgery <strong>of</strong> the Medical<br />
University <strong>of</strong> Gdansk.<br />
Material and methods<br />
In the period 1998-2002 all together 34 cases <strong>of</strong> primary epithelial<br />
liver tumors were treated in 11 Polish paediatric oncology<br />
centers. Twenty-eight were HB and 6 were HCC including<br />
one transitional (HB/HCC) liver tumor. Patients’ characteristics<br />
and stage are shown in Tab.1 and 2. Maximal tumor<br />
diameter ranged from 5 to 18 cm. Among HB 23 tumors (82%)<br />
were unifocal and 6 – multifocal. In HCC multifocal tumors<br />
prevailed: 4 out <strong>of</strong> 5. Eight HB cases (29%) were qualified to<br />
the high risk group according to the SIOPEL protocol definition.<br />
Alphafetoprotein (AFP) was elevated in all but one HB<br />
case (from 150 ng/ml to 2.480.000 ng/ml), in which AFP level<br />
was < 100 ng/ml. In all HCC cases AFP was elevated (from<br />
150 ng/ml to 2.500.000 ng/ml). Lung metastases were present<br />
in one HB case (3,6%) and in 3 HCC cases (50%). In one<br />
HCC case metastases involved also mediastinal and retroperitoneal<br />
lymph nodes.<br />
Treatment protocols were based on consecutive SIOPEL studies:<br />
SIOPEL 2 and 3. Standard imaging methods included:<br />
abdominal ultrasonography (US), chest X-ray (AP and lateral),<br />
computed tomography (CT) <strong>of</strong> the abdomen (with and<br />
without i.v. contrast) and chest (to detect eventual pulmonary<br />
metastases) and/or magnetic resonance imaging (MRI). Also<br />
complete blood count (including platelet level) and serum AFP<br />
were obtained at diagnosis. AFP, if elevated, was used to monitor<br />
response to treatment. The protocol required preoperative<br />
assessment <strong>of</strong> tumor extent according to PRETEXT classification,<br />
which is described in details elsewhere [12]. Closed<br />
needle biopsy was performed in 2 cases, open biopsies were<br />
done in 21 cases (18 – wedge and 3 – open needle biopsies).<br />
In one case liver biopsy was done laparoscopically. In 5 cases<br />
diagnosis was made on the clinical ground. In 4 patients data<br />
on biopsy are missing. Patients with biopsy proven HB and<br />
HCC were qualified to two risk groups on the basis <strong>of</strong> PRE-<br />
TEXT grouping. High risk tumors were those PRETEXT 4<br />
(involving the whole liver) or belonging to any PRETEXT<br />
category with the following features: significant intravascular<br />
involvement (V or P), extrahepatic extension and/or distant<br />
metastases (M). Hence high risk tumors were primarily<br />
unresectable. All others formed standard risk group. In tumors<br />
occurring between 6 months and 3 years <strong>of</strong> age with<br />
unequivocal imaging and increased AFP level diagnosis <strong>of</strong><br />
hepatoblastoma on clinical ground was allowed. Before definite<br />
surgery Doppler US and helical CT were required. All<br />
patients with hepatoblastoma received preoperative chemotherapy<br />
which was dependent on the risk group assignment.<br />
Standard risk tumors were treated either cisplatin monotherapy<br />
or PLADO regimen (those registered in the SIOPEL 3 trial<br />
were randomized), however few patients were not randomized.<br />
High risk patients were treated with SuperPLADO regimen,<br />
which included 2-weekly cisplatin alternating with<br />
doxorubicin administered together with carboplatin. Four triweekly<br />
chemotherapy courses were given. Postoperatively two<br />
more courses <strong>of</strong> the same chemotherapy were administered.<br />
For details <strong>of</strong> the treatment protocol check elsewhere [9, 10,<br />
11]. Cisplatin alone was used in 10 children, PLADO in 7<br />
cases and SuperPLADO in 9 cases. In 2 cases details on preoperative<br />
chemotherapy are missing. Twenty-one HB cases<br />
were operated in a delayed setting. Type and completeness <strong>of</strong><br />
performed surgery is shown in Table 3. Treatment <strong>of</strong> operable<br />
hepatocellular carcinoma (HCC) patients was started with tumor<br />
resection followed by 6 postoperative courses <strong>of</strong><br />
SuperPLADO regimen. Two HCC cases were primarily operated<br />
including one orthotopic liver transplantation Treatment<br />
<strong>of</strong> unresectable and/or metastatic HCC was identical with high<br />
risk HB. One child with HCC was operated in a delayed setting<br />
after partial response to preoperative chemotherapy. In<br />
non-responders (2 cases) chemoembolization was used.
109<br />
Results<br />
Among 28 HB patients 19 are alive with no evidence <strong>of</strong> disease,<br />
2 are alive with disease, 6 children died and one is lost to<br />
follow-up. Thus 3-year overall survival <strong>of</strong> hepatoblastoma<br />
patients was 75%, while 3-year event-free-survival was 64%.<br />
Three deaths resulted from disease progression and 3 from<br />
treatment complications: one was surgery-related (intestinal<br />
necrosis), one resulted from chemotherapy complications (severe<br />
neutropenia and typhlitis) and one was unexplained (possible<br />
anthracycline-related cardiomyopathy). Median followup<br />
time is 40 months (range from 24 to 72 months). Overall<br />
survival among standard risk patients was 90% (17 out <strong>of</strong> 19)<br />
in comparison with 66% (6 out <strong>of</strong> 9) in the high risk group.<br />
Preliminary analysis showed that 75% <strong>of</strong> standard risk<br />
patients (12 out <strong>of</strong> 16; in 3 cases data are not known) responded<br />
to preoperative chemotherapy (CDDP or PLADO), while from<br />
the high risk group 55% (5 out <strong>of</strong> 9) responded to<br />
SuperPLADO protocol.<br />
All together in HB cases 5 incomplete tumor resections<br />
were done: in 3 macroscopic residuum resulted and in<br />
two microscopic residuum was left. All patients with macroscopic<br />
residuum died, while one patients after microscopically<br />
incomplete resection is alive with no evidence <strong>of</strong> disease<br />
while another died due to surgical complications. In 4<br />
cases information on surgery is missing.<br />
Overall survival in HCC cases at 3 years is 33% but<br />
one <strong>of</strong> the two alive patients currently experienced recurrence.<br />
Among 6 patients with HCC in 2 cases primary tumor resection<br />
was done (including one orthotopic liver transplantation)<br />
was performed and 3 patients were treated with induction chemotherapy.<br />
In 2 non-responders chemombolization was used.<br />
Two patients were never made operable and in one data on<br />
surgery are missing.<br />
Table 1<br />
Localisation <strong>of</strong> liver tumors<br />
Localisation<br />
Hepatoblastoma<br />
Both lobem 12 4<br />
Right lobe 11 2<br />
Left lobe 5 -<br />
Table 2<br />
Liver tumors' stages<br />
PRETEXT<br />
Hepatoblastoma<br />
I 1 -<br />
II 14 1<br />
III 7 2<br />
IV 6 3<br />
Hepatocellular<br />
carcinoma<br />
Hepatocellular<br />
carcinoma<br />
Discussion<br />
Reported treatment results for HB are similar to those achieved<br />
by other study groups (OS=75%). Introduction <strong>of</strong> efficient<br />
chemotherapy has contributed to a significant progress in the<br />
treatment <strong>of</strong> hepatoblastoma as nowadays overall survival<br />
reaches 70%. Before this era only 25% <strong>of</strong> HB patients survived<br />
and tumor resection was possible in not more than 50%<br />
<strong>of</strong> patients, while half <strong>of</strong> them died later due to metastases<br />
[3]. Similarly retrospective analysis <strong>of</strong> the Polish treatment<br />
results for the period 1985-1995 showed inferior outcome with<br />
only 44% long term survival in hepatoblastoma due to the<br />
scarcely used preoperative chemotherapy and few extended<br />
liver resections done [1, 6]. In that period as many as 30% <strong>of</strong><br />
analyzed tumors were never made operable. Thus, currently<br />
achieved treatment results <strong>of</strong> hepatoblastoma in Poland constitute<br />
a significant improvement in comparison with our past<br />
series [1]. However despite overall improvement prognosis <strong>of</strong><br />
the high risk patients remains uncertain – with 66% overall<br />
survival vs. 90% for the standard risk group. Similar results<br />
were achieved in the SIOPEL 2 study, in which 3-year eventfree-survival<br />
for high risk patients was 47% vs. 89% for standard<br />
risk [9, 10]. Most failures resulted from tumor’s<br />
unresectability and insufficient or complete lack <strong>of</strong> response<br />
to preoperative chemotherapy. This confirms that high risk<br />
patients require some modifications in treatment strategy,<br />
which should be aimed at increase <strong>of</strong> resection rate. This includes<br />
more efficient induction chemotherapy, as well as more<br />
frequent use <strong>of</strong> liver transplantations in hepatoblastoma cases<br />
unresectable by conventional means [7, 8].<br />
Treatment results <strong>of</strong> hepatocellular carcinoma (33%<br />
overall survival) were clearly inferior to hepatoblastoma is<br />
confirmed by most international study groups, in which survival<br />
remained in the range <strong>of</strong> 20-30% [2, 5]. Complete tumor<br />
resection should be an essential treatment step, both in<br />
HB and HCC. In the reported series all patients after macroscopically<br />
incomplete tumor resections died, while all HB<br />
cases, who underwent complete resection, had been alive and<br />
well. Due to the relatively short follow-up <strong>of</strong> some patients,<br />
incomplete data and limited number <strong>of</strong> cases presented analysis<br />
has a preliminary character only.<br />
Conclusions<br />
1. Overall survival achieved in hepatoblastoma – 75%, as well<br />
as EFS = 64% are similar to other international reports and<br />
constitute a significant improvement in comparison with<br />
the Polish past series (1985-1995): OS = 44%.<br />
2. Complete tumor resection remains an essential step to<br />
achieve cure in primary epithelial liver tumors (HB and<br />
HCC). It is however difficult in high risk HB, as well as in<br />
HCC patients.<br />
3. High risk HB patients require modification <strong>of</strong> the current<br />
treatment strategy due to inferior survival than in standard<br />
risk HB.<br />
4. HCC are associated with poor prognosis and require completely<br />
different therapeutic strategy than HB.
Table 3<br />
Characteristics <strong>of</strong> surgical treatment<br />
Type <strong>of</strong> surgery Hepatoblastoma Hepatocarcinoma Radicality<br />
RT Hemihepatectomy 9 1 7rad. / 2 non-rad.<br />
LT Hemihepatectomy 3 - 3 rad.<br />
Extended Hemihepatectomy 7 - 5 rad. / 2 non-rad.<br />
Atypical 3 - 2 rad. /1 non-rad.<br />
Central resection 1 - 1 rad.<br />
Liver transplantation - 1 1 rad.<br />
Never operable 1 3 -<br />
Missing data 4 1 -<br />
References<br />
1. Czauderna P, Popadiuk S, Korzon M,<br />
et al (2001) Multicenter retrospective<br />
analysis <strong>of</strong> various primary pediatric<br />
malignant hepatic tumours management<br />
in the series <strong>of</strong> 47 Polish patients (1985-<br />
1995). Eur J Pediatr Surg 11:82-85<br />
2. Czauderna P, Mackinlay G, Perilongo<br />
G, et al (2002) Hepatocellular carcinoma<br />
in children – Results <strong>of</strong> the first prospective<br />
study <strong>of</strong> the International Society<br />
<strong>of</strong> <strong>Paediatric</strong> Oncology. J Clin Oncol<br />
20:2798-2804<br />
3. Ehrlich PF, Grereenberg ML, Filler<br />
RM (1997) Improved long-term survival<br />
with preoperative chemotherapy<br />
for hepatoblastoma. J Pediatr Surg<br />
32:999-1002<br />
4. Katzenstein HM, London WB,<br />
Douglass EC, Reynolds M, Plaschkes<br />
J, Finegold MJ, Bowman LC (2002)<br />
Treatment <strong>of</strong> unresectable and metastatic<br />
hepatoblastoma: a pediatric oncology<br />
group phase II study J Clin Oncol<br />
20:3438-3444<br />
5. Katzenstein HM, Krailo MD,<br />
Malogolowkin MH, et al (2002) Hepatocellular<br />
carcinoma in children and<br />
adolescents: results from the Pediatric<br />
Oncology Group and the Children’s<br />
Cancer Group Intergroup Study. J Clin<br />
Oncol 20: 2789-2797<br />
6. Korzon M, Popadiuk S, Stoba C, et al<br />
(1997) Analiza retrospektywna<br />
zlosliwych guzów watroby u dzieci w<br />
Polsce w latach 1985-1995. Pediatr Pol<br />
11 (Suppl):37-42 (in Polish)<br />
7. Ortega JA, Douglass EC, Feusner JH,<br />
et al (2000) Randomized comparison <strong>of</strong><br />
Cisplatin/Vincristine/5-Fluorouracil and<br />
Cisplatin/continuous infusion Doxorubicin<br />
for the treatment <strong>of</strong> paediatric<br />
hepatoblastoma (HB): a report from the<br />
Children’s Cancer Group and the <strong>Paediatric</strong><br />
Oncology Group. J Clin Oncol<br />
18:2665-2675<br />
8. Otte JB, Aronson DC, Brown J,<br />
Czauderna P, et al (2004) Liver transplantation<br />
for hepatoblastoma. results<br />
from the International Society <strong>of</strong> Pediatric<br />
Oncology (SIOP) study siopel-1<br />
and review <strong>of</strong> the world experience.<br />
Pediatr Blood Cancer 42:74-83<br />
9. Perilongo G, Shafford E, Plasches J<br />
(2000) SIOPEL trials using preoperative<br />
chemotherapy in hepatoblastoma. The<br />
Lancet Oncology 1:94-100<br />
10. Perilongo G, Shafford E, Maibach R<br />
(2004) Risk-adapted treatment for childhood<br />
hepatoblastoma. Final report <strong>of</strong> the<br />
second study <strong>of</strong> the International Society<br />
<strong>of</strong> Pediatric Oncology - SIOPEL 2.<br />
Eur J Cancer 40:411-421<br />
11. Pritchard J, Brown J, Shafford E (2000)<br />
Cisplatin, doxorubicin and delayed surgery<br />
for childhood hepato-blastoma: a<br />
succesful approach - Results <strong>of</strong> the first<br />
prospective study <strong>of</strong> the International<br />
Society <strong>of</strong> <strong>Paediatric</strong> Oncology J Clin<br />
Oncol 18:3819-3828<br />
12. Schnater JM, Aronson DC, Plaschkes<br />
J (2002) Surgical view <strong>of</strong> the treatment<br />
<strong>of</strong> patients with hepatoblastoma: results<br />
from the first prospective trial <strong>of</strong><br />
the International Society <strong>of</strong> Pediatric<br />
Oncology Liver Tumor Study Group<br />
(SIOPEL-1). Cancer 94:1111-1120<br />
13. Stoba C, Czauderna P, Narozanski<br />
(2001) Pierwotne nowotwory watroby<br />
u dzieci – aspekty chirurgiczne. In:<br />
Wybrane nowotwory jamy brzusznej<br />
u dzieci. A. Jankowski, P. Mankowski<br />
(Eds) Stowarzyszenie Pomocy<br />
Dzieciom Wymagajacym Leczenia<br />
Chirurgicznego, Poznan, pp. 12-30 (in<br />
Polish)
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Liver transplantation for primary malignant liver tumors<br />
in children – single center experience<br />
Piotr Kaliciñski 1 , Hor Ismail 1 , Andrzej Kamiñski 1 , Danuta Perek 2 , Joanna Paw³owska 3 ,<br />
Przemys³aw Kluge 4 , Joanna Teisserye 1 , Marek Szymczak 1 , Tomasz Drewniak 1 ,<br />
Pawe³ Nachulewicz 1 , Bo¿ena Dembowska-Bagiñska 2 , Marek Stefanowicz 1 ,<br />
Andrzej Byszewski 5 , Ma³gorzata Manowska 5<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
1<br />
Department <strong>of</strong> Pediatric Surgery and Organ Transplantation<br />
2<br />
Department <strong>of</strong> Oncology<br />
3<br />
Department <strong>of</strong> Gastrology, Hepatology and Immunology<br />
4<br />
Department <strong>of</strong> Patomorphology<br />
5<br />
Department <strong>of</strong> Anesthesiologu and Intensive Care<br />
The Children’s Memorial Health Institute,<br />
Warsaw, Poland<br />
Abstract<br />
The aim <strong>of</strong> the study was to analyse results <strong>of</strong> treatment <strong>of</strong> primary liver tumors in children in a center<br />
performing the liver transplant program. Clinical material consisted <strong>of</strong> 42 children treated for hepatoblastoma<br />
or hepatocarcinoma since 1990, since liver transplantant program was established. Retrospective comparison<br />
<strong>of</strong> results was performed according to type <strong>of</strong> the tumor and different treatments protocols. Survival <strong>of</strong><br />
patients with hepatoblastoma is similar after primary conventional treatment (chemotherapy and resection)<br />
and primary transplantation after chemotherapy, however number <strong>of</strong> transplanted patients is to low to draw<br />
any conclusions. Patients with tumor recurrence after resection probably should not be qualified for transplantation<br />
as their prognosis is very poor. In hepatocarcinoma group overall results after chemotherapy and<br />
primary transplantation seem to be much better than after conventional therapy. This observation should be<br />
confirmed however with longer follow-up <strong>of</strong> these patients. In conclusion liver transplantation should be<br />
considered as an option early in the process <strong>of</strong> treatment <strong>of</strong> primary malignant tumors in children particularly<br />
with hepatocarcinoma, and transplantation as a primary surgical treatment in all patients with unresectable or<br />
marginally resectable tumors and without extrahepatic extension.<br />
Key words: children, hepatoblastoma, hepatocellular carcinoma, liver transplantation, primary liver tumors<br />
Introduction<br />
Primary hepatic malignancies are main indication for liver<br />
transplantation in 2-4% pediatric recipients. This is well less<br />
than in adult population, where patients with hepatocellular<br />
carcinoma account for 11-12% <strong>of</strong> liver transplantations [3-5].<br />
In contrast to adult group, there are no established strict criteria<br />
for qualification for transplantation in children with primary<br />
liver tumors, particularly that various types <strong>of</strong> hepatic<br />
tumors may develop in childhood (hepatoblastoma,<br />
hepatocarcinoma, undifferentiated sarcoma, angiosarcoma<br />
etc.) [1, 7, 12]. The aim <strong>of</strong> this study is to summarize our<br />
experience with this particular group <strong>of</strong> liver transplant recipients.<br />
Material and methods<br />
Liver transplant program was initiated in our institution in<br />
march 1990. Since then 222 liver transplants were performed<br />
till July 2004. We have analysed retrospectively data <strong>of</strong> 42<br />
children treated for hepatoblastoma (HBL) or hepatocarcinoma<br />
(HCC) within the same period in our institution.<br />
Patients with HBL<br />
Between 1990 and 2004, 23 patients aged 5 months to 16<br />
years, most with advanced tumors, were treated for HBL.<br />
Twenty children with HBL were treated initially with chemotherapy<br />
and then by conventional surgery – partial liver resection.<br />
In two <strong>of</strong> them recurrence was suspected despite <strong>of</strong> mul-<br />
Address for correspondence<br />
Piotr Kalicinski MD, PhD<br />
Al. Dzieci Polskich 20<br />
04-736 Warsaw, Poland<br />
Phone: +48-22-8151360<br />
Fax: +48-22-8151450<br />
E-mail: piokal@czd.waw.pl
0000000000000000000<br />
0000000000000000000<br />
0000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
000000000000000000<br />
000000000000000000<br />
000000000000000000<br />
000000000000000000<br />
e<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000<br />
0000000000000000000<br />
0000000000000000000<br />
0000000000000000000<br />
ea<br />
00000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000<br />
0000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000<br />
0000000000000<br />
00000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<br />
0000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000<br />
00000000000000000<br />
00000000000000000<br />
e<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
0000000000000000000000000000000000000000000000000000<br />
00000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000<br />
00000000000000000<br />
00000000000000000<br />
ea<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
00000000000000000<br />
00000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
000000000000000000000000000000000000000000000000000000000000000000<br />
112<br />
tiple postoperative chemotherapy courses, and were qualified<br />
for total hepatectomy <strong>of</strong> the remaining liver and orthotopic<br />
liver transplantation. Another 2 children were transplanted<br />
immediately after initial chemotherapy. In 1 patient only palliative<br />
treatment (chemotherapy) was administered.<br />
Patients with HCC<br />
There were 19 patients aged 3 to 18 years treated for HCC. In<br />
9 children initial chemotherapy was administered, followed<br />
by partial liver resection, in 2 <strong>of</strong> them despite multiple resections<br />
tumor recurred and salvage transplantation was done in<br />
both <strong>of</strong> them. In 5 children liver transplantation was performed<br />
as primary surgical treatment. All <strong>of</strong> them exceeded Milano<br />
criteria for transplantation in patients with HCC. Initial chemotherapy<br />
was given in 4 <strong>of</strong> them. In 4 pts liver transplantation<br />
was performed due to suspected tumor development in<br />
cirrhotic liver (on the basis <strong>of</strong> CT or ultrasound findings or<br />
growing serum alphafetoprotein concentration). No<br />
pretransplant chemotherapy was administered to these patients.<br />
In 1 child only palliative chemotherapy was given.<br />
reccurence. One patient is alive after extensive resection, however<br />
with poor prognosis due to extrahepatic invasion <strong>of</strong> the<br />
tumor at the time <strong>of</strong> surgery.<br />
Among patients transplanted, 9/11 (81,8%) are alive,<br />
while 2 deaths were not related to tumor reccurence (early<br />
graft failure in 1 and chronic rejection in 1 (Fig. 2).<br />
In all 4 patients with cirrhosis and suspected tumor<br />
small HCC was found in explanted liver. One <strong>of</strong> these patients<br />
died <strong>of</strong> graft primary non-function. One <strong>of</strong> two patients<br />
who underwent multiple resections before transplantation presented<br />
pulmonary metastases almost 2 years after transplantation<br />
and extensive metastasectomy was performed, however<br />
prognosis for this patient is rather poor. No recurrence or<br />
metastatic dissemination was noted until now among 5 patients<br />
who underwent primary liver transplantation after total<br />
hepatectomy.<br />
Results<br />
Hepatoblastoma<br />
Twelve out <strong>of</strong> 23 (52,2%) children with HBL are alive and<br />
without active disease, while 11 patients died (47,8%). Best<br />
results were obtained with standard therapy consisting <strong>of</strong> chemotherapy,<br />
tumor resection and postoperative chemotherapy<br />
with long term survival <strong>of</strong> 11/20 pts (55,0%), including two<br />
patients who died after transplantation performed due to tumor<br />
recurrence. Among 2 patients who were transplanted primarily<br />
- 1 died 6 months after transplantation due to<br />
posttransplant lymphoproliferative disease. Another one is<br />
alive and well 25 months after Tx.Two additional children<br />
transplanted for tumor recurrence after previous resections died<br />
<strong>of</strong> metastatic disease despite <strong>of</strong> posttransplant chemotherapy.<br />
No graft involvement was observed in these patients (Fig. 1).<br />
Hepatocellular carcinoma<br />
Overall survival among 19 children with HCC is 12/19<br />
(63,2%), 42,9% (3/7) children are alive and free <strong>of</strong> tumor<br />
after CHT and resection, while all other died <strong>of</strong> tumor<br />
3<br />
3<br />
00000000000000000<br />
alive&well<br />
e e ea<br />
e a e alive wi<br />
Fig. 2 Hepatocarcinoma - actual results according to type <strong>of</strong> treatment (1990-<br />
2004)<br />
Posttransplant observation is still relatively short in survivors<br />
(range: 5 - 40 months). AFP concentration remains within<br />
normal limits in all, however it is necessary to say that it was<br />
not elevated in 2 <strong>of</strong> 11 before transplantation (Fig. 3). Chemotherapy<br />
(1-3 courses) was given after transplantation to 5<br />
patiens. It had to be stopped in most <strong>of</strong> them after 1-2 courses<br />
due to complications. Liver graft function is good in all but<br />
one patient who developed severe cholangitis after chemotherapy,<br />
further complicated by intrahepatic bile duct strictures.<br />
1<br />
1<br />
11<br />
0000<br />
000<br />
AFP (ng/ml)<br />
0000<br />
000<br />
0000<br />
1 1<br />
1<br />
000<br />
0<br />
before treatment before a t<br />
0000000000000000000<br />
alive&well<br />
e e ea<br />
e a e<br />
Fig. 1 Hepatoblastoma - results according to type <strong>of</strong> treatment (1990-2004)<br />
Fig. 3 Alphafetoprotein (AFP) in 9 patients with HCC after liver transplantation<br />
(follow up 5-40 months)
113<br />
Discussion<br />
Total hepatectomy with liver transplantation became an important<br />
therapeutic option for children with malignant primary<br />
hepatic tumors [1, 5, 9, 12]. Overall long term survival in pediatric<br />
liver transplant recipients is now reaching in leading<br />
centers 90-95% independently on indication for transplantation,<br />
while survival <strong>of</strong> children with hepatoblastoma and<br />
hepatocarcinoma after conventional treatment (chemotherapy<br />
+ resection) is much lower, 60-80% and 30-40% respectively<br />
[2, 4, 5, 11, 12]. Various protocols and trials have been tried<br />
to improve results <strong>of</strong> conventional treatment, and much success<br />
was achieved independently by SIOPEL group, German<br />
group or Japanese group, mostly in HBL, with less optimistic<br />
results in patients with HCC [9, 10]. The place <strong>of</strong> total hepatectomy<br />
and liver transplantation have been not clearly defined<br />
in pediatric population, although many patients benefited<br />
from this type <strong>of</strong> treatment on the individual qualification basis<br />
[1, 9, 12]. Standard qualification criteria for transplantation<br />
in patients with primary hepatic tumors included in most centers:<br />
unresectable tumor, no extrahepatic tumor extension, no<br />
distant metatases (or in case <strong>of</strong> hepatoblastoma pulmonary<br />
metastases which cleared with chemotherapy), [5, 9]. It is<br />
obvious that conventional complex treatment is best for most<br />
patients with hepatoblastoma, however in our opinion transplantation<br />
should be considered as first surgery in these children<br />
in which tumor is unresectable, but also in cases <strong>of</strong> successful<br />
response <strong>of</strong> large, unresectable tumors to chemotherapy<br />
which allows downstaging <strong>of</strong> the tumor and complete extensive<br />
but marginal resection. Although not all agree that narrow<br />
margin free <strong>of</strong> HBL in resected liver specimen is important<br />
for long term survival, but one should keep in mind that<br />
recurrence <strong>of</strong> HBL in these patients indicates almost uniformly<br />
poor prognosis also after transplantation [2, 5, 9, 12].<br />
Conventional treatment can not <strong>of</strong>fer such good results in children<br />
with hepatocarcinoma despite intensive chemotherapy<br />
and improvements in resection techniques. In adult population<br />
large groups <strong>of</strong> patients with HCC were qualified to liver<br />
transplantation since 25 years, however no criteria for transplantation<br />
in these patients existed until study done by<br />
Mazzaferro et all in 1996 [7, 8]. They defined so called Milano<br />
criteria which have been accepted by most adult transplant<br />
centers. According to these criteria liver transplantation should<br />
be <strong>of</strong>fered to patients with: one single tumor with diameter<br />
less than 5 cm, maximum number <strong>of</strong> 3 tumors with diameters<br />
less than 3 cm each no vascular invasion and no extrahepatic<br />
metastases. With these criteria 4 years survival after liver transplantation<br />
in adults achieve 75%, which is impossible to<br />
achieve by conventional treatment. One can not directly transfer<br />
Milano criteria to pediatric population, as tumor behaviour<br />
and response to chemotherapy in children are different in children<br />
and adults. There are no large enough groups to perform<br />
such analyses in pediatric patients however. Since all our patients<br />
with “non-accidentaloma” did not fit into Milano criteria<br />
one should expect very early tumor recurrence and dissemination<br />
in patients on immunosuppression. We did not<br />
observe such events in any patient till now with medium length<br />
follow-up. Multicenter analysis should be performed probably<br />
to try to define pediatric criteria for liver transplantation<br />
in patients with HCC, as single center can not collect number<br />
<strong>of</strong> patients necessary for such analysis.<br />
In conclusion, liver transplantation should be considered<br />
as an option early in the process <strong>of</strong> treatment <strong>of</strong> primary<br />
malignant tumors in children, particularly with<br />
hepatocarcinoma, and transplantation should be considered<br />
as a primary surgical treatment in all patients with unresectable<br />
or marginally resectable tumors and without extrahepatic extension.<br />
Living related donor transplantation is one <strong>of</strong> important<br />
solution in best timing <strong>of</strong> transplantation within treatment<br />
protocol [6].<br />
References<br />
1. Cillo U, Ciarleglio FA, Bassanello M,<br />
et al (2003) Liver transplantation for the<br />
management <strong>of</strong> hepatoblastoma. Transplant<br />
Proceed 35:2983-2985<br />
2. Dicken BJ, Bigam DL, Lees GM<br />
(2004) Association between surgical<br />
margins and long-term outcome in advanced<br />
hepatoblastoma. J Pediatr Surg<br />
39:721-725<br />
3. European Registry <strong>of</strong> Liver Transplantation<br />
Report (ELTR), 2003.<br />
4. Kaliciñski P (1997) Przeszczep w¹troby.<br />
Wybrane zagadnienia. Fundacja Polski<br />
Przegl¹d Chirurgiczny (Ed), pp 1-138<br />
5. Kamiñski A, Kaliciñski , Ismail H, et<br />
al (2003) Liver transplantation in children<br />
with hepatic tumors. Pediatr Transplant<br />
7(suppl):124<br />
6. Lo CM, Fan ST, Liu CL, Chan SC,<br />
Wong J (2004) The role and limitation<br />
<strong>of</strong> living donor liver transplantation for<br />
hepatocellular carcinoma. Liver Transpl<br />
10:440-447<br />
7. Mazzaferro V, Regalia E, Doci R, et al<br />
(1996) Liver transplantation for the<br />
treatment <strong>of</strong> small hepatocellular carcinomas<br />
in patients with cirrhosis. N Engl<br />
J Med 334:693-699<br />
8. Nart D, Arikan C, Akyildiz M, et al<br />
(2003) Hepatocellular carcinoma in liver<br />
transplant era: a clinicopathologic analysis.<br />
Transplant Proceed 35:2986-2990<br />
9. Otte JB, Pritchard J, Aronson DC, et al<br />
(2004) Liver transplantation for<br />
hepatoblastoma: results from the International<br />
Society <strong>of</strong> Pediatric Oncology<br />
(SIOP) study SIOPEL-1 and review <strong>of</strong><br />
the world experience. Pediatr Blood<br />
Cancer 42:74-83<br />
10. Perilongo G, Shafford E, Maibach R, et<br />
al (2004) Risk-adapted treatment for<br />
childhood hepatoblastoma. Final report<br />
<strong>of</strong> the second study <strong>of</strong> the International<br />
Society <strong>of</strong> <strong>Paediatric</strong> Oncology –<br />
SIOPEL 2. Eur J Cancer 40:411-421<br />
11. Prokurat A, Kluge P, Chrupek M,<br />
Koœciesza A (2002) Possibilities and<br />
limitations in the treatment <strong>of</strong> hepatocellular<br />
carcinoma in children. Ann<br />
Diagn Paediatr Pathol 6:51-57<br />
12. Srinivasan P, McCall J, Pritchard J, et al<br />
(2002) Ortotopic liver transplantation<br />
for unresectable hepatoblastoma. Transplantation<br />
74:652-655
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Hepatocyte ultrastructure in non-hemolytic hyperbilirubinemias<br />
El¿bieta Czarnowska, Bogdan WoŸniewicz<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
Departament <strong>of</strong> <strong>Pathology</strong>,<br />
The Children’s Memory Health Institute,<br />
Warsaw, Poland<br />
Abstract<br />
The non-hemolytic hyperbilirubienias comprise a group <strong>of</strong> syndromes that are clinically and some in cases<br />
biochemically and genetically well characterized, and ultrastructural investigations <strong>of</strong> biopsy samples have<br />
still diagnostic applications. In this study utrastructural analysis <strong>of</strong> biopsy tissues in order to identify pattern<br />
<strong>of</strong> features characteristic for different non-hemolytic hyperbirubinemias among group <strong>of</strong> patients with clinical<br />
presentation <strong>of</strong> hyperbilirubinemia and normal histopathology were done. A group <strong>of</strong> 62 patients was<br />
selected on the basis <strong>of</strong> mild unconjugated hyperbilirubinemia and, in some cases, on the basis <strong>of</strong> a mild<br />
unconjugated or conjugated hyperbilirubinemias in the presence <strong>of</strong> repeatedly normal liver function tests and<br />
absence <strong>of</strong> hyperhemolysis. Electron microscopic investigation distinguished between patients in three groups<br />
<strong>of</strong> primary hyperbilirubiemia: Gilbert syndrome (21 pts), Dubin-Johnson syndrome (5 pts), Rotor syndrome<br />
(3 pts) and a group with non specific changes (33 pts). The ultrastructural features <strong>of</strong> hepatocytes that univocally<br />
distinguish primary hyperbilirubinemias from secondary diseases were presented. Electron microscopic<br />
methods permit on recognition <strong>of</strong> non-specific changes in the ultrastructure <strong>of</strong> liver tissue among samples<br />
obtained from patients with non-hemolytic hyperbilirubinemias and can be still usefull in diagnosis <strong>of</strong><br />
jaundince.<br />
Key words: congenital hyperbilirubinemia, Dubin-Johnson disease, Gilbert disease, Rotor disease, ultrastructure<br />
Introduction<br />
Idiopathic hyperbilirubinemias may encompass several primary<br />
and secondary diseases <strong>of</strong> bilirubin metabolism [2]. Bilirubin,<br />
an oxidative product <strong>of</strong> the hem group <strong>of</strong> hemoglobin,<br />
myoglobin and cytochrome P-450, in the liver is conjugated<br />
with glucuronic acid and than excreted in bile via ATPdependent<br />
transporter [5]. Currently, injuries <strong>of</strong> molecular<br />
bases <strong>of</strong> this metabolic pathway are known [5]. Although, this<br />
knowledge allow for precision diagnosis <strong>of</strong> non-hemolytic<br />
hyperbilirubinemias in most cases, but still ultrastructural investigation<br />
<strong>of</strong> biopsy samples have diagnostic application.<br />
Clinically, conjugated and unconjugated hyperbilirubinemia<br />
can be distinguished on the basis <strong>of</strong> blood bilirubin level, normal<br />
liver tests and exclusion <strong>of</strong> hemolytic disease. In conjugated<br />
hyperbilirubinemias i.e Gilbert, Crigler-Najjar syndrome,<br />
transport <strong>of</strong> bilirubin from plasma into liver cells is<br />
impaired, while in conjugated hyperbilirubinemias, i.e. Dubin-<br />
Johnson, Rotor syndrome, microsomal enzymes transferase,<br />
bilirubin transport from hepatic cells into bile caniculi system<br />
are disturbed [2, 5]. In non-hemolytic hyperbilirubinemias,<br />
liver histopathology may present normal feature or cholestasis.<br />
These investigations were aimed to identify ultrastructural<br />
pattern <strong>of</strong> characteristic features for different nonhemolytic<br />
hyperbirubinemias among group <strong>of</strong> patients with<br />
clinical presentation <strong>of</strong> hyperbilirubinemia and normal histopathology.<br />
Material and methods<br />
Material<br />
62 biopsy samples from patients (age 6-17 years, mean 10,2<br />
± 4,6) with marked liver disfunction and clinical symptoms<br />
<strong>of</strong> non-hemolytic hyperbilirubinemia were selected for electron<br />
microscopic studies among samples collected in the registry<br />
<strong>of</strong> <strong>Pathology</strong> Department <strong>of</strong> CMHI. Tissue samples were<br />
routinely preserved for histological, histochemical and ultrastructural<br />
examination. All <strong>of</strong> the examinated patients had total<br />
bilirubin in the range <strong>of</strong> 1,3-5,1 mg% (Table 1).<br />
Address for correspondence<br />
Elzbieta Czarnowska, PhD<br />
Department <strong>of</strong> <strong>Pathology</strong><br />
The Children's Memory Health Institute<br />
Al. Dzieci Polskich 20, 04-730 Warsaw, Poland<br />
Phone: +48 22 815 48 15<br />
E-mail: czar@czd.waw.pl
116<br />
Table 1<br />
Total and direct bilirubin level in serum in distinguished groups <strong>of</strong> primary hyperbilirubinemia and with non-specific changes<br />
Disease<br />
Gilbert<br />
Compl.<br />
Incompl.<br />
Number <strong>of</strong> patients Age (years)<br />
10<br />
11<br />
10-17<br />
6-7<br />
Bilirubin (mg%)<br />
Total Average Direct Ave<br />
1,5-4,6 2,56 0,5-0,9 0,62<br />
1,2-5,1 2,48 0,3-1,1 0,95<br />
Dubin-Johnson 5 9-17 1,3-4,7 2,54 0,6-2,0 1,05<br />
Rotor 3 16-17 1,6-4,5 2,10 0,4-0,8 0,55<br />
Non specific 33 7-17 1,2-5,7 2,62 0,2-2,8 1,45<br />
Histology<br />
Five mm thick paraffin sections were stained in a routine manner<br />
with hematoxylin-eosin, azan, silver, PAS, PAS with<br />
diastaze digestion and than reviewed to exclude other disease<br />
than hyperbilirubinemia.<br />
Electron microscopy<br />
Samples were fixed in 2.5% glutaraldehyde in cacodylate<br />
buffer at pH 7.3, postfixed in 2% OsO 4,<br />
dehydrated in alcohols<br />
and embedded in Epon 812. Thick sections stained with toluidine<br />
blue were analysed under light microscope. Ultrathin<br />
sections stained with uranyl acetate and lead citrate were examined<br />
by electron microscopy.<br />
A<br />
B<br />
Results<br />
Examinations <strong>of</strong> paraffin and semi-thin sections showed in all<br />
cases an apparently normal liver, except for Dubin-Johnson<br />
that shown the existence <strong>of</strong> dark pigment predominantly in<br />
centrolobular areas.<br />
On the basis <strong>of</strong> EM analysis morphological equivalents<br />
<strong>of</strong> primary congenital hyperbilirubinemias were confirmed<br />
in 29 cases and secondary reactive symptomatic<br />
hyperbilirubinemias were recognized in 33 cases.<br />
Gilbert syndrome<br />
Gilbert syndrome was diagnosed in 21 cases. There were observed<br />
shortening and mal-developed vascular pole microvilli<br />
or loss <strong>of</strong> microvilli, and increase <strong>of</strong> collagen in the Disse<br />
space in various intensity. In all patients an increase <strong>of</strong> the<br />
endoplasmic reticulum pr<strong>of</strong>iles with coexisting dilatation <strong>of</strong><br />
rough endoplasmic reticulum with degranulation and pigment<br />
granules variable in size containing both electron dense material<br />
which alternate with less dense material and lipid droplets<br />
was observed (Fig. 1A). In 10 biopsy samples enlarged or<br />
giant, oval or polymorphic mitochondria with paracrystalline<br />
inclusions (Fig. 1B) were present. In all cases the biliary pole<br />
<strong>of</strong> hepatocytes shown normal caniculi and microvilli, but with<br />
numerous pigment granules around. Lip<strong>of</strong>uscin granules were<br />
Fig. 1 Gilbert syndrome: (A) vascular pole <strong>of</strong> hepatocyte with single microvilli.<br />
Mag. x 40 000, (B) mitochondrium containing paracrystallines, mag. x<br />
22 000<br />
common finding. The remaining group <strong>of</strong> 11 patients showed<br />
uncompleted ultrastructural features <strong>of</strong> Gilbert disease, i.e. lack<br />
<strong>of</strong> giant mitochondria and no paracristalline in mitochondrial<br />
matrix.<br />
Dubin-Johnson syndrome<br />
Dubin-Johnson syndrome was defined in 5 cases. There<br />
were not seen alterations in the vascular pole <strong>of</strong> hepatocytes,<br />
which exhibit normal microvilli. Slightly increased number<br />
<strong>of</strong> smooth endoplasmic reticulum pr<strong>of</strong>iles that formed small<br />
vesicles, normal mitochondria with some variation in size,<br />
well developed Golgi pr<strong>of</strong>iles located around bile canicules<br />
were common features. Dilation <strong>of</strong> bile caniculi with loss <strong>of</strong><br />
microvilli and characteristic pigment granules around were<br />
seen (Fig. 2). Pigment granules were composed mainly <strong>of</strong><br />
granular material, however vesicle-like or lipid components<br />
were also seen. They were polygonal in shape and delineated<br />
by a single membrane. The lack <strong>of</strong> lip<strong>of</strong>uscin in hepatocytes<br />
was common feature.
117<br />
Fig. 2 Dubin-Johnson syndrome: a bile pole <strong>of</strong> hepatocytes with pigment<br />
granules around the bile canicule. Mag.x 30 000<br />
Rotor Syndrome<br />
Rotor syndrome was recognised in 3 cases. Only slight changes<br />
in hepatocytes were observed: some <strong>of</strong> the bile canicules were<br />
dilated and exhibited reduced number <strong>of</strong> microvilli, the<br />
interhepatocytic junctional interspaces were dilatated and cell<br />
membranes along the lateral cell surface formed microvilli<br />
(Fig. 3a), cell membranes facing the Disse space showed reduced<br />
number <strong>of</strong> microvilli. In side <strong>of</strong> hepatocytes a few pleomorphic<br />
mitochondria or megamitochondria with<br />
paracristalline were seen. The most characteristic feature was<br />
lack <strong>of</strong> lipid component in pigment granule that composed <strong>of</strong><br />
electron dense and less dense granular material. They were<br />
distributed mainly around bile canicules (Fig. 3b).<br />
Non characteristic lesions<br />
Non characteristic ultrastructural fine lesions accompanying<br />
secondary hyperbilirubinemia were found in 33 cases. Reactive<br />
changes were recognized in 9 cases. There were increased<br />
number and elongation <strong>of</strong> microvilli on the vascular pool (Fig.<br />
4), polymorphic mitochondria (sometimes with paracrystalline<br />
inclusions), increased number <strong>of</strong> smooth endoplasmic reticulum<br />
pr<strong>of</strong>iles, the presence <strong>of</strong> single lipid droplets and pigment<br />
or lip<strong>of</strong>uscin granules in cytoplasm, and collagen fibrils<br />
in Disse spaces.<br />
Fig. 4 Non specific changes. Vascular pole <strong>of</strong> hepatocyte with numerous,<br />
elongated microvilli. Mag.x 40 000<br />
Discussion<br />
In about 50% <strong>of</strong> the patients with clinical symptoms <strong>of</strong> hyperbilirubinemia<br />
electron microscopy confirmed primary congenital<br />
hyperbilirubinemia. Among <strong>of</strong> them, complete ultrastructural<br />
features <strong>of</strong> Gilbert syndrome were presented in 10 cases,<br />
uncomplete Gilbert in 11 cases, Dubin-Johnson in 5 cases<br />
and Rotor in 3 cases.<br />
In seventies the ultrastructural observations were helpful<br />
to establish the morphological equivalent <strong>of</strong> primary hyperbilirubinemia<br />
and distinguish combination <strong>of</strong> defects impairing<br />
primary hyperbilirubinemias, particularly in Gilbert<br />
syndrome when complete and incomplete features coexisted<br />
[1, 4, 6]. Our patients with Gilbert disease clinically were characterized<br />
by relatively low-grade direct bilirubin and they<br />
reached a higher proportion <strong>of</strong> unconjugated bilirubin. These<br />
abnormalities were correlated with decrease or the lack <strong>of</strong> microvilli<br />
at sinusoidal pole.<br />
It is known that the liver in Dubin-Johnson syndrome<br />
might be characterized by slight and inconsistant changes. In<br />
our patients, the canicular pole exhibited normal microvilli or<br />
disappearing microvilli coexisting with a slightly dilated lumen.<br />
These results suggest that disturbances <strong>of</strong> bile flow were<br />
caused by different disfunctions <strong>of</strong> the canicular area. These<br />
are in agreement <strong>of</strong> with distinct mechanism <strong>of</strong> bilirubin glucuronide<br />
transport involving ATP-dependent and ATP-independent<br />
system that have been proposed [7].<br />
Fig. 3 Rotor syndrome: (A) lateral hepatocytes<br />
surface with number <strong>of</strong> microvilli. Mag. x<br />
50 000; (B) pigment granules composed <strong>of</strong><br />
dense granular and lipid material, mag.x20 000<br />
A<br />
B
Patients with Rotor syndrome ultrastructurally presented fairly<br />
similar features to Gilbert and to Dubin-Johnson simultaneously:<br />
some injury <strong>of</strong> vascular and canicular pole concomitant<br />
with an increase <strong>of</strong> smooth endoplasmic reticulum and<br />
pleomorphic mitochondria in hepatocytes. These similarities<br />
between some ultrastructural features <strong>of</strong> Gilbert and Dubin-<br />
Johnson syndrome were signaled in literature before [8]. The<br />
presence <strong>of</strong> microvilli along the lateral surface <strong>of</strong> hepatocytes<br />
was a particular feature, which distinguished patients with<br />
Rotor syndrome from other patients. Patients with Rotor syndrome<br />
exhibited lower level <strong>of</strong> direct bilirubin than<br />
unconjugated, and this observation does not agree with main<br />
idea <strong>of</strong> liver defect [5]. However, similar data on a direct bilirubin<br />
in serum have been mentioned in literature [3].<br />
Electron microscopic methods permit on recognition<br />
<strong>of</strong> non-specific changes in the ultrastructure <strong>of</strong> the liver tissue<br />
among samples obtained from patients with non-hemolytic<br />
hyperbilirubinemias and can be still usefull in diagnosis <strong>of</strong><br />
jaundince.<br />
References<br />
1. Bethelot P, Dhumeaux D (1978) New<br />
signts in the classification and mechanism<br />
<strong>of</strong> hereditiary, chronic, nonhaemolytic<br />
hyperbilirubinemias. Gut<br />
19:474-480<br />
2. Chowdhury JR, Wolk<strong>of</strong>f AW, Wolk<strong>of</strong>f<br />
N, Chodhury R, Arias JM (1995)<br />
Hereditiary jaundice and disorders <strong>of</strong><br />
bilirubin metabolism. In: Scriver ChR,<br />
Beaudet AL, Sly WS, Walle D (eds) The<br />
metabolic basis <strong>of</strong> inherited diseases,<br />
New York, Vol 1, pp 2161-2208<br />
3. Czarnecki J, Cichosz H, Slomke M,<br />
Siezieniewska G, Czechowska G (1988)<br />
Clinical, biochemical and morphologic<br />
analysis <strong>of</strong> congenital non-hemolytic<br />
hyperbilirubinemia. Wiad Lek<br />
11(17):1151-1156 (in Polish)<br />
4. Dawson J, Carr-Loske DL, Talbot JC,<br />
Rossenthal FD (1978) Hepatic ultrastructure<br />
in Gilbert syndrome: evidence<br />
two populations. Gut 19A:995-999<br />
5. Iyanagi T, Emi Y, Ikushiro S (1998) Biochemical<br />
and molecular aspects <strong>of</strong> genetic<br />
disorders <strong>of</strong> bilirubin metabolism.<br />
Biochem Biophys 1407:173-184<br />
6. McGee JOD, Allan JG, Russel RJ,<br />
Patrick RS (19750 Liver ultrastructure<br />
in Gilbert syndrom. Gut 16: 220-224<br />
7. Nishida T, Gatmaitan Z, Roy Chodhry<br />
R, Arias IM (1992) Two distinct mechanisms<br />
for bilirubin glucuronide transport<br />
by rat ble membrane vesicles. Demonstration<br />
<strong>of</strong> defective ATP-dependent<br />
transport in rats (TR-) with inherited<br />
conjugated hyperbilirubinemia. J Clin<br />
Invest 90:21-2135<br />
8. Okolicsanyi L, Torrado A, Nussle D,<br />
Gardid D, Gautier A (1969) Etude<br />
clinique et ultrastructurale d’un cas de<br />
syndrome de Rotor. Revue Int Hepat<br />
19:393-398
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Congenital Heart Diseases Database: analysis <strong>of</strong> occurrence,<br />
diagnostics and coexistence with anomalies <strong>of</strong> other systems.<br />
Single institution experience<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
Anna Rybak, Aneta Wójcik, Bogdan WoŸniewicz<br />
Department <strong>of</strong> <strong>Pathology</strong><br />
The Children’s Memorial Health Institute<br />
Warsaw, Poland<br />
Abstract<br />
The Congenital Heart Diseases Database was created in the Children’s Memorial Health Institute during<br />
the period <strong>of</strong> 2001 – 2003. It contains over 1000 preparations <strong>of</strong> congenital heart defects <strong>of</strong> children aged<br />
from 0 till 14 years. According to our data, the most common defect was ventricular septal defect. The<br />
compatibility <strong>of</strong> the clinic and pathological diagnoses was high (about 80% <strong>of</strong> the diagnoses were confirmed),<br />
however significantly higher after 1990. Although in our Database plenty <strong>of</strong> coexisting anomalies<br />
and diseases <strong>of</strong> the other systems or organs occurred, we found no significant relations between them and<br />
congenital heart defects.<br />
Key words: congenital heart disease, database, heart defects<br />
Introduction<br />
Since 1980 until now, the Children’s Memorial Health Institute<br />
<strong>of</strong> Warsaw has assembled over 1200 congenital heart defects<br />
preparations from patients aged 0-14 years. Between<br />
September 2001 and March 2003 we have made the repeated<br />
sections <strong>of</strong> those preparations and created “The Congenital<br />
Heart Diseases Database” (CHDDb) that includes 1037 records<br />
with full descriptions <strong>of</strong> the hearts’ and defects’ anatomy, clinical<br />
and sectional diagnoses, anomalies <strong>of</strong> other systems and<br />
performed operations. This is to present the direct conclusions<br />
that have arisen from this Database, including the frequency<br />
<strong>of</strong> occurrence <strong>of</strong> the particular heart defects, compatibility <strong>of</strong><br />
the clinical and autopsy diagnoses and finally, regularity in<br />
coexistence <strong>of</strong> the congenital heart defects with the anomalies<br />
<strong>of</strong> the other systems.<br />
Material and methods<br />
The Congenital Heart Diseases Database is composed <strong>of</strong> 1037<br />
preparations <strong>of</strong> the hearts with the congenital defects. They<br />
are fully described in four files which contain personal patients’<br />
data, clinical diagnoses with the descriptions <strong>of</strong> defects<br />
Address for correspondence<br />
Bogdan Wozniewicz<br />
Department <strong>of</strong> <strong>Pathology</strong><br />
The Children's Memorial Health Institute<br />
Aleja Dzieci Polskich 20, 04-736 Warsaw, Poland<br />
<strong>of</strong> the other systems and types <strong>of</strong> performed operations, pathologic<br />
diagnoses <strong>of</strong> the heart defect and coexisting diseases.<br />
The last file shows complete measurement <strong>of</strong> all the hearts<br />
including external dimensions as well as internal measurements<br />
<strong>of</strong> the valves, arteries, veins or myocardium.<br />
The patients’ age was between 1 day and 14 years.<br />
There were 437 female and 600 male patients described and<br />
they were all admitted to Children’s Memorial Health Institute<br />
during the period 1980 – 2003 and almost half <strong>of</strong> them<br />
were operated because <strong>of</strong> the heart defect.<br />
A nomenclature for the congenital heart disease was<br />
based on the International Nomenclature for Congenital Heart<br />
Surgery that was <strong>of</strong>ficially adopted at the Annual Meeting <strong>of</strong><br />
the EACTS in Glasgow on September 6, 1999 [3].<br />
Results and discussion<br />
Occurrence <strong>of</strong> the congenital heart defects<br />
The most common anomaly that appeared in our material was<br />
ventricular septal defect (VSD) with the frequency just under<br />
30% (Fig.1). In details, there were 31 cases <strong>of</strong> VSD in muscular<br />
part <strong>of</strong> the septum (VSD single–29; VSD multiple-2 cases)<br />
and 259 cases <strong>of</strong> this defect in other parts <strong>of</strong> the interventricular<br />
septum (VSD; NOS).<br />
Phone: +4822-815-1960<br />
E-mail: b.wozniewicz@czd.waw.pl
%<br />
30<br />
25<br />
20<br />
15<br />
10<br />
5<br />
0<br />
VSD PDA TGA ASD TOF AVC CoA HLHS PA HRV PS DORVTAPVC<br />
Fig. 1 Occurrence <strong>of</strong> the congenital heart diseases<br />
The frequency <strong>of</strong> patent arterial duct (PDA) was about 19%.<br />
Similarly, other congenital heart defects like transposition <strong>of</strong><br />
the great arteries (TGA) and atrial septal defect (ASD) are<br />
about 18%. Although there were over 160 ASD diagnosed,<br />
the largest group was due to persisted foramen ovale (PFO )<br />
type (50%). ASD secundum type appeared in 69 cases that<br />
was just over 40% <strong>of</strong> all atrial defects. Other atrial defects,<br />
like ASD type sinus venosus, coronary sinus type or single<br />
atrium, appeared rarely (14 cases).<br />
Tetralogy <strong>of</strong> Fallot (TOF) was diagnosed in about 12%<br />
<strong>of</strong> all cases. Atriovertricular canal (AV canal) as well as coarctation<br />
<strong>of</strong> aorta (CoA) concerned 9% <strong>of</strong> all heart defects. Hypoplastic<br />
left heart syndrome (HLHS) likewise pulmonary atresia<br />
(PA) were visible in 7% <strong>of</strong> the examined preparations. Similarly<br />
hypoplastic right ventricle (HRV) or pulmonary stenosis<br />
(6,5%). Double outlet from the right ventricle (DORV) and total<br />
anomalous pulmonary venous connection (TAPVC) appeared<br />
in less than 5% <strong>of</strong> all cases. The rarest were aortic atresia (3<br />
patients), aortic valve hypoplasia (1 patient), pseudotruncus (3<br />
patients) and inversion <strong>of</strong> the ventricles (2 patients).<br />
There is also some regularity with reference to the gender<br />
<strong>of</strong> the patients. The difference is most significant in the<br />
group <strong>of</strong> diseases like partial anomalous pulmonary venous<br />
connection or right ventricle outlet obstruction, which occurred<br />
two to five times more <strong>of</strong>ten in the female group than in the<br />
male group. However aortic atresia, Bland-White-Garland syndrome<br />
and cor triatriatum occurred in our material only in<br />
reference to the male group. Such defects like truncus arteriosus,<br />
aortic stenosis, HLHS, TGA or mitral atresia occurred<br />
over two times more <strong>of</strong>ten in the group <strong>of</strong> boys than in the<br />
group <strong>of</strong> girls.<br />
Clinical and autopsy diagnosis<br />
There are 1037 congenital heart diseases in the Database, however<br />
clinical diagnostics and diagnoses were established due<br />
to 867 patients. In this group, autopsy diagnoses differed from<br />
clinical diagnoses in about 19% (166 cases).<br />
Clinical diagnostics was based on physical examination, ECG,<br />
blood pressure measurement, echocardiography and invasive<br />
cardiology, which was used from the beginning 1990. Because<br />
<strong>of</strong> that fact, we decided to divide our data into two groups: in<br />
the first group there were patients that had been admitted to<br />
the Children’s Memorial Health Institute till the end <strong>of</strong> 1989<br />
(533 patients); the second group included rest <strong>of</strong> the patients<br />
(334 patients). The results <strong>of</strong> a comparison between clinical<br />
and pathologic diagnoses were as follows: 166 children (22%)<br />
from the first group were misdiagnosed during their hospitalization.<br />
In the second group, where the patients were additionally<br />
diagnosed by means <strong>of</strong> the invasive cardiology, the<br />
number <strong>of</strong> misdiagnoses has fallen to 15% (Table 1). Among<br />
166 incorrectly diagnosed congenital heart defects, the most<br />
<strong>of</strong>ten was HLHS (about 13%), than TGA and AV canal (just<br />
under 9%). In contrast, the greatest conformity between clinic<br />
and autopsy was due to interrupted aortic arch (over 90%)<br />
and TAPVC or PDA (about 80%).<br />
Table 1<br />
Compatibility between clinical and autopsy diagnoses<br />
Period<br />
1980-1989 78%<br />
1990-2003 85%<br />
Compatibility<br />
Coexistence <strong>of</strong> the congenital heart defects with the<br />
anomalies <strong>of</strong> other systems<br />
In reference to the CHDDb there were no significant relations<br />
between heart defects and other anomalies. The most common<br />
were malformations <strong>of</strong> the alimentary tract, polysplenia,<br />
asplenia, urinary tract defects and additional superior caval<br />
vein which occurred mainly in reference to heart defects like<br />
AV canal, coarctation <strong>of</strong> aorta, TAPVC and TOF. There were<br />
eight patients with situs inversus, although with different heart<br />
defects.<br />
In the group <strong>of</strong> patients with chromosome aberrations<br />
there were 24 patients with Down syndrome. Over 62% <strong>of</strong><br />
these patients suffered from atrioventricular canal and about<br />
34% from VSD. There was one patient with Patau syndrome<br />
that had coarctation <strong>of</strong> aorta and one patient with Edward’s<br />
syndrome who suffered from VSD.<br />
In our Database occurred six patients with developmental<br />
multiply malformations. Three patients with Pierre-<br />
Robin sequence suffered from ASD, VSD and TOF. Two children<br />
with DiGeorge syndrome had TOF and tricuspid valve<br />
atresia, while in literature, the most common are the anomalies<br />
<strong>of</strong> the aortic arch [1, 2]. The congenital heart disease <strong>of</strong><br />
one patient with Noonan syndrome was AV canal (in literature,<br />
over 50% patients with Noonan syndrome suffer from<br />
pulmonary stenosis) [2].<br />
References<br />
1. Becker AE, Anderson RH (1985) Pathologie des Herzens. Georg<br />
Thieme Verlag<br />
2. Connor M, Ferguson-Smith M (1998) Podstawy genetyki<br />
medycznej, PZWL (in Polish)<br />
3. Lacour-Gayet F, Maruszewski B, Mavroudis C, Jacobs JP, Elliott<br />
MJ (2000) Presentation <strong>of</strong> the International Nomenclature for<br />
Congenital Heart Surgery. Eur Journ Card-Thor Surg 18:128-<br />
135
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
Solid pseudopapillary tumor <strong>of</strong> pancreas.<br />
Case report and the review <strong>of</strong> literature<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
Andrzej Chilarski 1 , Anna Piaseczna-Piotrowska 1 , Jan Strzelczyk 2 , Stanis³aw £ukaszek 3 , Andrzej Kulig 3<br />
1<br />
Depart. <strong>of</strong> Pediatric Surgery<br />
3<br />
Depart. <strong>of</strong> <strong>Pathology</strong>,<br />
Polish Mother’s Health Institute,<br />
Lodz, Poland<br />
2<br />
Depart. <strong>of</strong> General Surgery and Transplantology,<br />
Medical University,<br />
Lodz, Poland<br />
Abstract<br />
Authors describe the case <strong>of</strong> 14 year-old girl operated on because <strong>of</strong> the neoplasm <strong>of</strong> tail <strong>of</strong> pancreas proved<br />
to be solid pseudopapillary pancreatic tumor. Radical resection was curative. After surgery she made uneventful<br />
recovery being symptoms’ free for 8 months. The review <strong>of</strong> literature on this rare, relatively low,<br />
malignant tumor is presented.<br />
Key words: pancreas, pseudopapillary tumor, solid tumors<br />
Introduction<br />
Solid pseudopapillary tumors <strong>of</strong> pancreas (SPTP) first described<br />
by Frantz in 1959 are rare findings among other pancreatic<br />
tumors [5, 6, 9, 10, 11, 13]. To date a bit more then 500<br />
cases have been described in the literature [16]. SPTP occurs<br />
predominantly in teenage girls and young women although<br />
all age groups may be affected and also males are not disease<br />
– free [12, 15, 17, 18].<br />
The tumors are reckoned as a low-grade malignant papillary<br />
– cystic neoplasms <strong>of</strong> the pancreas <strong>of</strong> unclear histogenetic<br />
origin, but with highly characteristic, distinct histology and<br />
usually quite benign biologic behaviour [3, 9, 10, 13, 15, 18].<br />
Their clinical presentation is vague and non characteristic. The<br />
most common symptoms are abdominal pains, nausea, emesis,<br />
sometimes palpable abdominal mass and jaundice – if the<br />
head <strong>of</strong> pancreas is involved [1]. Asymptomatic course is not<br />
uncommon and diagnosis can be established incidentally following<br />
blunt abdominal trauma [3, 9, 19]. Complete resection<br />
is usually curative and so the radical surgery is the treatment<br />
<strong>of</strong> choice. No adjuvant therapy is recommended.<br />
Case report<br />
Patient<br />
Girl 14-year-old girl (J. P.; files 054774B) was transferred to<br />
Department <strong>of</strong> Pediatric Surgery, Polish Mother’s Health Institute<br />
from local hospital because <strong>of</strong> suspected pancreatic tumor.<br />
She gave the history <strong>of</strong> year-long, moderate, occasional<br />
abdominal pain and nausea and single incident <strong>of</strong> syncope<br />
just before admission to the hospital. Her general condition<br />
was quite good. Physical examination revealed palpable mass<br />
in upper abdomen on left side. No other abnormalities have<br />
been detected. Laboratory investigations were all within normal<br />
range. In abdominal ultrasonography a solid tumor in left<br />
upper quadrant, originating probably from pancreating tail and<br />
reaching spleen, was found. CT scan confirmed this finding<br />
(Fig. 1) showing the tumor <strong>of</strong> pancreas tail about 6 cm in<br />
diameter in the vicinity <strong>of</strong> spleen and its vessels. The indications<br />
for surgical treatment were established. Exposure <strong>of</strong> the<br />
pancreas revealed the presence <strong>of</strong> the well vascularized mass<br />
arising from the tail <strong>of</strong> pancreas and reaching to the hilum <strong>of</strong><br />
the spleen. Main splenic vessels were surrounded by the tumor<br />
and could not be liberated. The resection <strong>of</strong> the tumor<br />
Address for correspondence<br />
Andrzej Chilarski,<br />
Depart. <strong>of</strong> Pediatric Surgery,<br />
Polish Mother's Health Institute, Lodz<br />
Rzegowska St. 281/289<br />
Lodz, Poland<br />
Phone: + 48 42 2712136<br />
E-mail: klinikachirdziec@poczta.onet.pl
122<br />
In the cystic part <strong>of</strong> the tumor there were foci <strong>of</strong> degeneration<br />
and haemorrhage resulting in creation <strong>of</strong> pseudocystic and<br />
pseudopapillary pattern, particularly around small vessels (Fig.<br />
3). No vascular invasion was found. On the borderline <strong>of</strong> the<br />
tumor and pancreatic parenchyma a few otherwise normal<br />
glands were found with the lining partly consisting <strong>of</strong> tumor<br />
cells (Fig. 4). The tumor cells showed: positive immunostaining<br />
for á 1<br />
antitrypsin (Fig. 5), chromogranin, vimentin, neuron –<br />
specific enolase (NSE) and synaptophysin. The final histopathologic<br />
diagnosis was - solid pseudopapillary tumor <strong>of</strong> pancreas<br />
(SPTP).<br />
Fig. 1 CT scan: tumor <strong>of</strong> the tail <strong>of</strong> pancreas<br />
was performed “en bloc” with the spleen and distal part <strong>of</strong> the<br />
pancreas 1 cm from the borderline – within healthy tissue.<br />
The hemostasis was achieved and the line <strong>of</strong> resection <strong>of</strong> pancreatic<br />
tissue protected with continuous 4.0 nonabsorbable<br />
suture. No other abnormalities were detected in abdominal<br />
cavity and parietes were closed in layers.<br />
Because <strong>of</strong> splenectomy that has been performed together<br />
with the tumor’s resection - vaccinations against Streptococcus<br />
pneumoniae, Haemophilus influenzae and Neisseria<br />
meningitidis were carried out. Now, eight months postoperatively<br />
girl is well, free <strong>of</strong> symptoms. The patient has made an<br />
uneventful recovery and was discharged home on 12 th postoperative<br />
day.<br />
Histopathology<br />
The specimen consisted <strong>of</strong> tumor – 6 cm in diameter with margin<br />
<strong>of</strong> normal pancreatic tissue attached to the hilum <strong>of</strong> the spleen,<br />
without its infiltration, encompassing splenic vessels. The tumor<br />
was well demarcated, its architecture was partly solid and<br />
partly cystic. The solid part was built <strong>of</strong> unifrom, medium-size<br />
cells with faintly eosinophilic cytoplasm and round nuclei. Mitoses<br />
were not numerous, but foci <strong>of</strong> increased mitotic activity<br />
were present as well. The tumor’s cells formed solid structures,<br />
cords and trabeculae (Fig. 2).<br />
Fig. 3 Pseudopapillary pattern, particularly around small vessels. (HE 100x)<br />
Fig. 4 Tumor's cells within the lining <strong>of</strong> some glands. (HE 200x)<br />
Fig. 2 General architecture <strong>of</strong> the tumor - the solid part. Two mitoses are<br />
present. (HE 100x)<br />
Fig. 5 Positive immunostaining for alfa1 antitrypsin. (HE 100x)
123<br />
Discussion<br />
Preoperative diagnosis <strong>of</strong> pancreatic tumor, putting aside uncharacteristic<br />
clinical symptoms as far as its size, localization,<br />
detailed anatomy and topography is concerned, is based<br />
upon ultrasonography, computed tomoghraphy, magnetic resonance<br />
image [4, 7, 15, 17]. Still diagnostic failures, such as<br />
pseudocyst or ruptured hepatic mass are described in literature<br />
[17, 19]. Some authors advocate preoperative fine needle<br />
biopsy to establish exact histopatology <strong>of</strong> neoplasm [3, 17].<br />
However such a policy is controversial as needle biopsy may<br />
not allow an undisputed diagnosis and the indications for operation<br />
exist, this way or another. This was a case in our patient,<br />
too. Aggressive surgery and complete resection produces<br />
the specimen to be meticulously examined [1, 5, 13, 15, 16].<br />
In 1996 solid pseudopapillary tumor was introduced in<br />
WHO classification <strong>of</strong> tumors <strong>of</strong> the exocrine pancreas [8, 11].<br />
It is usually included into cystic group <strong>of</strong> exocrine neoplasm <strong>of</strong><br />
pancreas that encompasses [8, 20]:<br />
- serous cystis neoplasms,<br />
- mucinous cystic neoplasms,<br />
- solid papillary neoplasms,<br />
- intraductal pancreatic mucinous neoplasm.<br />
Prognosis for the patients with these tumors is much<br />
better than that <strong>of</strong> patients with adenocarcinoma, although in<br />
about 5% <strong>of</strong> patients with SPTP malignant course with metastases<br />
and peritoneal spread can develop [2, 6]. It is estimated<br />
that after surgical resection the outcome is excellent<br />
resulting in long – term survival in about 90% <strong>of</strong> patients [5,<br />
9, 15, 16, 18]. Complete radical resection may need extension<br />
to neighbouring organs e. g. transverse colon or spleen – as<br />
was a case in our patient. Recurrence has been described in<br />
approximately 10% <strong>of</strong> cases [2, 5, 10, 15]. Solid<br />
pseudopapillary tumor <strong>of</strong> pancreas should be always taken<br />
into consideration in the differential diagnosis <strong>of</strong> pancreatic<br />
neoplasm.<br />
Acknowledgements<br />
Authors greatly appreciate the assistance <strong>of</strong> Tomasz Krawczyk,<br />
MD in preparing microscopic pictures.<br />
References<br />
1. Akiyama H, Ono K, Takano M, Sumida<br />
K, Ikuta K, Miyamoto O (2002) Solidpsudopapillary<br />
tumor <strong>of</strong> the pancreatic<br />
head causing marked distal atrophy: a<br />
tumor originated posterior to the main<br />
pancreatic duct. Int Gastrointest Cancer<br />
32(1):29-31<br />
2. Andronikou S, Moon A, Usser R (2003)<br />
Peritoneal metastatic disease in a child<br />
after excision <strong>of</strong> a solid pseudopapillary<br />
tumor <strong>of</strong> the pancreas: a unique case.<br />
Pediatr Radiol 33(4):269-271<br />
3. Asthon J, Sutherland F, Nixon J, Nayak<br />
V (2003) A case <strong>of</strong> solid-pseudopapillary<br />
tumor <strong>of</strong> the pancreas: preoperative cyst<br />
fluid analysis and treatment by<br />
enueclation. Hepatogastroenterology<br />
50(54):2239-2241<br />
4. Cantisani V, Mortele KJ, Levy A,<br />
Glickman JN, Ricci P, Passariello R, Ros<br />
PR, Silverman SG (2003) MR imaging<br />
features <strong>of</strong> solid pseudopapillary tumor<br />
<strong>of</strong> the pancreas in adult and pediatric<br />
patients. AJR Am J Roentgenol<br />
181(2):395-401<br />
5. Cervantes-Montiel F, Florez-Zorrilla C,<br />
Alvarez-Martinez I (2002) Solid-cystic<br />
pseudopapillary tumor <strong>of</strong> the pancreas:<br />
acute post-traumatic presentation. Case<br />
report review <strong>of</strong> the literature. Rev<br />
Gastroenterol Mex 67(2):93-96<br />
6. Illert B, Luhrs H, Timmermann W,<br />
Muller JG (2003) Solid-pseudopapillary<br />
tumor <strong>of</strong> the pancreas as differential diagnosis<br />
in pancreatic tumors <strong>of</strong> the<br />
young. Zentralbl Chir 128(5):438-442<br />
7. Kato T, Egawa N, Kamisawa T, Tu Y,<br />
Sanaka M, Sakaki N, Okamoto A, Bando<br />
N, Funata N, Isoyama T (2002) A case<br />
<strong>of</strong> solid psudopapillary neoplasm <strong>of</strong> the<br />
pancreas and tumor doubling time.<br />
Pancreatology 2(5):495-498<br />
8. Kloppel G, Bogomoletz WV (2003)<br />
<strong>Diagnostic</strong> histopathology <strong>of</strong> tumors.<br />
Ch. Fletcher (Ed), Churchill,<br />
Livingstone, p. 470<br />
9. Mancini GJ, Dudrick PS, Grindstaff<br />
AD, Bell JL (2004) Solidpseudopapillary<br />
tumor <strong>of</strong> the pancreas:<br />
two cases in male patients. Am Surg<br />
70(1):29-31<br />
10. Martin RC, Klimstra DS., Brennan MF,<br />
Conlon KC (2002) Solid<br />
pseudopapillary tumor <strong>of</strong> the pancreas:<br />
a surgical enigma Ann Surg Oncol<br />
9(1):35-40<br />
11. Meyer S, Aliani S, Graf N, Bonkh<strong>of</strong>f<br />
H, Schneideer G, Reinhard H (2002)<br />
Solid-pseudopapillary tumor <strong>of</strong> the pancreas<br />
in a 9-year-old girl. Klin Pediatr<br />
214(5):316-318<br />
12. Molino D, Perriotti P, Napoli V,<br />
Antropoli C, Gargano E, Antropoli M,<br />
D’Antonio D, Vicenzo L, Boscaino A,<br />
D’Anna L, Guidi G (2003) Solid<br />
pseudopapillary tumour <strong>of</strong> the pancreas.<br />
Report <strong>of</strong> a case. Minerva Chir<br />
58(6):815-821<br />
13. Nachulewicz P, Kalicinski P, Polnik D,<br />
Chy¿yñska A, Broniszczak, D (2002)<br />
Solid and papillary epithalial tumor <strong>of</strong><br />
the pancreas. A case report <strong>of</strong> surgically<br />
curable tumor. Surg Childh Intern 3:148-<br />
150<br />
14. Nadler EP, Novikov A, Landzberg BR,<br />
Pochapin MB, Centeno B, Fahey TJ,<br />
Spigland N (2002) The use <strong>of</strong> endoscopic<br />
ultrasund in the diagnosis <strong>of</strong> solid<br />
pseudopapillary tumors <strong>of</strong> the pancreas<br />
children. J Pediatr Surg 37(9):1370-1373<br />
15. Patel VG, Fortson JK, Weaver WL,<br />
Hammami A (2002) Solidpseudopapillary<br />
tumor <strong>of</strong> the pancreas<br />
masquerading as a pancreatic<br />
pseudocyst. Am Surg 68(7):631-632<br />
16. Pettinato G, Di Vizi D, Manivel JC,<br />
Pambuccian SE, Somma P, Insabato L<br />
(2002) Solid-pseudopapillary tumor <strong>of</strong><br />
the pancreas: a neoplasm with distinct<br />
and highly characteristic cytological<br />
features. Diagn Cytopathol 27(6):325-<br />
334<br />
17. Pezzolla F, Lorusso D, Caruso ML,<br />
Demma I (2002) Solid pseudopapillary<br />
tumor <strong>of</strong> the pancreas. Consideration <strong>of</strong><br />
two cases. Anticancer Res 22(3):1807-<br />
1812<br />
18. Pedevin J, Triau S, Mirallie E, Le<br />
Borgne J (2003) Solid-pseudopapillary<br />
tumor <strong>of</strong> the pancreas: a study <strong>of</strong> five<br />
cases, and review <strong>of</strong> the literature. Ann<br />
Chir 128(8):543-548<br />
19. Potrc S, Kavalar R, Horvat M, Gadzijev<br />
EM (2003) Urgent Whipple resection for<br />
solid pseudopapillary tumor <strong>of</strong> the pancreas.<br />
J Hepatobiliary Pancreat Surg<br />
10(5):386-389<br />
20. Sheehan MK, Beck K, Pickleman J,<br />
Aranha GV (2003) Spectrum <strong>of</strong> cystic<br />
neoplasms <strong>of</strong> the pancreas and their surgical<br />
management. Arch Surg<br />
138(6):657-660
<strong>Annals</strong> <strong>of</strong> <strong>Diagnostic</strong> <strong>Paediatric</strong> <strong>Pathology</strong> 2004, 8(3-4):<br />
© Copyright by Polish <strong>Paediatric</strong> <strong>Pathology</strong> Society<br />
The invited lecture<br />
Liver tumors <strong>of</strong> childhood - pathology. Report <strong>of</strong> the Kiel Pediatric<br />
Tumor Registry*<br />
Dieter Harms<br />
<strong>Annals</strong> <strong>of</strong><br />
<strong>Diagnostic</strong><br />
<strong>Paediatric</strong><br />
<strong>Pathology</strong><br />
Department <strong>of</strong> Pediatric <strong>Pathology</strong>,<br />
University <strong>of</strong> Kiel,<br />
Kiel, Germany<br />
Dear Colleagues,<br />
Over the years I have collected a series <strong>of</strong> 522 primary liver<br />
tumors. Hepatoblastomas, accounting for 51.3% <strong>of</strong> the cases,<br />
are by far the most frequent liver tumors in the files <strong>of</strong> the<br />
Registry, followed by infantile hemangioendothelioma and<br />
hepatocellular carcinoma (15.5%, each). All other liver tumors,<br />
including mesenchymal hamartoma, focal nodular hyperplasia,<br />
embryonal rhabdomyosarcoma and undifferentiated<br />
sarcoma, are rare.<br />
Hepatoblastoma has the peak incidence in the first two years<br />
<strong>of</strong> life, and up to 90% <strong>of</strong> the cases occur before the age <strong>of</strong> five<br />
years. As it is well known, the wide majority <strong>of</strong><br />
hepatoblastomas present as a single mass involving in decreasing<br />
frequency the right lobe, both lobes and the left lobe. Approximately<br />
20% <strong>of</strong> the cases are multifocal. Microscopically,<br />
the more frequent epithelial hepatoblastomas (56%) and the<br />
less frequent (44%) mixed epithelial and mesenchymal<br />
hepatoblastomas have to be distinguished. With regard to the<br />
subtypes mixed epithelial/mesenchymal tumors without teratoid<br />
features are most frequent (34%), followed by pure fetal<br />
(31%), fetal/embryonal (19%) and mixed teratoid<br />
hepatoblastomas (10%). The macrotrabecular and the small<br />
cell/anaplastic hepatoblastoma variants are very rare (3%,<br />
each). Notably, a pure embryonal variant <strong>of</strong> epithelial<br />
hepatoblastoma does virtually not exist.<br />
Nevertheless, data from the Liver Tumor Study HB 94<br />
show that the histologic subtype does not influence the prognosis<br />
significantly. By contrast, significant prognostic factors<br />
are the tumor growth pattern in the liver, vascular invasion,<br />
distant metastases, surgical radicality, initial levels <strong>of</strong> AFP,<br />
and the response to chemotherapy. The overall survival rate<br />
<strong>of</strong> patients with hepatoblastoma in different multicenter studies<br />
is approximately 75%.The prognostically much more unfavorable<br />
hepatocellular carcinoma (HCC) is significantly less<br />
frequent than hepatoblastoma except in countries with high<br />
hepatitis B virus infection rates. In the files <strong>of</strong> the Kiel Pediatric<br />
Tumor Registry 81 cases <strong>of</strong> HCC including 14 cases <strong>of</strong> the<br />
fibrolamellar variant are collected. The proportion <strong>of</strong> HCC to<br />
hepatoblastoma is 0,3:1. Most cases <strong>of</strong> HCC did occur clini-<br />
cally in the second decade <strong>of</strong> life, this in contrast to the wide<br />
majority <strong>of</strong> hepatoblastomas. Microscopically, pediatric HCC<br />
are similar to HCC <strong>of</strong> the adults. Usually the tumor cells are<br />
larger than the surrounding normal hepatocytes. The tumor<br />
cells can be arranged in a pseudoglandular, trabecular, or<br />
pseudoacinar pattern. In most cases the cytoplasm shows an<br />
intensive eosinophilia. Rarely HCC displays tumor cells with<br />
clear cytoplasm similar to clear-cell renal carcinoma and to<br />
some fetal-epithelial hepatoblastomas. Mitotic activity and<br />
nuclear atypia are variable from case to case and may be variable<br />
even in the same tumor. In this case at least moderate<br />
atypia and some mitotic figures can be seen.<br />
Immunohistochemically, tumor cells express AFP, and vessel<br />
invasions are very common. Since many HCC are hepatitis B<br />
virus (HBV)-associated, it is important to look for features <strong>of</strong><br />
preceding HBV infections.The fibrolamellar variant <strong>of</strong> HCC<br />
is not associated with virus infections and, moreover, is not<br />
associated with other conditions like metabolic diseases or<br />
biliary atresia, which are well-known risk factors for the development<br />
<strong>of</strong> classic liver cell carcinoma. In our files 17% <strong>of</strong><br />
the liver cell carcinomas belong to the fibrolamellar variant.<br />
Fibrolamellar carcinoma occurs predominantly in older children,<br />
adolescents and young adults and usually presents as a<br />
solitary, well-circumscribed tumor mass with a predilection<br />
to the left lobe. Microscopically, cords <strong>of</strong> relatively large tumor<br />
cells are separated by paucicellular collagen bands. The<br />
cytoplasm is intensively eosinophilic, and frequently contains<br />
lumina. The proliferation activity is comparably low indicating<br />
slow tumor growth. Late tumor relapses can occur, and in<br />
so far the final prognosis <strong>of</strong> fibrolamellar carcinoma is not so<br />
favorable as was supposed initially.<br />
The most important mesenchymal tumors <strong>of</strong> the liver<br />
are infantile hemangioendothelioma, mesenchymal hamartoma,<br />
embryonal rhabdomyosarcoma, and undifferentiated<br />
(embryonal) sarcoma with 15.5%, 4.8%, 5.6%, and 2.9%, respectively,<br />
<strong>of</strong> the cases collected in our Registry. With regard<br />
to the age at clinical manifestation, significant differences<br />
between these tumors become overt. Thus, most cases <strong>of</strong> infantile<br />
hemangioendothelioma are diagnosed in very young<br />
children. Referring to our publication on tumors <strong>of</strong> the newborn<br />
and the very young infant [3], 86% <strong>of</strong> the<br />
* The lecture was presented during the Meeting <strong>of</strong> the Polish Pediatric Group for the Solid Tumors’ Treatment (Liver Tumors),<br />
22-24.04.2004, Gdansk, Poland
126<br />
hemangioendotheliomas occured in children below the age <strong>of</strong><br />
6 months. For comparison, 9 hepatoblastomas have manifested<br />
in this age class, and the proportion <strong>of</strong> hemangioendothelioma<br />
to hepatoblastoma is 2.1 to 1 in early infancy. Mesenchymal<br />
hamartoma can be present at birth, like hemangioendothelioma.<br />
The wide majority <strong>of</strong> mesenchymal hamartomas occurs<br />
in patients under the age <strong>of</strong> 2 years. Embryonal rhabdomyosarcoma<br />
<strong>of</strong> the liver has a broad age distribution, but<br />
the majority <strong>of</strong> rhabdomyosarcomas develop within the first<br />
5 years <strong>of</strong> life, this by contrast to the probably rhabdomyosarcoma-related<br />
undifferentiated (embryonal) sarcoma (malignant<br />
mesenchymoma <strong>of</strong> the liver in the old nomenclature),<br />
for which the peak incidence is between five and ten years <strong>of</strong><br />
age. Infantile hemangioendothelioma occurs as a solitary mass<br />
or consists <strong>of</strong> multiple tumor nodes involving large parts <strong>of</strong><br />
the liver. Under the microscope infantile hemangioendotheliomas<br />
are composed <strong>of</strong> multiple, sometimes dilated vascular<br />
channels lined by plump endothelial cells. Large or multicentric<br />
lesions can be complicated clinically by consumption<br />
coagulopathy or disseminated intravascular coagulation<br />
(Kasabach-Merritt-syndrome) or, due to intralesional vascular<br />
anastomoses, by severe congestive heart failure. Most infantile<br />
hemangioendotheliomas have to be classified according<br />
to DEHNER’s proposal [2] as type I-hemangioendotheliomas.The<br />
rare type II-hemangioendothelioma shows a more<br />
distinct papillary pattern and endothelial cells with more atypical<br />
nuclei than in type I -tumors. Type II-infantile<br />
hemangioendotheliomas are now considered to be pediatric<br />
angiosarcomas, but malignant behavior <strong>of</strong> infantile<br />
hemangioendotheliomas is generally rare. The majority <strong>of</strong> the<br />
tumors are principally benign lesions. The prognosis depends<br />
on size and distribution <strong>of</strong> the tumor throughout the liver, on<br />
the severity <strong>of</strong> complications, and the resectability, which may<br />
be impossible in multifocal disease. Mesenchymal hamartomas<br />
are generally solitary, no encapsulated and can be very<br />
large. Up to 30% <strong>of</strong> the tumors are pedunculated.Typically,<br />
mesenchymal hamartomas show cysts containing a clear fluid.<br />
Microscopically, in typical cases a so-called ductal-plate pattern<br />
with tortous bile ducts, surrounded by loose connective<br />
tissue, and at the periphery by a more dense fibrous tissue,<br />
can be seen, so that ductal-plates are reminiscent on fibrocystic<br />
disease <strong>of</strong> the female breast. Some bile ducts may show slight<br />
nuclear atypia. Fluid accumulations in the tumor tissue my<br />
cause lymphangioma-like spaces and cysts, which are lined<br />
by flattened non-endothelial, fibroblastic cells. Taking together<br />
these macroscopic and microscopic findings and with regard<br />
to the very young age <strong>of</strong> the patients the diagnosis <strong>of</strong> mesenchymal<br />
hamartoma is easy, except in small biopsies, in which<br />
it may be impossible to exclude undifferentiated sarcoma <strong>of</strong><br />
the liver. The prognosis <strong>of</strong> mesenchymal hamartomas is very<br />
favorable. Tumor relapses are rare.<br />
Embryonal rhabdomyosarcoma <strong>of</strong> the liver developes<br />
either in the extrahepatic bile ducts or intrahepatic. Occlusion<br />
<strong>of</strong> larger bile ducts induces obstruction jaundice. Microscopically,<br />
rhabdomyosarcomas <strong>of</strong> the liver are in most cases embryonal<br />
rhabdomyosarcomas. Particularly, they present as the<br />
botryoid variant <strong>of</strong> embryonal RMS exhibiting the characteristic<br />
subepithelial cambium layer. This layer consists <strong>of</strong> parallel<br />
to the surface arranged, at least moderately differentiated,<br />
intensivly desmin-positive rhabdomyoblasts. This diagnostic<br />
cambium layer the botryoid RMS usually shows small<br />
stellate-like cells arranged in a loose pattern. By contrast to<br />
botryoid rhabdomyosarcomas <strong>of</strong> other locations, the surface<br />
<strong>of</strong> the tumor proliferations can be covered by cylindrical or<br />
cuboidal epithelial cells and not by metaplastic squamous<br />
epithelial cells. Treatment should be done according to the<br />
well-established s<strong>of</strong>t-tissue sarcoma therapy protocols. The<br />
same is true for undifferentiated sarcoma <strong>of</strong> the liver.<br />
Undifferentiated (embryonal) sarcoma <strong>of</strong> the liver usually<br />
develops in children between five to ten years <strong>of</strong> life. The<br />
median age <strong>of</strong> 17 patients with undifferentiated sarcoma treated<br />
in a cooperative Italian/German study [1] was seven years.<br />
Macroscopically, this undifferentiated sarcoma (this specimen<br />
stems exceptionally from an adult patient) shows a grayishwhite<br />
to red and brown cut surface with intensive necrosis.<br />
Under the microscope the tumor consists <strong>of</strong> spindle and seellate<br />
cells arranged within a myxoid stroma. In addition to these<br />
comparably small cells some larger and pleomorphic tumor<br />
cells can be seen. Typically, the periphery <strong>of</strong> the tumor shows<br />
entrapped bile ducts with slight nuclear atypia. These bile ducts<br />
can appear with moderately dilated lumina.<br />
Immunohistochemically, the tumor cells express vimentin intermediate<br />
filaments. In addition, some tumor cells are positive<br />
for desmin too, but true rhabdomyoblasts, particularly<br />
more differentiated rhabdomyoblasts with cross striations do<br />
not occur, this in contrast to embryonal rhabdomyosarcoma.<br />
Nevertheless, the histologic features <strong>of</strong> undifferentiated sarcoma<br />
and embryonal rhabdomyosarcoma may overlap. However,<br />
basically, the undifferentiated sarcoma is a more primitive<br />
sarcoma than embryonal rhabdomyosarcoma. The prognosis<br />
<strong>of</strong> undifferentiated sarcoma <strong>of</strong> the liver was very poor in<br />
the past (mortality about 80 % - STOCKER and ISHAK 1978).<br />
Introduction <strong>of</strong> multimodal s<strong>of</strong>t-tissue sarcoma therapy strategies<br />
has improved the prognosis dramatically. According to<br />
data <strong>of</strong> the forementioned Italin/German study 12 from 17<br />
patients (approximately 70 % <strong>of</strong> the cases) have survived with<br />
follow-up ranging from 2,4 to 20 years [1].<br />
Liver tumor pathology covers a wide variety <strong>of</strong> malignant<br />
and benign, epithelial and mesenchymal tumor entities.<br />
The wide majority <strong>of</strong> principally epithelial tumors<br />
(hepatoblastomas and liver cell carcinomas) are malignant,<br />
whereas the majority <strong>of</strong> mesenchymal tumors (except undifferentiated<br />
sarcoma and embryonal rhabdomyosarcoma) are<br />
morphologically benign. The prognosis <strong>of</strong> malignant liver tumors<br />
has improved dramatically during the recent few decades.<br />
Improvement <strong>of</strong> prognosis is due to interdisciplinary cooperation<br />
in multimodal therapy studies. Another milestone was<br />
the development <strong>of</strong> new pediatric surgery strategies and techniques,<br />
which have contributed significantly to the prognostical<br />
success in malignant and in surgically problematic benign tumors<br />
<strong>of</strong> the liver too.
1. Bisogno G, Pilz T, Perilongo G (2002) Undifferentiated<br />
sarcoma <strong>of</strong> the liver in childhood: a curable disease. Cancer<br />
94(1):252-257<br />
2. Dehner LP (1978) Hepatic tumors in the pediatric age group:<br />
a distinctive clinicopathologic spectrum. Perspect Pediatr<br />
Pathol 4:217-268<br />
3. Harms D, Schmidt D, Leuschner I (1989) Abdominal, retroperitoneal<br />
and sacrococcygeal tumours <strong>of</strong> the newborn and<br />
the very young infant. Report from the Kiel <strong>Paediatric</strong> Tumour<br />
Registry. Eur J Pediatr 148(8):720-728<br />
127